
COMMONWEALTH OF THE NORTHERN MARIANA ISLANDS SAIPAN, TINIAN, ROTA, & NORTHERN ISLANDS



COMMONWEALTH REGISTER
VOLUME 28
NUMBER 08

AUGUST 24, 2006

COMMONWEALTH REGISTER

VOLUME 28 NUMBER 08 AUGUST 24, 2006

TABLE OF CONTENTS

EMERGENCY DECLARATION:

Extension of Emergency - Volcanic Activity on Anatahan Office of the Governor/Emergency Management Office..... 25990 **EXECUTIVE ORDER:** Executive Order No. 2006-005 **Subject:** .Northern Marianas Council for the Improvement of the Criminal Justice System Authority: Executive Order 16 dated March 28, 1980 (amending Executive Order No. 6, dated July 10, 1978) and Public Law 11-47 (repealing Executive Order 94-3 § 303(a)) Office of the Governor..... 25991 **DIRECTIVE:** Subject: Cancellation of Furlough of Civil Service Employees Office of the Governor - Directive No. 257..... 25995 **EMERGENCY REGULATION:** Public Notice of Emergency Regulations and Notice of Intent to Adopt Amendments to the Immigration Regulations 25997 Office of the Attorney General/Division of Immigration..... Public Notice of Emergency Regulations and Notice of Intent to Adopt Amendments to the Immigration Regulations and Alien Labor Rules and Regulations

Office of the Attorney General/Division of Immigration/Department of Labor.....

26020

COMMONWEALTH REGISTER

VOLUME 28 NUMBER 08 AUGUST 24,2006

TABLE OF CONTENTS

PROPOSED RULES AND REGULATIONS:

Proposed Amendments to the Rules and Regulations Governing the Group Health Insurance Program	
NMI Retirement Fund	26029
Proposed Amendments to Public School System Regulations Regarding Teacher Certification: Changing Provisional Certification Name Public School System	26104
NOTICE AND CERTIFICATION ON ADOPTION OF REGULATIONS:	
Notice and Certification of Adoption of Office of the Attorney General, Consumer Counsel, Part I, Retail Advertising Regulations, Section 1 et. seq. Office of the Attorney General	26128
Notice and Certification of Adoption of Postsecondary Education Policy Northern Marianas College Board of Regents	26129
Notice and Certification of Adoption of Amendments to Board of Education Regulations Regarding Praxis Testing for School Administrators, Librarians, Counselors and Curriculum and Instruction Employees	
Public School System	26130



COMMONWEALTH OF THE NORTHERN MARIANA ISLANDS

Benigno R. Fitial Governor

Timothy P. Villagomez
Lieutenant Governor

EXTENSION OF EMERGENCY Volcanic Activity on Anatahan

WHEREAS, On January 23, 2006, a Declaration of Emergency was issued with respect to volcanic activity on the island of Anatahan; and

WHEREAS, said Declaration declared the island of **Anatahan** as unsafe for human habitation and restricted all travel to said island with the exception of scientific expeditions; and

WHEREAS, the volcanic activity and seismic phenomena which prompted said Declaration continues to exist on the island of Anatahan;

NOW, THEREFORE, I, TIMOTHY P. VILLAGOMEZ, by the authority vested in me as Acting Governor, and pursuant to Article III, Section 10 of the Commonwealth Constitution and 3 CMC §5121, do hereby extend a state of disaster emergency in the Commonwealth with respect to the island of **Anatahan** under the same terms and conditions as are contained in the original Declaration.

This Extension of Emergency shall remain in effect for **thirty** (30) days, unless the Governor shall, prior to the end of the 30-day period, notify the Presiding Officers of the Legislature that the state of emergency has been revoked or further extended for alike term, and giving reasons for extending the emergency.

Dated this 2nd day of August 2006.

BENIGNO R. FITIAL

cc: Lt. Governor (Fax: 664-2311)

Senate President (Fax: 664-8803)

House Speaker (Fax: 664-8900)

Mayor of the Northern Islands (Fax: 664-2710)

Executive Assistant for Carolinian Affairs (Fax: 235-5088)

Director of Emergency Management (Fax: 322-7743)

Attorney General (Fax: 664-2349) Secretary of Finance (Fax: 664-1115)

Commissioner of Public Safety (Fax: 664-9027)

Special Assistant for Management and Budget (Fax: 664-2272) Special Asst. for Programs and Legislative Review (Fax: 664-2313)

Press Secretary (Fax: 664-2290)

COMMONWEALTH REGISTER VOLUME 28 NUMBER 08 August 24, 2006 PAGE 25390

Caller Box 10007 Saipan, MP 96950 Telephone: (670) 664-2200/2300 Facsimile: (670) 664-2211/2311



COMMONWEALTH OF THE NORTHERN MARIANA ISLANDS

Benigno R Fitial Governor

Timothy P. Villagomez Lieutenant Governor

EXECUTIVE ORDER NO. 2006-_005_

SUBJECT: Northern Marianas Council for the Improvement of the Criminal

Justice System

AUTHORITY: Executive Order 16 dated March 28,1980 (amending Executive

Order No. 6, dated July 10, 1978) and Public Law 11-47 (repealing

Executive Order 94-3 §303(a))

WHEREAS, on March 28,1980, Executive Order No. 16 ("EO 80-16") created the Northern Marianes Commonwealth Council for the Improvement of the Criminal Justice System ("Council") under the Governor's Office; and

WHEREAS, on August 23,1995, Executive Order 94-3 took effect placing the Council under the jurisdiction of the Department of Public Safety Plan for the purposes of coordination and administration; and

WHEREAS, on November 20,1998, pursuant to Public Law 11-47, the Council was transferred back under the Governor's Office; and

WHEREAS, the Northern Marianas Criminal Justice Planning Agency ("CJPA") was established under the Council tasked to comply with the Federal Omnibus Crime Control and Safety Streets Act of 1968, as amended; and

WHEREAS, the Council's duties as outlined below pursuant to Section 6 of EO 80-16 include the following:

- a) To supervise the Agency in performing its powers and duties under EO **80-1**6.
- b) To review, approve and maintain general oversight of the State Plan and its implementations.
- c) To prepare an **Annual** Report detailing its work during the preceding calendar year which shall be submitted to the Governor and the Legislature and made available to the public. Other studies, evaluations, crime data analysis and

- reports may be submitted to the Governor or Legislature upon request or as may be deemed appropriate by the **Council**.
- d) To guide the CJPA to define goals and develop standards for the criminal justice system; conduct or authorize a criminal justice plan and annual revisions to it and other appropriate planning studies for the improvement of law enforcement and criminal justice; build on work already completed, including studies pertaining to the protection of juveniles in criminal proceedings; provide advice to the Governor in areas of its competence; identify, conduct, oversee or coordinate programs, including demonstration projects, for the prevention of crimes, effectiveness of criminal procedures, and the care, treatment and rehabilitation of offenders; monitor and assess criminal justice activities; and recommend legislation or regulations to the Governor as may be appropriate. The Council shall serve in an advisory coordinative capacity to the branches and agencies of the government in its area of competence and may provide technical advice or request.
- e) To advise and assist the Governor in developing policies, **plans**, programs, and budgets for improving the coordination, **administration** and effectiveness of the criminal **justice** system in the Commonwealth; and

WHEREAS, the current Council is composed of sixteen (16) members, 10 of whom are ex officios; and

WHEREAS, the Chairman of the Youth Advisory Council is **the** only ex officio member required pursuant to 42 U.S.C. 5633; and

WHEREAS, the **remaining** 9 ex officio members, in their official capacity, may at times have an interest in certain grant awards, causing the Council to become biased **and/or causing** the Council members to bargain with each other,

WHEREAS, it is the intent of this Executive Order to **minimize** the number of members who may have an interest in **grant** awards; and

WHEREAS, the total number of Council members currently established is excessive;

NOW, THEREFORE, to conduct Council's duties fairly and objectively, it is hereby

ORDERED:

That the number of Council members be reduced to nine (9). The members shall include the following:

- 1) Chairman, Youth Advisory Council
- 2) Chief Justice, NMI Supreme Court
- 3) President of the Saipan Chamber of Commerce or his/her designee;
- 4) Chairman, Judicial and Governmental Operations Committee, CNMI House of Representatives;
- 5) Five (5) citizen members of the CNMI appointed in accordance with Public Law 1-8.

With the exception of the representatives **from** the Youth Advisory Council, the NMI Supreme Court, the Saipan Chamber of Commerce, and the Judicial and Governmental Operations Committee of the CNMI House of Representatives whose terms are valid only for the duration of their position, the remaining members shall serve a term of four (4) years, shall be non-government employees, board members, agents, or elected officials and shall be appointed by the Governor in accordance with Public Law **1-8**; with representation among citizen members of each senatorial district, one member of Carolinian descent, and one female member.

IT IS FURTHER ORDERED:

That the Youth Advisory Council's participation will solely be in an advisory and non-voting position. The Chairman, or **his/her** designee, *shall* participate in the **development** and review of **CNMI's** juvenile justice plan before it is submitted to the Council for final action and shall have thirty (30) days to review and comment on juvenile justice and delinquency prevention grant applications.

IT IS **FURTHER** ORDERED:

That with the exception of the representatives **from** the Youth Advisory Council and the NMI Supreme Court, the remaining members shall not have any direct interest in federal grants managed under the Council. They may not be employed by, affiliated

with, or involved in an agency, department, or group that is an applicant for grants maintained by the Council.

Benigno/R. Fitial



COMMONWEALTH OF THE NORTHERN MARIANA ISLANDS

Benigno R Fitial Governor

Timothy P. Villagomez
Lieutenant Governor

DIRECTIVE

DATE: AUG 1 8 2006

No. 257

TO: All Department and Activity Heads

FROM: GOVERNOR

SBJ.: Cancellation of Furlough of Civil Service Employees

On July 14, 2006, I issued Directive No. 256 providing notification of my decision to authorize a **30-day** furlough of civil service employees holding **non-critical** positions. As I stated in this Directive, **this** furlough action was one alternative to a full **Reduction-in-**Force. Since the **issuance** of that Directive I have continued to review alternatives to seek the best balance of decreasing **government** expenditures, while minimizing the adverse affect upon government employees. Working with the Legislature, the Administration **has** determined that this balance can be better attained by limiting that **furlough** to just one day per pay period, over **an** extended period of time, and increasing the number of employees affected.

Accordingly, I have signed Public Law No. 15-24, establishing austerity holidays on alternating, non-payday Fridays with the closure of those offices and services that **would** normally be closed on a legal holiday. The Director of **Personnel and all** Department and Activity Heads will work for the immediate implementation of this statute, with due consideration to any contractual requirements.

Directive No. 256 is cancelled. I do appreciate the efforts of all who were involved in preparing and processing the *necessary* documents for the planned furlough. However, I am confident that this alternative will better serve both employees and the Government.

BENIGNO R. FITIAL

cc: Lieutenant Governor

Special Legal Coursels, Office of the Governor
Legal Coursel, Office of the Lt. Governor
Senate President and all Senators
Speaker of the House of Representatives and all Representatives
Mayors of Saipan, Rota, Tinian and Aguiguan, and the Northern Islands
Chairs, Municipal Councils of Saipan, Rota, Tinian and Aguiguan

Executive Directors of all Public Corporations and Autonomous Agencies Special Assistant to the Administration

PUBLIC NOTICE OF EMERGENCY REGULATIONS AND NOTICE OF INTENT TO ADOPT AMENDMENTS TO THE IMMIGRATION REGULATIONS

EMERGENCY: The Attorney General finds that the public interest requires that Section 706(H) of the Immigration Regulations (Foreign Student Entry Permits) be amended to allow foreign elementary and secondary students to study in the CNMI and to make the eligibility requirements less onerous for students from comity countries. These changes will allow young foreign students who are interested in studying abroad in an English-speaking country, but who do not want to travel as far as mainland United States or Hawaii, to pursue their educational objectives in the CNMI. The establishment of such schools promises not only economic growth for the CNMI, but also presents educational and cultural opportunities to CNMI students and residents who in many cases will be eligible to apply to attend these institutions and will have other opportunities to interact with the foreign students. The Attorney General further finds that it will serve the public interest to at the same time amend Immigration Regulation Section 706(R) (Alien Student Attendance Permit) to harmonize this provision with the amendments to Section 706(H). Finally, the Attorney General finds it to be in the public interest to also amend Section 706(J) (Distinguished Merit Entry Permit) to allow nonresidents of exceptional merit in very limited circumstances to operate a small business in their field of expertise. This amendment will also spur much-needed economic growth and innovation in the CNMI. The Attorney General has determined that under 1 CMC § 9104(b), the public interest mandates adoption of these regulations upon fewer than thirty (30) days notice, and that these regulations shall become effective immediately after filing with the Commonwealth Register, subject to the concurrence of the Governor, and shall remain effective for 120 days.

REASONS FOR EMERGENCY: It has recently come to the attention of the Governor and the Attorney General that there are a number of educational and artistic projects under development that cannot be implemented under the current regulations. Any delays in amending the regulations could jeopardize the success of these projects whose backers are eager to implement their projects as soon as possible. Given the difficult economic circumstances facing the Commonwealth Government, and the community as a whole, and the great economic and cultural promise offered by these projects and those of a similar nature that may follow, the Attorney General finds that, in the interest of the public, it is necessary that these regulations are approved and adopted immediately.

INTENT TO ADOPT: It is the intent of the Attorney General to adopt these emergency amendments to the Immigration Regulation as permanent, pursuant to 1 CMC § 9104(a)(1) and (2). Interested persons may submit written comments on these emergency recommendations to Matthew T. Gregory, Attorney General, Second Floor, Juan A. Sablan Memorial Bldg., Saipan, MP 96950 or by fax to (670) 664-2349, during the thirty-day period immediately following publication of the proposed amendments.

Submitted by: 7/26/06

Matthew T. Gregory
Attorney General

7/26/06

Date

PAGE

Concurred by:	Benigno R. Fitial Governor	7-27.86 Date
Received by:	Esther Flaming Special Assistant for Administration	8/01/00 Date
Filed and Recorded by:	BERNADITA B. DE LA CRUZ Commonwealth Register	Date Soulog

Pursuant to 1CMC §2153, as amended by Public Law 10-50, the emergency rules and regulations attached hereto have been reviewed and approved as to form and legal sufficiency by the CNMI Attorney General's Office.

Dated this 1st day of July, 2006.

Matthew T. Gregory Attorney General

PUBLIC NOTICE EMERGENCY AMENDMENTS TO THE IMMIGRATION REGULATIONS

This amendment is promulgated in accordance with the Administrative Procedure Act, 1 CMC § 9101, et seq. The Attorney General is proposing to amend the Immigration Regulations that were initially adopted as permanent in Commonwealth Register, Vol. 7, No. 5, May 20, 1985, as subsequently amended and restated in their entirety in the Commonwealth Register, Vol. 27, No. 02, February 17,2005.

Citation of

Statutory Authority: The Office of the Attorney General is authorized to promulgate

regulations governing the movement of aliens into and away from the Commonwealth of the Northern Mariana Islands pursuant to

Executive Order 03-01 and 3 CMC § 4312(d).

Short Statement of Goals and Objectives:

The emergency amendments to the Immigration Regulations will for the first time allow foreign elementary and secondary students to study in the CNMI and to make the eligibility requirements less onerous for students from comity countries. These changes will open the door to young foreign students who are interested in studying abroad in an English-speaking country, but who do not want to travel as far as mainland United States or Hawaii, to pursue their educational objectives in the CNMI. The amendments will also amend the section of the Immigration Regulations governing Alien Student Attendance Permit to harmonize this provision with the amendments to the Foreign Student Entry Permit Section. Finally, the amendments will allow nonresidents of exceptional merit in very limited circumstances to operate a small business in their field of expertise.

Brief Summary of the Proposed Amendments:

These emergency amendments are promulgated to:

- (1) Amend Section 706(H) of the Immigration Regulations (Foreign Student Entry Permits) to allow foreign elementary and secondary students to study in the CNMI and to make the eligibility requirements less onerous for students from comity countries.
- (2) Amend Section 706(R) of the Immigration Regulations (Alien Student Attendance Permit) to harmonize this provision with the amendments to Section 706(H).

(3) Amend Section 706(J) of the Immigration Regulations (Distinguished Merit Entry Permit) to allow nonresidents of exceptional merit in very limited circumstances to operate a small business in their field of expertise.

For Further

Information Contact: Dorothy E. Hill, Assistant Attorney General, Office of the

Attorney General, telephone (670) 236-0910 or facsimile (670)

236-0990.

Citation of Related and/or Affected Statutes, Rules and Regulations, and Orders:

The emergency amendments affect Immigration Regulations

Sections 706 (H), (J) and (R).

Submitted by:

Matthew T. Gregory
Attorney General

NOTISIAN PUPBLIKU POT ENSIGIDAS NA REGULASION SIHA YAN NOTISIAN INTENSION PARA U MA'ADOPTA I AMENDASIONSIHA PARA I REGULASION IMIGRASION SIHA

ENSIGIDAS: I Abugådu Heneråt masodda na I interes pupbliku a rekomenda na I Seksiona 706 (H) gi Regulasion Imigrasion (Petmisun Entråda Para Estudiånten Estrangheru)u ma'amenda pot para u sedi I estudianten estrangheru para u fan man estudia gi eskuelan elementario yan segundario gi halom CNMI yan para u na libianu I nisisidåt I kuålifikasion siha para I estudiånte ginen I man respetåyon na bario (countries) siha. Este siha na tinilaika siempre a sedi I **estudianten** estrangheru **ni** man enteresão man estudia gi ottro na lugăt anai manguekuentus fino' engles, lão ti man malagu man hånao lachagu para Hawaii osino Estådus Unidos, ya para u makontinua I edukasion niha gi hålom I CNMI. Yanggen ma'establesi este na opottunidåt edukasion ti a promemesa solamente I minaolek ekonomia para I CNMI, låo a presesenta lokkue opottunidåt edukasion yan kuttura para I estudiånten CNMI yan residente siha anai meggai **na kåosa** siempre man **kuålifikåo** para **u** fan man **aplika** ya **u** ma'atiende este siha na institusion ya siempre guaha siha ottro na opottunidat para u fan atungo' yan I **estudiånten** estrangheru siha. I **Abugådu Heneråt** a sodda **mås na** siempre a setbi I interes pupbliku para I parehu na manera u amenda I Regulasion Imigrasion Seksiona 706 (R) (Petmisun Attendance I Estudianten Estrangheru) para u tattiyi este na probension ni I amendasion para I Seksiona 706 (H). In fin, I Abugådu Heneråt a sodda na gaige gi interes pupbliku para u ma'amenda lokkue Seksiona 706 (J) (Distinguished Merit Entry Permit) para u sedi I ti man residente siha ni supiriot na kreditu gi I mamidi na manera para **u kalamtini I dikike'** na bisnis gi I **mapraktitika na ekspiriensian** niha. Este na amendasion siempre a na kalamtin didide' I Ekonomia yan I tinilaika siha gi CNMI. Maditetmina ni I Abugådu Heneråt na papa I lai 1 CMC Seksiona 9104 (b), mamanda ni interes pupbliku I inadoptasion este siha na regulasion gi hålom trenta (30) diha siha na notisia, ya debi di **u efektibu** este siha **na** regulasion ensigidas despues di **mapolu** gi Rehistran I Commonwealth, anai kininsiste ni Gubietno, ya u efektitibu para siento bente (120) diha siha.

RASON I ENSIGIDAS: Esta matto gi atension I Gubietno yan I Abugådu Heneråt na guaha siha loskuåntos na Chochu Edukasion yan Atista papa I adulåntao ni ti siña makalamtini gi papa I man eksiste na regulasion siha. Yanggen guaha chinanda mientras ma'amemenda I regulasion siha siiia inafekta I che'cho' siha ni mana kepusipble amanu siiia na chinaddek. **Patikulatmente** I prubleman ekonomia ni a fa'fa'na I **Gubietnamenton** I Commonwealth, yan enteramente I komunidat, yan I promesa ni ma'ofresi ginen este siha na cho'chu' para I minaolek I ekononia yan I kuttura yan **eyu** man parehu na **manera** ni u tinatiyi, I Abugådu Heneråt a sodda na, gi I interes I pupbliku, nisisårio na este siha na regulasion man ma'aprueba yan adopta imidiamente.

INTENSION PARA U MA'ADOPTA: Intension I Abugådu Heneråt para u adopta este ensigidas na amendasion siha para I Regulasion Imigrasion petmanente, sigun I lai 1 CMC Seksiona 9104 (a)(1) yan (2). I man interesão na petsona siña man nahalom tinige' opinion pot este ensigidas na rekomendasion siha guatto as Matthew T. Gregory, I

Abugådu Heneråt, gi mina dos bibienda, gi Juan A. Sablan Memorial Building, giya Saipan, MP 96950 osino fæx guatto gi (670) 664-2349, durånten I trenta (30) diha na tiempo insigidas tinatitiyi I pupblikasion este man mapropone na amendasion siha.

Ninahalom as:	Matthew T. Gregory	Fecha
	Abugådu Heneråt	
KininfotmA as:	Benigno R. Fitial Gubietno	Fecha
Maresibe' as:	Esther Fleming Espesiåt Na Ayudante Para I Atministrasion	8/2//06 Fecha
Pinelo' yan Marikot	as: Adda Orux BERNADITA B. DELA CRUZ Rehistradoran I Commonwealth	8/21/46 Fecha
areklamento yan reg	eksiona 2153. ni inamenda ni Lai Pupbliku 10-: ulasion siha ni man che'che'ton esta man ma'in åt sufisiente ginen I Ofisinan I Abugådu Henerå	a yan ma'aprueba pot
Mafecha este gi min	a na ha'åne gi Agostu, 2006.	
Matthew T. Gregory Abugådu Heneråt	 7	

NOTISIAN PUPBLIKU

ENSIGIDAS NA AMENDASION PARA I REGULASION IMIGRASION SIHA

Este na amendasion ma'establesi para u kininsiste ni Akton Areklamenton Atministrasion, lai 1 CMC Seksiona 9101, et. seq. I Abugådu Heneråt a propopone para u amenda I Regulasion Imigrasion ni esta man ma'adopta petmanente gi Rehistran I Commonwealth, Baluma 7, Numiru 5, gi Måyu 20,1985, anai tumatatte' ma'amenda ya mamensiona enterarnente gi halom I Rehistran I Commonwealth, Baluma 27, Numiru 02, gi Febreru 17,2005.

Annok I Aturidåt I Lai:

I Ofisinan I Abugådu Heneråt ma'aturisa para u establesi regulasion siha ni ginibebietna I kinalamten I estrangheru siha gi halom yan hiyong I Commonwealth I Sankattan Siha Na Isla Marianas sigun I Otden Eksekatibu 03-01 yan lai 3 CMC Seksiona 4312 (d).

Kadada Na Menslhen Finiho yan **Diniseha:**

I ensigidas na amendasion para I Regulasion Imigrasion siempre para I fine'nina na biahe' u masedi I estudianten estrangheru para u fan man estudia gi eskuelan elementårio yan segundario gi hålom CNMI yan para u na libianu I nisisidåt I kuålifikasion siha para I estudiånte ginen I man respetayon na bario (countries) siha. Este siha na tinilaika siempre a sedi I estudiânten estrangheru ni man enteresão man estudia gi ottro na lugăt anai manguekuentus fino' engles, låo ti man malagu man hånao lachagu para Hawaii osino Estadus Unidos, ya para u makontinua I edukasion niha gi hålom I CNMI. Siempre lokkue I amendasion siha a amenda I seksiona gi Regulasion Imigrasion ni ginibebietna I Petmisun Attendance I Estudianten Estrangheru para u tattiyi este na probension siha yan i amendasion para I Seksionan Petmisun Entradan Estudianten Estrangheru. In fin, I amendasion siempre a sedi I ti man residente siha ni supiriot na kreditu gi I mamidi na manera para u kalamtini I dikike' na bisnis gi I mapraktitika na ekspiriensian niha.

Kadada Na Mensåhe Pot I Man Mapropone Na Amendasion Siha:

Este man **ensigidas** na amendasion siha man ma'establesi para:

- 1) Amenda Seksiona 706 (H) gi I Regulasion Imigrasion (Petmisun Entrada Para Estudianten Estrangheru) para u sedi I estudianten estrangheru para u fan man estudia gi eskuelan elementario yan segundario gi halom CNMI yan para u na libianu I nisisidat I kualifikasion siha para I estudiante ginen I man respetayon na bario (countries) siha.
- (2) Amenda Seksiona 706 (R) gi I Regulasion Imigrasion (Petmisun Attendance I Estudianten Estrangheru) para u tattiyi este na probension ni I amendasion siha gi Seksiona 706 (H).
- (3) Amenda seksiona 706 (J) gi Regulasion Imigrasion siha (Distinguished Merit Entry Permit) para u sedi I ti man residente siha ni supiriot na kreditu gi I mamidi na manera para u kalamtini I dikike' na bisnis gi I mapraktitika na ekspiriensian niha.

Para Mås Infotmasion Agang:

Si Dorothy E. Hill, Ayudanten I Abugidu Henerit, gi Ofisinan I Abugådu Heneråt, numirun tilifon (670) 236-0910 **osino** facsimile (670) 236-0990.

Annok I Man Achule' Yan/pat Inafekta na Lai, Regulasion, Areklamento yan Otden Siha:

Este insigidas na amendasion siha a afekta I Regulasion Imigrasion Seksiona 706 (H), (J) yan (R).

Ninahalom as:		
	Matthew T. Gregory	Fecha
	Abugådu Heneråt	

PAGE

EMERGENCY AMENDMENTS TO SECTION 706 H OF THE **IMMIGRATION REGULATIONS**

Immigration Regulation 706 H is hereby repealed and re-enacted to read as follows:

H. Foreign Student Entry Permit

- 1. Student Eligibility for a Foreign Student Entry Permit
 - In order to qualify for a Foreign Student Entry Permit for entry into the Commonwealth of the Northern Mariana Islands (CNMI) under this subsection, an applicant must be admitted to matriculate full-time in an approved institution. Full-time may be defined as the equivalent of 12 semester hours of study per semester and 9 semester hours for a summer semester of study as defined by the learning institution.
 - b. An applicant may apply for a "Student Authorization for Entry" that will allow the applicant to travel to and enter the CNMI temporarily, in order to enroll in an approved educational institution. Applicants from countries whose citizens or nationals are not required to obtain Visitor Entry Permits to enter the CNMI under section 703(B) are exempt from this requirement.
 - After the applicant has been accepted by an approved educational institution the c. applicant may be issued a "Foreign Student Entry Permit". Any application fee paid for a Student Authorization for Entry may be credited toward the applicant's Foreign Student Entry Permit.
 - d. Applicants may apply for a Foreign Student Entry Permit prior to formal enrollment with an approved institution, but the permit will not be issued until proof of enrollment is received and verified by the Office of the Attorney General, Division of Immigration (DOI).
 - A Foreign Student Entry Permitissued pursuant to this subsection shall be valid for e. no more than one year and is renewable if the applicant continues to meet all conditions of the original issuance. The validity of a Foreign Student Entry Permit shall not exceed the length of time required to complete the degree or training program plus reasonable time necessary for repatriation or participation in graduation ceremonies.
 - f. Dependents (children under the age of eighteen and spouses) of a holder of a Foreign Student Entry Permit may be granted "Immediate Relative of Alien" entry permits pursuant to Immigration Regulation 706(E) (a cash bond in the amount of twice the cost of return travel to the point of origin at the time of application); provided however, that in addition to the requirements of that Regulation, the

applicant must also submit proof that sufficient funds are available from an identified and reliable source to defray living expenses for the dependent during the applicant's Foreign Student Entry Permit. The applicant must provide a repatriation bond as required by Immigration Regulation 706(E) and proof of a bond or insurance valid in the CNMI sufficient to cover the dependent's medical expenses. An Immediate Relative of an Alien Entry Permit issued pursuant to this subsection shall be valid for the same time period as is granted to the student who holds a valid Foreign Student Entry Permit. Dependents of applicants from countries whose citizens or nationals are not required to obtain Visitor Entry Permits to enter the CNMI under section 703(B) are exempt from this requirement.

2. Employment of Students

Nothing in this subsection shall authorize the holder of a Foreign Student Entry Permit to work in the Commonwealth except a student may participate in an on campus work/study program intended to defray the cost of tuition and/or living expenses. A foreign student may seek the approval of the Director of Immigration to participate in paid activities whose focus is on academic research or training provided that the activity must be related to the applicant's primary field of education and may not last for more than one year.

3. Proof of Economic Condition of Student Applicants

Applicants must prove that sufficient funds are or will be available from an identified and reliable financial source to defray living and school expenses for the student during the period of the anticipated study. Applicants must provide evidence that they have adequate financial capability and/or insurance to defray all health care costs for them and their dependents. Proof may be made by showing a letter of employment of the person(s) who will be responsible for supporting the student while in the Commonwealth describing the person's salary, together with a letter of commitment stating that the person agrees to be financially responsible for the student, a bank statement showing financial ability to support the student, proof of a student loan or grant or scholarship for the student, or any other information that establishes proof of financial ability.

4. Application Requirements for Student Applicants

Each applicant for a Foreign Student Entry Permit shall pay a non-refundable application fee of one hundred dollars (\$100.00) and submit:

- a. a permit application, signed under penalty of perjury by the applicant, or, if the applicant is less than 18 years of age, the applicant's parent or guardian;
- b. a completed biographical form;
- c. a copy of an applicant's passport;

PAGE

- d. for applicants older than 12 years of age, a certified copy of a police clearance reflecting an applicant's criminal record;
- e. legal documents showing that the student, if the student is under the age of eighteen (18), has a legal guardian appointed and that guardian resides in the CNMI;
- f. for students entering a private elementary or secondary institution, a certification of physical examination and proof that the child has received all of the immunizations required by the Department of Public Health. If all immunizations have not been completed, remedial action must be taken within two weeks of entry into school. Failure to do so may result in the exclusion of the student from school and revocation of the student's Foreign Student Entry Permit;
- g. a fee paid for a Student Authorization for Entry will be credited toward the Foreign Student Entry Permit.

5. Transfer of Students Attending an Approved School

A student attending an approved school under a Foreign Student Entry Permit may transfer to another approved school so long as both schools **notify** the **DOI** with 15 working days of the transfer and the receiving school certifies that the student is enrolled in a full-time course of study as defined in section 706 H(1)(a) and that the student meets all other eligibility and enrollment requirements.

6. Approval of Institutions

The DOI must approve in writing, a school which intends to enroll foreign students in a program for a degree or certificate. The approval shall only reflect a school's authorization to accept foreign students who are in the CNMI or seeking to enter the CNMI under a Foreign Student Entry Permit. The approval or denial shall in no way affect or impinge upon the school's accreditation by the Board of Regents or other accreditations.

- a. Eligibility of schools and definition of schools
 - (1) Eligible schools include, but are not limited to, private elementary and secondary schools, post-secondary institutions, such as colleges, universities, community colleges or junior colleges, offering recognized associate, bachelor's, master's, doctor's or professional degrees, as well as "transitional schools" language schools, religious schools, vocational schools, sports schools, professional training programs.

COMMONWEALTHREGISTER VOLUME 28 NUMBER 08 August 24, 2006 PAGE 26007

(2) A "transitional school", is further defined as a school which specializes in preparing students for entry into post-secondary institutions in the CNMI or the United States.

b. Petition for approval by the DOI

An eligible school seeking approval as a bona fide school eligible for attendance by foreign students shall file a petition with the DOI. The petition shall include:

- (1) A letter of request for certification from an authorized representative of the school that (i) describes the basic program, including the curriculum, for which certification is requested; (ii) the number of years the school has existed and operated; (iii) any established affiliation with other institutions inside or outside the CNMI; (iv) current number of students; (v) number of foreign students requested and anticipated in the first two years after approval; (vi) number of current faculty members and administrators and (vii) the tuition to be charged to each foreign student for the complete course of study, including any potential scholarships, or tuition waiver programs.
- (2) All petitioning institutions providing post-secondary instruction must provide proof of certification by the Board of Regents of the CNMI under 2 CMC §1316(k);
- (3) All petitioning institutions providing elementary and secondary instruction must certify that they are in compliance with the Student Health Requirements set forth in 3 CMC § 1161, et seq.
- (4) A petitioning institution must provide:
 - (i) a certification that the school is licensed, approved, or accredited by a recognized national or international authority or body, signed by an official of such authority or body who shall also certify that he or she is authorized to do so. If the school commenced operations within the last two years, it may instead provide a plan to attain a license, approval or accreditation which must be achieved within two years. DOI may condition approval of a school's petition upon achieving the plan's goal(s), and failure to do so may result in revocation of the school's certification to teach foreign students;
 - a petitioning secondary and post-secondary institution must provide evidence that it confers (or will confer if the institution has been in existence for less than four years) upon its graduates recognized high school, associate, bachelor, master, doctor, professional, or divinity degrees, or evidence that its credits are, or have been, accepted by at least three institutions that do confer such degrees; and

3 August **M** 2006 PAGE 2608

(iii) a school catalogue, if one is issued, including a printout of web pages operated by the school, that advertise or explain its program. If a catalogue is not issued, or if not included in the catalogue, the school shall provide a written statement describing the size and physical nature of its plant, nature of its facilities for study and training, qualifications and salaries of the administrators and faculty, attendance and scholastic grading policy, and statement of finances (which must be certified by a licensed accountant and state the school's net worth, income and expenses). A charter, authorization to do business, or instrument of corporation must also be provided but shall not be considered approval or accreditation.

c. Interview of petitioning school representative

An authorized representative of the petitioning school may be required to appear in person, under oath, before the DOI prior to the adjudication of the petition concerning the school's approval status.

d. Approval of school's petition

To be eligible for approval, the petitioner must establish that: (i) it is a bona fide school; (ii) it is an established institution of learning; (iii) it possesses the necessary facilities, personnel and finances to conduct instruction in recognized courses; and (iv) it is, in fact, engaged in instruction in those courses.

The DOI shall notify the petitioner in writing of the decision to approve or deny. Initial approval for a six (6) month period, may be granted at the discretion of the Attorney General on a conditional basis. The approval status is renewable for an additional six-month period provided that the Attorney General is satisfied that the school has complied with the terms of this Section. Thereafter the approval status is renewable in 3-year increments subject to review at any time during the approval status. An approved school must report immediately to the DOI, any material modification to its facility, name, address, or curriculum for a determination of continued eligibility for approval. The approval is valid for only the type of program and students specified in the approval notice. The approval may be revoked in accordance with the provisions of paragraph 5(1) of this Section.

e. Denial of petition and appeal.

If the petition is denied, the petitioning school shall be notified of the reasons for the denial and of the right to appeal. Any appeal shall be submitted within fifteen (15) working days after the service of the written denial. The reasons for the appeal shall be stated in the notice of appeal, and supported by a statement and supporting documentation setting forth the grounds for contesting the denial of the approval.

f. Record keeping requirements for the school.

An approved school must keep records containing certain information and documents relating to each foreign student while the student is attending the school. Such records shall be readily available to the DOI and shall be retained by the school for a period of two years following the departure of the student. The information and the documents that the school must keep on each student attending the school under a Foreign Student Entry Permit are as follows:

- (1) A photocopy of the student's Passport and Foreign Student Entry Permit;
- (2) Current address and an accurate description of where the student and his or her dependents physically reside.
- (3) Date of the commencement of studies;
- (4) Degree program and field of study;
- (5) The student's current academic status;
- (6) Termination date and reason, if known;
- (7) The number of credits completed each semester;
- g. Reporting requirements for the school by term or session.

Once every term or session, a designated school official must file with the DOI a certified list of foreign students which indicates the name of each foreign student and whether the student is enrolled for a full course-load or has dropped below a full course-load or failed to enroll.

h. Additional Reporting requirements for the school.

Schools are required to report to the DOI, within fifteen (15) working days of occurrence, the following events:

- (1) A foreign student under a Foreign Student Entry Permit fails to enroll or register for classes following the respective deadlines for enrollment or registration;
- (2) A foreign student under a Foreign Student Entry Permit fails to complete his or her program in the time typically required to complete the program;
- (3) A change of the student's or dependent's legal name, mailing address or location of residence;

- (4) A student graduates prior to the scheduled program end date;
- (5) Any other request made by the DOI with respect to the academic status of the student.

i. Advertising by the school.

A school must provide to the DOI a copy of any advertisement, catalogue, brochure, pamphlet, literature, or any other material printed, reprinted, or published, including via the internet, by or for an approved school containing any statement or representation concerning attendance by foreign students. Such copies must be received by the DOI prior to distribution to the public.

j. School's signing the Foreign Student Entry Permit application.

A designated official of a school approved under this section must sign any completed Foreign Student Entry Permit application for either a prospective or continuing student. The designated official shall sign the Foreign Student Entry Permit application only if the following conditions are met:

- (1) The prospective student has made a written application to the school.
- (2) The written application, the student's transcripts or other records of courses taken, proof of financial responsibility for the student and the dependents, and other supporting documents have been received, evaluated and deemed satisfactory by the school.
- (3) The official responsible for admission to the school has accepted the prospective student for enrollment in a full course of study.
- k. Designated school official.

"Designated school official" ("DSO") means a member of the school administration designated by the president, owner or head of the school. A DSO may not be primarily responsible for recruitment of foreign students and must be a citizen or lawful permanent resident of the United States. A DSO may not delegate this designation to any other person. Each school may designate up to three designated officials. Each DSO must sign a certificate that the official is familiar with the regulations relating to the requirements for admission and the maintenance of status of foreign students attending the school under the authority of a Foreign Student Entry Permit and the school's approval requirements and current status under this section.

- 1. Revocation of approved school status.
 - (1) Revocation on notice.

If a school's approval is revoked on notice, the school is not eligible to file another petition for approval until one year after the effective date of the revocation. The approval of a petition by a school for the attendance of foreign students under a Foreign Student Entry Permit may be revoked on notice by the DOI in its discretion for any valid and substantive reason including, but not limited to, the following:

- (i) Failure to immediately notify the DOI if a student falls below full-time status or has excessive days of uriexcused absences;
- (ii) Failure to comply with the reporting requirements set forth in paragraphs 6(d) approval of petition, 6(f) record keeping requirements, 6(g) reporting requirements and 6(h) additional reporting requirements of this subsection;
- (iii) Willful issuance by a designated official of a false statement or certification in connection with an application for approval or other document related to the acceptance for enrollment of a foreign student;
- (iv) A designated official does not meet or comply with the requirements set forth in paragraph 6(k) designated school official, of this subsection;
- (v) Failure to employ qualified professional personnel, to maintain proper facilities and curriculum, or to attain or maintain such accreditation or licensing as required in the petition;
- (vi) Failureto provide the DOI with the materials as prescribed in paragraph 6(i) advertising materials and representations, of this Section or if the Attorney General finds that such materials or representations contain materially false or misleading representations or statements;
- (vii) Any conduct on the part of a school or designated official that does not comply with the regulations set forth herein.
- (2) Automatic revocation of approved school status.

If an approved school terminates its operations, approval will be automatically revoked as of the date of termination of the operations. If an approved school experiences a change of ownership that results in the change of control of the school, the school is required to file a new petition for school approval status. If the DOI finds that the approval should not be

continued, the DOI shall institute revocation proceedings in accordance with sub-paragraph 5(1) revocation on notice and (3) of this Section, revocation proceedings.

Revocation proceeding.

- (i) Should the DOI believe that an approved school is no longer entitled to approval, a proceeding shall be commenced by service of a notice of intent to revoke the approval upon the school's designated official. The notice of intent to revoke shall describe the grounds upon which the revocation is based and shall inform the school that it may, within (30) working days of the date of service of the notice, submit a written response to the revocation notice setting forth reasons why the approval should not be revoked and that the school may, at the time of filing the answer, request an interview before the DOI in support of the written response.
- If the school admits all of the allegations, or if the school fails to file a response within the thirty (30) day period, the DOI shall revoke the approval and shall notify the designated school official. If the school admits to the allegations or fails to answer within the thirty (30) day period, it shall have waived its right to appeal.
- (iii) If the school contests the allegations, then the school shall in its response provide all the information, including documentary evidence, that it wants to have considered, all of which shall be included in the record, on which the school's response is based.
- Should the school request an interview; the school shall be given notice of the date for the interview. At the discretion of the DOI, the interview may be recorded.
- The DOI shall issue a written decision either revoking the approval or (v) granting continued approval, including a discussion of the evidence of findings. The written decision shall be served upon the school or the designated school official together with the notice of the right to appeal.
- (vi) Any appeal of a revocation by the DOI shall be taken within fifteen (15) working days after the service of the written decision. The reasons for the appeal shall be stated in the notice of appeal and supported by a statement setting forth the grounds for contesting the revocation of the approval.

August 24, 2006 PAGE 26013

(4) Appeals.

Should an institution wish to appeal a decision denying or revoking approved status, such appeal shall be taken by filing a notice of appeal with the Office of the Attorney General. The notice shall be accompanied by a brief or statement setting forth the specific grounds for the appeal. The Attorney General at his discretion may rely solely on the record or may supplement the record with new evidence. The Attorney General shall confirm or modify the DOI decision in writing within sixty (60) days. The decision of the Attorney General shall constitute a final agency decision.

COMMONWEALTHREGISTER VOLUME 28 NUMBER 08 August 24; 2006 PAGE 26014

EMERGENCY AMENDMENTS TO SECTION 706 R OF THE IMMIGRATION REGULATIONS

Immigration Regulation 706 R is hereby repealed and re-enacted to read as follows:

- R. Alien Student Attendance Permit for Alien Minors Residing with Legal Guardian Elementary and Secondary School
 - 1. Enables an alien minor under the age of eighteen (18), who is the child of an alien parent(s) residing legally in the Commonwealth with a legal guardian, to remain in the Commonwealth while enrolled in and attending an educational institution within the Commonwealth provided the following conditions are adhered to:
 - a. The guardian is a resident or is in the Commonwealth pursuant to a Short-Term Business Entry Permit, Regular—Term Business Permit, Immediate Relative of a Non-alien Entry Permit, Foreign Press Entry Permit, Distinguished Merit Entry Permit, Minister of Religion Permit, Religious Missionary Permit, Diplomat or Consular Entry Permit, or Retiree Investor Entry Permit;
 - b. The guardian posts twenty thousand (\$20,000) as a cash bond with the Commonwealth Treasury or provides a letter of credit in the same amount from a financial institution agreeable to the Attorney General; the Attorney General shall have the right to reimbursement from the aforementioned funds for any expense incurred by the Commonwealth as a result of the presence of the minor alien, and the entire amount shall be forfeited at the discretion of the Attorney General should the Attorney general determine that the alien minor or an alien parent(s) or guardian has knowingly violated any term or condition described herein, or has committed a material violation of any Commonwealth immigration law or regulation. At a minimum, the financial security shall be sufficient to cover medical expenses of \$3000 (unless the child is covered by a medical insurance plan that will pay for expenses incurred in the CNMI) and repatriation of the child to his or her country of residence;
 - c. Alien minors from countries whose citizens or nationals are not required to obtain Visitor Entry Permits to enter the CNMI under section 703(B) are exempt from the requirements of section 706 R(b), above. The guardian must, instead, submit a sworn affidavit, satisfactory to the Attorney general, detailing the living arrangements for the alien minor and explaining how all costs of living, potential medical costs, as well as tuition and related educational expenses, will be met;
 - d. If the alien minor is enrolled full time in a CNMI Public School, the guardian must submit proof that the costs of schooling are paid in advance;

- The principal or president of the public or private school which the alien minor is e. attending must:
 - (1) Submit a sworn affidavit that he or she will: (i) fully cooperate with the office of the Attorney General in ensuring the alien minor and the alien parent(s) or guardian are complying with applicable Commonwealth immigration laws and regulations, including providing records of the alien minor which may have bearing on his or her immigration status as set forth in section 706 H; (ii) notify the Division of Immigration should the alien minor have excessive unexcused absences; (iii) acknowledge that a failure to do any of the above may result in the revocation of any accreditation or qualification of the school under this or any other Commonwealth immigration law or regulation; and
 - Verify to the Division of Immigration that all tuition and fees for the (2) upcoming school year have been paid for the alien minor in full if attending a public school, in advance of the student attending the school for the school year or any portion thereof.

2. Term of Permit-

- A permit issued under this section is dependent on the immigration status of the guardian and shall be valid for a period of thirty (30) days before the commencement of classes and while the student is enrolled in and attending the educational institution, and for thirty (30) days after graduation from High School. The Permit will be issued for twelve (12) months and must be renewed annually thereafter.
- Should the attending school have its qualification revoked for a violation of the b. enumerated requirements under Section 706 R(1)(d)(1) above, the alien minor student shall have fourteen (14) working days in which he or she must transfer to another qualified school or otherwise regularize his or her immigration status to an appropriate classification.
- Unless forfeited pursuant to these regulations, the cash bond or letter of credit described in section 706 R(1)(6) shall expire upon satisfactory final departure of the alien minor prior to expiration of the Permit, or upon other regularization of the child's immigration status. Any amounts outstanding shall be returned to the alien parents thereafter.

3. Fees-

There shall be a non-refundable application fee of one hundred (\$100), paid upon submission of the initial application, and a renewal fee of one-hundred dollars (\$100) which includes the annual alien registration fee of twenty-five dollars (\$25).

VOLUME 28 NUMBER 08

4. Revocation-

A permit issued under this section shall be revoked, and the alien minor shall be required to immediately depart the Commonwealth upon occurrence of any of the following events:

- a. The qualifying immigration status of the parent or guardian is no longer in effect or the parent(s) is ordered to depart the Commonwealth for any reason under Commonwealth law;
- b. The Attorney General determines that the guardian, or the alien child has knowingly violated any term or condition described herein, or has committed a material violation of any Commonwealth immigration law or regulation;
- c. The alien minor's guardian fails to inform the Division of Immigration in writing that the alien minor has withdrawn or transferred **from** the attending school or;
- d. The Attorney General determines that the presence of the alien minor is no longer in the best interest of the Commonwealth.

EMERGENCY AMENDMENTS TO SECTION 706 J OF THE IMMIGRATION REGULATIONS

Immigration Regulation 706 J is hereby repealed and re-enacted to read as follows:

J. Distinguished Merit Entry Permit — An alien who has residency in a foreign country, which he or she does not intend to abandon, who is of distinguished merit and ability, and who is coming temporarily to the CNMI to perform temporary service of an exceptional nature requiring such merit and ability, may remain in the CNMI for up to one year at the discretion of the Director of Immigration. This permit is renewable indefinitely. A permit holder under this section may legally engage in any work in the CNMI, including operating a business, so long as at least fifty percent of the work performed is in the permit holder's field in which he or she has achieved distinction. Aliens performing services on a contract basis either directly or indirectly for the Federal Government and who otherwise satisfy the requirements of this section may be granted a DMEP upon request by the contracting agency or employer.

PUBLIC NOTICE OF EMERGENCY REGULATIONS AND NOTICE OF INTENT TO ADOPT AMENDMENTS TO THE IMMIGRATION REGULATIONS AND ALIEN LABOR RULES AND REGULATIONS

EMERGENCY: The Department of Labor finds that the public interest requires that there be an increase in the fee to be paid to the Commonwealth Treasury to seek exemption relief from the moratorium on nonresident worker hiring as set forth in 3 CMC § 4601. It will also change the procedure to be followed to file an application for an exemption and establish that a Critical Services exemption shall be good for no more than one year unless renewed pursuant to the same procedures required to obtain the initial exemption. Imposition of these amendments are necessary to promote the aims of the moratorium by discouraging applications that do not meet the strict exemption requirements set forth in 3 CMC § 4601. These amendments may also increase revenue to the Commonwealth Government which is critical during these challenging economic times. The Department of Labor further finds that under 1 CMC § 9104(b), the public interest mandates adoption of these regulations upon fewer than thirty (30) days notice, and that these regulations shall become effective immediately after filing with the Commonwealth Register, subject to the approval of the Attorney General and the concurrence of the Governor, and shall remain effective for 120 days.

REASONS FOR EMERGENCY: It was recently determined that a significant number of applications for exemption from the moratorium were being filed, and that in many cases, no fees were being collected by the Commonwealth Government. This has encouraged the filing of inappropriate applications, taxing already strained government personnel and resources. Given the difficult economic circumstances facing the Commonwealth Government, and the community as a whole, the Department of Labor finds that, in the interest of the public, it is necessary that these regulations are approved and adopted immediately.

INTENT TO ADOPT: It is the intent of the Department of Labor to adopt these emergency amendments to the Alien Labor Rules and Regulations, as permanent, pursuant to 1 CMC § 9104(a)(1) and (2). Interested persons may submit written comments on these emergency recommendations to Gil San Nicolas, Secretary of Labor, Department of Labor, Afetnas Square Building, San Antonio, Saipan, MP 96950 or by fax to (670) 236-0990.

Submitted by:	GilM, San Nicolas	<u>07/27(06</u> Date
Concurred by:	Benigno R. Fitial Governor	8/03/06 Date
Received by:	Esther Fleming Special Assistant for Administration	8/04/04 Date

Filed and Recorded by:

Commonwealth Register

8/4/04

Pursuant to 1CMC §2153, as amended by Public Law 10-50, the emergency rules and regulations attached hereto have been reviewed and approved as to form and legal sufficiency by the CNMI Attomey General's Office.

___ day of Jay, 2006. Dated this 3

Matthew T. Gregory Attorney General

PUBLIC NOTICE EMERGENCY AMENDMENTS TO THE IMMIGRATION REGULATIONS AND ALIEN LABOR RULES AND REGULATIONS.

This amendment is promulgated in accordance with the Administrative Procedure Act, 1 CMC § 9101, et seq. The Department of Labor is amending the Alien Labor Rules and Regulations that were published in the Commonwealth Register, Vol. 26, No. 06, June 24,2004.

Citation of

Statutory Authority: The Secretary of Labor is authorized to promulgate regulations

regarding the requirements for employment of alien workers under

3 CMC § 4424(a)(1).

Short Statement of Goals and Objectives:

The emergency amendments to the Alien Labor Rules and Regulations Sections V and XIV will increase the fee charged to employers seeking an exemption **from** the moratorium on nonresident worker hiring under Immigration classification 706 (K). It will also change the procedure to be followed to file an

application for an exemption.

Brief Summary of the Proposed New Section:

These emergency amendments are promulgated to:

Increase the fee for processing an application for an exemption from the moratorium on nonresident worker hiring (3 CMC § 4601) from \$200.00 to \$500.00, and to clarify that the fee is mandatory and non-refundable, whether or not the application is granted. The amendments also change the procedure for submitting applications and establish that a Critical Services exemption shall be good for no more than one year unless renewed pursuant to the same procedures

required to obtain the initial exemption.

For Further

Information Contact: Dorothy E. Hill, Assistant Attorney General for the Department of

Labor, Office of the Attorney General, telephone (670) 236-0910

or facsimile (670) 236-0990.

Citation of Related and/or Affected Statutes, Rules and Regulations, and Orders:

The emergency amendments affect the Alien Labor Rules and

Regulations Sections V and XIV.

Submitted by:

07/27/06 Date

Secret of Labor

NOTISIAN PUPBLIKU POT ENSIGIDAS NA REGULASION YAN NOTISIAN INTENSION PARA U MA'ADOPTA I MAN MA'AMENDA NA REGULASION IMIGRASION YAN AREKLAMENTO YAN REGULASION HOTNALERUN ESTRANGHERU

Ensigidas: I Dipåttamenton I Hotnaleru a sodda mås na I interes pupbliku a rekomenda na **u mahåtsa** I **åpas ni** para **u ma'åpsi** I Commonwealth Treasury yanggen para **u** madespensa ni I moratorium yanggen para u ma'emplea I hotnalerun estrangheru siha ni mamensiona gi lai 3 CMC Seksiona 4601. Siempre lokkue a tulaika I areklamento ni para **u** matatiyi yanggen para **u** mana **hålom** (file) I aplikasion pot I dispensasion ya **u** ma'establesi tiempon-ña I dispensasion Setbisiun Kritikåt na maolek ha' para I un åñu na tiempo solu u mariñueba konsiste na parehu manisisita na areklamento yanggen para u machule' solamente I despensasion. Chinanda este siha na amendasion nisisario para u ma'atbånsa I dinisehan I moratorium yanggen madeskonsuela I aplikasion yanggen ti makumple I man rekto siha na nisisidåt I dispensasion ni mamensiona gi lai 3 CMC Seksiona 4601. Siña lokkue este siha na amendasion ma'adilanta I fengkas para I Gubietnamenton I Commonwealthni gof kritikåt durånten este tiempon chinandan ekonomia. I Dipåttamenton I Hotnaleru a sodda mås papa I lai 1 CMC Seksiona 9104 (b), na I interes pupbliku a månda I inadoptasion este siha na regulasion siha menos di trenta (30) diha siha na notisia, ya este siha na regulasion u fan efektibu ensigidas despues di mapolu gi Rehistran I Commonwealth, suhetu gi I inaprueban I Abugådu Heneråt yan I kinonfotmen I Gubietno, ya debi di u efektibu este siento bente (120) di ia siha.

Rason Para I Ensigidas: Nuebu ha' anai maditetmina na loskuåntos siha na aplikasion para I dispensasion I moratorium man mana fan hålom (file), ya meggai na kåosa siha, tåya åpas man marikohe' ni Gubietnamenton I Commonwealth. I ti man propio na aplikasion sumu'on mona I marektuyi I åpas yanggen para u mana fanhålom (file) I aplikasion pot rason na a'annok na I gubietnamento a nisisita para u adilanta I empleao yan I fengkas niha. Sigun I maneran I ekonomia ni ta chåchanda mona gi Commonwealth, yan enteramente I komunidåt, I Dipåttamenton I Hotnaleru a sodda mås na, gi I interes pupbliku, nisisårio na u maprueba yan ma'adopta ensigidas este siha na regulasion siha.

Intension Para U Ma'adopta: Intension I Dipåttamenton I Hotnaleru para u ma'adopta este na amendasion ensigidas para I Areklamento yan Regulasion Hotnalerun Estrangheru, petmanente, sigun I lai 1 CMC Seksiona 9104 (a)(1) yan (2). I man enteresåo na petsona siña munahalom tinige' opinion pot I ensigidas na rekomendasion guatto as Gil San Nicolas, Sekritårion I Hotnaleru, gi Dipåttamenton I Hotnaleru, gi Afetnas Square Building, gi San Antonio, giya Saipan MP, 96950 osino fax guatto gi (670) 236-0990.

Ninahålom as:	
Gil M. San Nicolas Sekritårion I Hotnaleru	Fecha
Kinonfotma as: Benigno R. Fitial Gubietno	Fecha
Maresibe' as: Esther Fleming Espesiåt Na Ayudånte Par	
Pinelo' yan Rinikot as: Bernadita B. Dela GRehistradoran I Co	Fecha S 21 Ub
	nenda ni Lai Pupbliku 10-50, I ensigidas na he'che'ton esta men ma'ina yan ma'aprueba pot an I Abugådu Heneråt I CNMI.
Mafecha gi este mina	na ha'åne, gi Agostu, 2006.
Matthew T. Gregory Abugådu Heneråt	

NOTISIAN PUPBLIKU ENSIGIDAS NA AMENDASION PARA I REGULASION IMIGRASION SIHA YAN AREKLAMENTO YAN REGULASION HOTNALERUN ESTRANGHERU

Este na amendasion ma'establesi para u **kininsiste** ni **Akton** Areklamenton **Atministrasion**, **lai** 1 CMC Seksiona 9101, et. seq. I **Dip*attamenton** I **Hotnaleru** a amemenda I Areklamento yan Regulasion **Hotnalerun** Estrangheru siha ni mapupblika **gi** Rehistradoran I Commonwealth, **Baluma** 06, Numiru 06, gi **Junio** 24,2004.

Annok I Aturidåt I Lai:

I Sekritårion I Hotnaleru ma'aturisa para u establesi regulasion siha ni tineteka I nisisidåt siha para u ma'emplea I hotnalerun estrangheru siha papa I lai 3 CMC Seksiona 4424 (a)(1).

Kadada Na Mensiihe Pot Finiho yan Diniseha:

I ensigidas na **amendasion** para I areklamento yan regulasion I hotnalerun estrangheru siha yan **Regulasion** Seksiona V yan XIV siempre **mahåtsa** I **åpas** para I man manempleleha **ni** marekomemenda dispensasion para I moratorium I para u **maempleha** hotnalerun estrangheru siha papa **Klasifikasion Imigrasion** 706 (K). Siempre lokkue a tulaika I areklamento ni para u matatiyi yanggen para u manahalom I aplikasion despensasion.

Kadada Na Mensiihe Pot I Nuebu Na Seksiona Ni Mapropone:

Este ensigidas **na** amendasion siha man maestablesi para:

U mahåtsa I åpas para u machogue I aplikasion dispensasion para I moratorium I para u ma'empleha hotnalerun estrangheru siha (3 CMC Seksiona 4601) ginen \$200.00 para \$500.00, ya para u klarifika na debi di u ma'apåsi ya ti refundable, maseha ma'aprueba pat ti ma'aprueba I aplikasion. Siempre lokkue a tulaika I areklamento ni para u matatiyi yanggen para u mana hålom (file) I aplikasion pot I dispensasion ya u ma'establesi tiempon-ña I dispensasion Setbisiun Kritikåt na maolek ha' para I un åñu na tiempo solu u mariñueba konsiste na parehu manisisita na areklamento yanggen para u machule' solamente I despensasion.

PAGE

Para Mås Infotmasion Ågang:	Si Dorothy E. Hill, Ayudånten I Dipåttamenton I Hotnaleru, gi Ofis numirun tilifon (670) 236-0910 os 0990.	sinan I Abugådu Heneråt,
Annok I Man Achule' Yan/pat Man Inafekta Na Lai, Areklamento, Regulasion yan Otden Siha:	I ensigidas na amendasion siha a Regulasion Hotnalerun Estrangher	<u> </u>
Ninahalom as:	Gil M. San Nicolas Sekritårion I Hotnaleru	Fecha

EMERGENCY AMENDMENTS TO Sections V and XIV subsection E of the Alien Labor Rules and Regulations

Section V(A) is amended to read:

Only the Governor may approve an exemption under 3 CMC § 4601(d) and (e). Any request for these exemptions shall be put in writing and forwarded, with supporting documentation to substantiate the exemption criteria, to the Office of the Governor. and a nonrefundable, nontransferable fee of \$500.00 for each exemption requested, to the Director of Labor for initial certification. After certification that the basic exemption criteria has been met. the Director of Labor will forward the request and accompanying documentation to the Governor for final consideration.

Section **V(B)** is amended by adding the following sentence to the end of the section:

An exemption request granted under 3 CMC §4601(d), Major New Developments, shall remain in effect for the duration of the project and need not be renewed on an annual basis.

Section V(C), first paragraph is amended to read:

For an exemption under 3 CMC § 4601(e), Critical Services, only those positions that are professional in nature to be filled by individuals with extensive training in traditional education institutions, technical training certification courses or on-job experience in the field shall be considered. An exemption under 3 CMC § 4601(e), Critical Services, shall never be granted for unskilled or semi-skilled semi-skilled positions. An exemption granted under this provision shall be effective for no more than one year, but may be renewed by submitting a renewal request for an exemption in the same manner as an initial application. It shall be the requesting employer's burden to satisfy produce the proper-documentation necessary to demonstrate that it has met the following mandatory criteria:

Section XIV(E) is amended to read:

<u>A new or renewal application for</u> Exemption Relief from P.L. 11-6, as amended, must be accompanied by a nonrefundable, nontransferablefee of \$500.00 for each exemption requested.

PUBLIC NOTICE

PROPOSED AMENDMENTS TO THE RULES AND REGULATIONS GOVERNING THE GROUP HEALTH INSURANCE PROGRAM

The Board of Trustees of the NMI Retirement Fund, pursuant to its authority under 1 CMC \$8424, hereby gives notice to the general public and particularly members of the CNMI Group Health Insurance Program of the proposed amendments to the Rules and Regulations Governing the Group Health Insurance as published in the Commonwealth Register as adopted in Volume 28, Number 6, at pages 25883 through 25912 (effective June 29, 2006). These proposed amendments would revise the Drug Formulary and increase the premium contributions paid by employees by an additional \$1.10 under Article 10, Section 10.15.

The Board is soliciting comments regarding these proposed amendments to the rules and regulations in accordance with 1 CMC §9104(a). Copies of these proposed amendments may be obtained at any of the NMI Retirement Fund offices on Saipan, Tinian and Rota. Written comments should be submitted to the Administrator, NMI Retirement Fund, P.O. Box 501247 CK, Saipan, MP 96950-1247. Comments must be received by the Fund within 30 days of the date this notice is published in the Commonwealth Register.

JOSEPH & REYES Chairman, Board of Trustees Administrator, NMI Retirement Fund **NMI** Retirement Fund

Reviewed for Legal Sufficiency by Legal Counsel for the NMI Retirement Fund:

The proposed amendments to the rules and regulations attached hereto have been reviewed and approved as to form and legal sufficiency by the Legal Counsel for the NMI Retirement Fund.

AMES É. HOLLMAN

Legal Counsel, NMI Retirement Fund

PAGE 26029 August 24,2006

Dated this ______day of July 2006.

Certification by the Office of the Attorney General:

Pursuant to 1 CMC §2153(e) and ■ CMC §9104(a)(3), the proposed amendments attached hereto have been reviewed and approved as to form and legal sufficiency by the CNMI Attorney General and shall be published pursuant to his authority under 1 CMC §2153(f).

Dated this <u>24</u> day of July 2006.

Attorney General

Filed by:

Commonwealth Register/Secretary

Received at the Governor's Office by:

Date:

Special Assistant to the Governor for Administration

NOTISIA PARA I PUPBLIKU PUT I MA PROPOPONE SIHA NA AMENDASION PARA I AREKLAMENTO YAN REGULASION NI GINIBEBIETNA PUT I PRUGRAMA GROUP HEALTH INSURANCE

I Board of Trustees i NMI Retirement Fund sigun gi aturidat i Board gi papa 1 CMC §8424, ginen este ha infofotma i pupbliku henerat van patikulatmente avu siha na membru gi prugraman i Group Health Insurance pot i ma propopone siha na amendasion para i areklamento yan regulasion ni ginibebietna put i prugraman Group Health Insurance, ni ma pupblika gi Rehistran Commonwealth ni ma adopta gi Baluma 28, Numiru 6, qi pahina 25883-25912 (efektibu qi Junio 29, 2006). Este siha na amendasion siempre ha nbisa i Drug Formulary yan para u ma hatsa i premiu ni ma apapasi nu I emploivao ta'lo \$1.10 gi papa Atikulu 10. Seksion 10.15.

I Board ha sosoyo hayi malago para u fana'halom komentu rekomendasion pot i mapropopone siha na amendasion gi Areklamento yan Regulasion sigun gi ■ CMC §9104(a). Kopian este i mapropopone siha na amendasion sina manmachule gi maseha amanu siha na ofisinan NMI Retirement Fund giya Saipan, Tinian yan Luta. Todo manmatugi na komentu debi na u ma submite guato gi ofisinan i Administradot i NMI Retirement Fund, gi P.O.Box 501247 CK, Saipan, MP 96950-1247. Todo komentu debi na marisibi nu i Fund gi halom trenta (30) dias desde i primet na pupblikasion este na nutisia gi halom I Rehistran Commonwealth.

Mafecha guine na dia i mina' / gi Julio 2006.

JOSEPHIC, REYES

Chairman, Board of Trustees NMI Retirement Fund

Fecha: _7/1/06

Administradot, NMI Retirement Fund

August 24,2006

Rinibisa yan Settefikasion i Legal Counsel para i NMI Retirement Fund:

I prinipone siha na amendasion gi areklamento yan regulasion ni chechetton guine, esta manmaeksaminan maolek yan manma apreba nui Legal Counsel i NMI Retirement Fund.

AMES E. HOLLMAN

Legal Counsel, NMI Retirement Fund

PAGE 26031

Settefikasion i Ofisinan Abugadon Henerat CNMI: Sigun gi ■ CMC §2153 yan 1 CMC §9104(a)(3), i areklamento yan regulasion siha ni chechetton guine esta manma ribisa yan ma apreba ginen i Ofisinan Abugadon Henerat CNMI ya u ma pupblika sigun gi aturidat i Abugadon Henerat gi papa 1 CMC §2153(f). Mafecha guine na dia i mina' ____ gi Julio 2006. MATTHEW T. GREGORY Abugadon Henerat Rinekot As: Rehistradoran Kotporasion Commonwealth gi Sankattan Siha na

> **ESTHER S. FLEMING** Delegadon I Gobietno

Commonwealth gi Sankattan Siha na

Islas Marianas

Islas Marianas

Rinisibe As:

Fecha:

NORTHERN MARIANA ISLANDS RETIREMENT FUND

PROPOSED AMENDMENTS TO THE RULES & REGULATIONS **GOVERNING THE GROUP HEALTH INSURANCE PROGRAM**

Citation of Statutory Authority:

The Board of Trustees of the NMI Retirement Fund proposes to make amendments to the CNMI Group Health and Life Insurance Trust Fund rules and regulations (Plan Description) pursuant to its authority under 1 CMC §8424.

Statement of Goals and Objectives:

The Program is underwritten exclusively by the CNMI Government to provide an affordable health insurance plan for the benefit of CNMI government employees. The Program is designed to be self sufficient, and therefore. must establish rates sufficient to pay for administration of the Program and particularly claims incurred by Enrollees in the Plan. The goals and objectives of these rules are to provide guidelines in managing a bona fide benefit plan that complies with local and federal laws.

Brief Summary of the **Proposed Amendments:**

The proposed amendments to the Plan Description would revise the Drug Formulary by implementing the Drug Formulary of its Third Party Administrator, Aetna Global Benefits, and would increase employee premiums under Article 10, Section 10.15, by an additional \$1.10 for pharmaceutical services to be provided by Aetna due to the falling through during contract negotiations between the Program and PharmaCare for Pharmacy Benefits Management.

For Further Information Contact:

Karl T. Reves, Administrator NMI Retirement Fund or Dolores S. Moore, GHLITF Director

P.O. Box 501247 CK Saipan, MP 96950-1247

Telephone: (670) 322-3863 / Facsimile: (670) 664-8080

Citation of Related and/or Affected Statutes. Regulations and Orders:

The Rules and Regulations Governing the Group Health Insurance Program as previously published in the Commonwealth Register as adopted in Volume 28, Number 6, at pages 25883 through 25912 (effective June 29, 2006), will be amended specifically Article 10, Section 10.15 (Chart - Contribution Rates) and the Drug Formulary.

FUNDON RITIRÅON I SANKATTAN SIHA NA ISLAN MARIANA

MAN MAPROPONE I AMENDASION SIHA PARA I AREKLAMENTO YAN REGULASION NI TINETEKA I PROGRÅMAN GROUP HEALTH INSURANCE

Annok I Aturidåt I Lai:

I Kuetpon I <u>Trustees</u> I **Fundon** I **Ritiråo gi** Sankattan Siha na Islan Mariana, (NMI Retirement Fund) a propopone para u ma'establesi amendasion siha para I areklamento yan regulasion siha ni tineteka I CNMI Group Health and Life Insurance Trust Fund (plan discription) sigun I aturidåt papa I 1 CMC Seksiona 8424.

Mensåhen Finiho' Yan Diniseha:

Matugi I progråma solamente nu I Gobietnamenton I CNMI pot para u guaha sånu na plånun Health Insurance ni malangat (affordable) para benifisiun I empleåo I gobietnamenton I CNMI. I programa madesigna para u sufisienten maisa ya debi di u establesi sufisiente na åpas para I progråma ni para u ma'atministreha patikulåtmente I claims incuured nu I empleåo siha gi hålom I plånu. I finiho' yan diniseha siha gi regulasion siha pot para u giha mona I manehånten I plånun bonafide benefit ni umafakcha yan I lai siha gi lukåt yan federåt.

Kada'da' Na Mensåhe Pot I Man Mapropone Na Amendasion Siha:

I man mapropone **na** amendasion siha para I **madeskribi** Na **Plånu** para u maribisa I Drug: Formulary gi Third Party Administrator, I Aetna Global Benefits yan para u fan mahåtsa I premium I empleåo siha gi papa I Attikulu 10, Seksiona 10.15 nu I ma'omenta \$1.15 para I **setbisiun** pharmaceutical ni para u maprobeniyi ni Aetna pot I pineddong gi durånten I nigosiun I kontråta gi entalo I progråma yan I PharmaCare para I benifisiu siha gi manehånten I Pharmacy.

Para Mås

Karl T. Reyes, Atministradot

Infotmasion Ågang: Fundon Ritirão gi Sankattan Siha Na Islan Mariana osino

Dolores S. Moore, Direktot I GHLITF

P.O. Box 501247 CK Saipan, MP 96950-1247

Numirun Tilifon: (670) 322-3863 / Facsimile: (670) 664-8080

Annok I Man Achule' I Areklamento yan Regulasion siha ni Ginibiebetna I Programan Otden Siha:

Yan/pat Inafekta na I Group Health Insurance ni esta mapupblika gi Rehistran I Lai, Regulasion van Commonwealth ni ma'adopta gi Baluma 28, Numiru 6, gi Påhinan

25883 esta 25912 (efektibu gi Junio 29, 2006), siempre

ma'amenda spesifikåtmente Attikulu 10. Seksiona 10.15 (Chart –

Contribution Rates) yan I Drug Formulary.

Proposed Amendments to Article 10, Section 10.15:

Contribution Rates Rates Effective July 1, 2006

Type of Enrollment	Enrollment Code Number	Contribution Distribution	Retiree Semi-monthly Cost	Active Bi-weekly Cost
Single	1	Government Contribution Subscriber Contribution Total Premium	\$14.66 <u>\$55.34</u> <u>56.44 \$70.00 <u>71.10</u></u>	\$13.55 <u>\$51.45</u> <u>52.55</u> \$65.00 61.10
Couple	2	Government Contribution Subscriber Contribution Total Premium	\$ 26.53 <u>\$103.47 104.57</u> \$130.00 <u>131.10</u>	\$ 24.51 \$ 90.49 91.59 \$115.00 <u>116.10</u>
Family	3	Government Contribution Subscriber Contribution Total Premium	\$ 50.49 <u>\$139.51 140.61</u> \$1 90.00 <u>191.10</u>	\$ 46.60 \$133.40 134.50 \$180.00 181.10

Enrollees' premium rates may vary from time to time. In the event an increase in premiums is necessary, the Board of Trustees of the NMI Retirement Fund will promulgate this increase in the Commonwealth Register pursuant to the Administrative Procedures Act.

August 24,2006 PAGE

COMMONWEALTH REGISTER

Group Health and Life Insurance Trust Fund

DRUG FORMULARY

Effective July 1,2006

This list is designed to serve as a reference guide and assist in the selection of cost effective pharmaceutical products. The formulary is not intended to be a substitute for your clinical knowledge and judgment. In all cases, the prescriber is expected to select appropriate drug therapy for the individual patient and provide high quality healthcare. Preferred Brand Medications are listed below. All covered generic medications are preferred and covered at 20% coinsurance for participating providers, 30% for non-participating providers. Brand medications that have a generic equivalent are covered at 20% coinsurance for participating providers, 30% for non-participating providers with the member also absorbing the cost difference between the brand and generic alternative. Non-formulary Brand medications require a 50% member coinsurance amount.

NON-FORMULARY DRUGS	FORMULARY ALTERNATIVE(S)
A/T/S	Erythromycin
Accutane	Amnesteem
	Claravis
	<i>Isotretinoin</i>
	Sotret
Aceon	Accupril
	Altace
	Benazepril
	Captopril
	Enalapril
	Lisinopril
	Quinapril
Aciphex	Omeprazole
	Prevacid
	Protonix
Actigall	Ursodiol
Acuflex	APAP W/Codeine
Acular LS	Alomide
	Dexamethasone
	Fluorometholone
	Livostin
	Patanol Patanol
	Prednisolone
	Zaditor
Adalat CC	Nifedipine CC
Adderall	<u>Amphetamine</u>
	<u>Dextroamphetamine</u>
Adoxa / PAK	Doxycycline

NON-FORMULARY DRUGS	FORMULARY ALTERNATIVE(S)
Advance Diebetic Supplies	Accu-Chek / Simplicity
••	Chemstrip BG
	FastTake
	One Touch / Ultra
	Sure Step / Pro
Aero Otic HC	Acetasol HC
Aerobid / M	Azmacort
	Flovent / HFA
	Pulmicort
Alamast	Alomide
	Livostin
	Patanol
	Zaditor
Albalon	Naphazoline
Alcortin	Hydrocortisone Valerate
Aldactazide 25/25mg	Spironolactone / HCTZ
Aldactone	Spironolactone
Alesse	Aviane
	Lessina
	Levora
	Nordette
	Portia
Alinia	Metronidazole
Alocril	Patanol
	Zaditor
Altoprev	Lipitor
•	Lovastatin
	Vytorin
Amerge	Imitrex
	Maxalt / MLT
	Zomig /- ZMT
Amevive	Dovonex
	Tazorae
Anamantle HC	<i>Hydrocortisone</i>
	Lidocaine
Anaprox / DS	Arthrotec
,	Etodolac
	Fhirbiprofen
	Nabumetone
	Naproxen
	Oxaprozin

August 24,2006

NON-FORMULARY DRUGS	FORMULARY ALTERNATIVE(S)
Anaspaz	Dicyclomine
•	Glycopyrrolate
	Hyoscyamine
	Pro-Banthine
Ancobon	Diflucan
	Fluconazole
	Griseofulvin
	Ultramicrosize
	Itraconazole
	<u>Ketoconazole</u>
	Lamisil
	Nystatin
	Sporanox
Android	Androderm
	Androgel
·	Testim
Ansaid	Arthrotee
	Etodolac
	Flurbiprofen
	Nabumetone Nabumetone
	Naproxen
	Oxaprozin
Ascensia	Accu-Chek / Simplicity
	Chemstrip BG
	FastTake
	One Touch / Ultra
	Sure Step / Pro
At Last	Accu-Chek / Simplicity
	Chemstrip BG
	FastTake
	One Touch / Ultra
	Sure Step / Pro
Atacand / HCT	Cozaar
	Diovan / HCT
·	Hyzaar
Atarax	Hydroxyzine HC1
Ativan	Lorazepam
Atrovent Nasal Spray	Ipratropium Nasal Spray
Avalide	Diovan HCT
	Hyzaar
Avapro	Cozaar
1 Trupio	Diovan

NON-FORMULARY DRUGS	FORMULARY ALTERNATIVE(S)
Avar Gel	Differin
	Sulfacetamide Sodium / Sulfur
	<i>Tretinoin</i>
Avelox / ABC	Ciprofloxacin
·	Levaquin
Aventyl	Nortriptyline
Avinza	Actiq
	Hydrocodone / APAP
	Hydromorphone
	MS Contin
	MSIR
	Oxycodone / APAP
	Oxycontin
Axert	Imitrex
	Maxalt / MLT
	Zomig / ZMT
Axid	Cimetidine
	Ranitidine
Aygestin	Norethindrone Acetate
Azelex	Avita
	BenzaClin
	Clindamycin
	Differin
	Erythromyein
	Retin-A Micro
	Tazorac
	Tretinoin .
B-D Test Strips	Accu-Chek / Simplicity
	Chemstrip BG
	FastTake
	One Touch / Ultra
	Sure Step / Pro
B-D Ultra Fine	One Touch / UltraSoft
	Softclix
	Soft Touch
Bactrim / DS	SMZ-TMP / DS
Baraclude	Epivir HBV
Benadryl	Diphenhydramine
Benicar / HCT	Cozaar
	Diovan / HCT
	Hyzaar

NON-FORMULARY DRUGS	FORMULARY ALTERNATIVE(S)
Bentyl	Dicyclomine
	Glycopyrrolate
	Hyoscyamine
	Pro-Banthine
Benzamycin / PAK	BenzaClin
-	Duac
	Erythromycin-Benzoyl
Betagan	Alphagan P
	Azopt
	Betaxolol
	<i>Brimonidine</i>
	Levobunolol
	Lumigan
	Timolol / XE
	Xalatan
Betapace	Sotalol
Bio-Throid	Levothroid
•	Levothyroxine
	Levoxyl
	Synthroid
	Unithroid
Bleph-10	Sodium Sulfacetamide
Boniva	Actonel
	Fosamax
Bravelle	Follistim AQ
	Gonal-F
	Repronex
Brevicon	Necon
	Nortrel
BuSpar	Buspirone
Calafol Rx	Glutofac ZX
	Nu-Iron-V
·	Vitafol
Calan / SR	Verapamil / SR
Campral	Antabuse
Cantil	Dicyclomine
	Glycopyrrolate
	Hyosycamine
	Pro-Banthine
Capital W-Codeine	APAP W/Codeine

NON-FORMULARY DRUGS	FORMULARY ALTERNATIVE(S)
Capoten	Accupril
	Altace
	<i>Benazepril</i>
	<u>Captopril</u>
	Enalapril
	<i>Lisinopril</i>
	Quinapril
Capozide	Accuretic
_	Benazepril / HCTZ
	Captopril / HCTZ
	Enalapril / HCTZ
	Lisinopril / HCTZ
	Quinaretic
Carafate Tabs	Sucralfate
Cardene / SR	Felodipine ER
	Nifedipine
	Norvase
	Plendil
	Verelan PM
Cardizem / CD / LA / SR	Diltiazem
	Felodipine ER
	Norvasc
	Plendil
	Verelan PM
Cardura	Doxazosin
Cataflam	Arthrotec
	Diclofenac Potassium
	Etodolac
	Nabumetone
	Oxaprozin
Catapres	Clonidine
Ceclor	Cefadroxil
	Cefpodoxime
	Cefuroxime
	Cefzil
	Cephalexin
	Cephradine
	Omnicef
	Vantin
	} v (M10111

NON-FORMULARY DRUGS	FORMULARY ALTERNATIVE(S)
Cedax	Cefadroxil
	Cefpodoxime
	Cefuroxime
	Cefzil
	Cephalexin
	Cephradine Cephradine
	Omnicef
	Vantin
Ceftin Tabs	Cefuroxime
Cenestin	Estropipate
	Premarin
Cenogen Ultra	NatalCare
Centany	Mupirocin
Cerefolin	V-C Forte
	Vicon Forte
Chromagen / FA / Forte	Ferotrinsic
	Foltrin
•	Trinsicon
Cialis	Caverject
	Edex
	Viagra
Ciloxan	Ofloxacin
	Vigamox
Cipro / XR	Ciprofloxacin
Cipro HC Otic	Acetic Acid / HC Otic
•	Ciprodex
	Floxin Otic
	Neomycin / Polymyxin / HC Otic
Clarinex / D	Allegra / D
	Zyrtec / D
Clenia	Differin
	Sulfacetamide Sodium / Sulfur
	Tretinoin
Cleocin Caps 150mg, 300mg	Clindamycin
Cleocin-T	Clindamycin Phosphate
	Finacea
	MetroCream
	MetroGel
	MetroLotion
	Metronidazole
	Sodium Sulfacetamide / Sulfur
	Domain Dagacolamac - Isagar

NON-FORMULARY DRUGS	FORMULARY ALTERNATIVE(S)
Clindagel	Clindamycin Phosphate
	Finacea
	MetroCream
	MetroGel
	MetroLotion
	Metronidazole
	Sodium Sulfacetamide / Sulfur
Clindesse	Cleocin Vaginal Cream
	<u>Clindamax</u>
Clindets	Clindanycin Phosphate
	Finacea
	MetroCream
	MetroGel
	MetroLotion
	Metronidazole
	Sodium Sulfacetamide / Sulfur
Clinoril	Arthrotec
	Etodolae
	Nabumetone
	Oxaprozin
	Sulindae
Clobex	Clobetasol Propionate
Clomid	Clomiphene
Cognex	Aricept
	Exelon
	Namenda
<u> </u>	Reminyl
Coly-Mycin M	Tobi
	<i>Tohramycin</i>
Coly-Mycin S	Acetic Acid / HC Otic
	Ciprodex
	Floxin Otic
	Neomycin / Polymyxin / HC Otic
Colyte / Flavored	PEG 3350 / Electrolytes
Combunox	Oxycodone / APAP
	Oxycodone / ASA
Compazine	Prochlorperazine
Concerta	Metadate CD
	Metadate ER
	Methylin ER
	Methylphenidate ER
	Ritalin LA

NON-FORMULARY DRUGS	FORMULARY ALTERNATIVE(S)
Cortane-B-Otic	Acetic Acid/HC Otic
	Ciprodex
	Floxin Otic
	Neomycin / Ploymyxin / HC Otic
Cortisoprin Oint.	Bacitracin / Polymyxin / Neomycin / HC
Cortisporin / TC Otic	Acetic Acid / HC Otic
	Ciprodex
	Floxin Otic
	Neomycin / Polymyxin / HC Otic
Cosopt	Alphagan P
	Azopt
	Betaxolol
	Brimonidine
	Levobunolol
	Lumigan
	Timolol / XE
	Xalatan
Covera-HS	Diltiazem
	Felodipine ER
	Norvasc
	Plendil
	Verelan PM
Crestor	Lipitor
	Lovastatin
	Vytorin
Cutivate	Aclovate
	Alclometasone
	Betamethasone Valerate
	Elocon
	Fluocinolone
	Acetonide
	Fluticasone
	Hydrocortisone Valerate
	Mometasone Furoate
	Triameinolone Acetonide
Cymbalta	Effexor / XR
Cystospaz / M	Dicyclomine
	Glycopyrrolate
	Hyoscyamine
	Pro-Banthine
Cytotec	Misoprostol
D.H.E. 45	Ergomar
	Isometheptene APAP / Dichloralphenazone
	Migranal

NON-FORMULARY DRUGS	FORMULARY ALTERNATIVE(S)
Darvocet A500	Propoxyphene / APAP
Darvocet-N 100	Propoxyphene-N
	Acetaminophen
Darvon	Propoxyphene HC1
Darvon Compound	Propoxyphene / APAP
Daypro	Oxaprozin
Delatestryl	Androderm
	Androgel
	Testim
Deltasone	Prednisone
Demadex	<i>Torsemide</i>
Demerol	Meperidine HC1
Demulen	Cesia
Beindien	Cyclessa
	Estrostep Fe
	Necon
	Nordette
	Portia
	Trivóra
	Velivet
	Yasmin
	Zovia
Depo-Subq Provera	<i>Leuprolide</i>
	Lupron / Depot
Depo-Testosterone	Androderm
	Androgel
	Testim
Desogen	Apri
_ :::8::::	Solia
Desowen	Desonide
Desyrel	Trazodone
Dexacidin	Neomycin / Ploymyxin / Dexamethasone
Diabeta	Actos
Diaocta	Amaryl
	Avandamet
	Avandia
	Glipizide √ ER
	Glucotrol XL
	Glucovance
	Glyburide
	Glyburide / Metformin
	Geyom too : Integoriment
	1 *
Didronel	Metformin / ER Actonel


NON-FORMULARY DRUGS	FORMULARY ALTERNATIVE(S)
Dilacor XR	Diltiazem XR
Diprosone	Betamethasone
21p1 000ne	Dipropionate
Dispermox	Amox / K Clavulanate
Disperinox	Amoxicillin
	Ampicillin
	Augmentin / ES / XR
	Dicloxacillin
Ditropan	Detrol / LA
Diaopan	Ditropan XL
	Oxybutynin Chloride
	Oxytrol
Diuril	Chlorothiazide
Dolobid 500mg	Diffunisal
Domeboro	Acetic Acid / HC Otic
Domeooro	Ciprodex
	Floxin Otic
	Neomycin / Polymyxin / HC Otic
Dostinex	Bromocriptine
	Pergolide
Duoneb	Atrovent
	Combivent
	Ipratropium
	Spiriva HandiHaler
Duratuss / GP / HD	Guaifenesin / Pseudoephedrine
	Guaifenesin / Phenylephrine
Duricef	Cefadroxil
	Cefuroxime
	Cefzil
	Cephalexin
	Omnicef
Dyazide	Triamterene / HCTZ
Dynabac	Biaxin / XL
	Erythromycin
	Zithromax
EC-Naprosyn	Arthrotee
	Etodolae
	Nabumetone
	Naproxen
,	Oxaprozin — — — — — — — — — — — — — — — — — — —
Econopred Plus	Prednisolone Acetate
Edecrin	Bumetanide
	Torsemide
Elavil	Amitriptyline

NON-FORMULARY DRUGS	FORMULARY ALTERNATIVE(S)
Eldepryl	Selegiline
Elestat	Alomide
	Livostin
	Patanol
	Zaditor
Emadine	Alomide
	Livostin
	Patanol
	Zaditor
Enablex	Detrol/LA
	Ditropan XL
	Oxybutynin
	Oxytrol
Entex ER / PSE	Guaifenesin / Pseudoephedrine
Entocort EC	Prednisone, Prednisolone
Equetro	Carbamazepine
•	Carbatrol
	Tegretol / XR
Ertaczo	Ciclopirox
	Econazole
	Ketoconazole
	Loprox
	Oxistat
Erye	Erythromycin
Erycette	Erythromycin
Erygel	Erythromycin
Esgic	Butalbital / APAP / Caffeine
Estinyl	Premarin
Estrace Tabs	Estradiol
Estrasorb	Alora
	Climara
	Esclim
	Estraderm
	Estradiol
	Vivelle / DOT
EstroGel	Alora
	Climara
	Esclim
	Estraderm
	Estradiol
Evoclin	Clindamyein
	Erythromycin

NON-FORMULARY DRUGS	FORMULARY ALTERNATIVE(S)
Focalin	Adderall XR
	Amphetamine / Dextroamphetamine
	Metadate CD
	Metadate ER
	Methylin ER
	Methylphenidate-ER
	Ritalin LA
Folpace Rx	Glutofac ZX
	Nu Iron V
	<u>Vitafol</u>
Fortamet	Metformin ER
Fosrenol	Renagel
	Sensipar
Freestyle	Accu-Chek / Simplicity
-	Chemstrip BG
	FastTake
	One Touch / Ultra
	Sure Step / Pro
Frova	Imitrex
	Maxalt / MLT
	Zomig / ZMT
Gabarone	Gabapentin
	Neurontin
Ganirelix Acetate	Cetrotide
Geodon	Abilify
	Clozapine
	Clozaril
	Fazaelo
	Risperdal
	Seroquel
	_L Zyprexa
Glucometer / Dex / Elite / Encore	Accu-Chek / Simplicity
	Chemstrip BG
	FastTake
	One Touch / Ultra
	Sure Step / Pro
Glucophage / XR 500 mg	Metformin / ER
Glucosource Lancets	One Touch / Ultra Soft
	Sofelix
	Soft Touch
Glucotrol	Glipizide

FORMULARY ALTERNATIVE(S)
Accu-Chek / Simplicity
Chemstrip BG
FastTake
One Touch / Ultra
Sure Step / Pro
Ciprofloxacin
Levaquin
Acyclovir
Valtrex
Arthrotec
Etodolac
Nabumetone Nabumetone
Oxaprozin .
Piroxicam
Vicon Forte
Follistim AQ
Gonal-F
Repronex
Butalbital / APAP / Caffeine
Butalbital / APAP / Caffeine / Codeine
ASA / Caffeine / Butalbital
Butal - ASA - CAFF - COD
Prochieve 4%
Prometrium
Androderm
Androgel
Testim
Metronidazole
Cyclobenzaprine HC1
Percogesic
Phenyltoloxamine / APAP
Fludrocortisone
Clobestasol Propionate
Diprolene / AF
Halobetasol Propionate
Ultravate
Ciprofloxacin
Levaquin

NON-FORMULARY DRUGS	FORMULARY ALTERNATIVE(S)
Glynase / Pres Tab	Actos
	Amaryl
	Avandamet
	Avandia
	Glipizide / ER
	Glucotrol XL
	Glucovance
	Glyburide
	Glyburide / Micronized
	Metformin / ER
Golytely	PEG-3350 / Electrolytes



August 24,2006 PAGE 26050

Take this booklet with you when you see your doctor. Do you have a question or need more information?

Call the Member Services number on your ID card. Customer Service representatives are available to take your calls during the following hours:

VVeekdays 7 a.m. – 1.1 p.m. ET

Saturday 8 a.m. - 9:30 p.m. ET

Sunday 8 a.m. – 6 p.m. ET

Visit www.aetna.com for the most up-to-date information

TDD for hearing or speech impaired 1-800-628-3323

Dear Member:

Insurance coverage For prescription drugs continues to be one of the most important benefits in a health care plan. To help you determine which medications are covered by your plan, we are pleased to provide you with a copy of our 2006 Preferred Drug Guide. The drugs that appear on the Preferred Drug List were selected based an their effectiveness, quality, safety and value.

This book is designed to provide you with easy to understand and accessible information on the Aema Preferred Drug List, as well as details on your pharmacy benefit design. We encourage you to take this guide with you when you see your doctor, so you can discuss whether any medications recommended by your physician are covered under your pharmacy benefit.

Many commonly prescribed medications, along with their preferred drug status are listed in this book. Please remember that this is not a complete list of medications covered under your plan. Because there are thousands of medications included in your pharmacy benefit, we only list the most commonly prescribed ones.

In accordance with state law, California HMO members who are receiving coverage for medications that are added to the Precertification or Step-Therapy lists will continue to have those medications covered, for as long as the treating physician continues prescribing them, provided that the drug is appropriately prescribed and is considered safe and effective for treating the enrollee's medical condition. Nothing in this section shall preclude the prescribing provider from prescribing another drug covered by the plan that is medically appropriate for the enrollee, nor shall anything in this section be construed to prohibit generic drug substitutions.

For members in Texas, additions to the 2006 Preferred Drug list will be effective no later than January 1, 2006 In accordance with state law, full-risk member in Texas who receive coverage for medications that are removed from the Preferred Drug list during the plan year will continue to have those medications covered at the same benefit level until their plan renewal date.

Step-therapy, precertification and quantity limits do not apply in all service areas. For example, step-therapy does not apply to fully insured members in New Jersey and Indiana. Please refer to your plan documents or call the Member Service number on your ID card for further Information.

Table of Contents

	What Pharmacy Benefits Plan Do I Have?
	What is the Preferred Drug List?2
Y	Who Reviews Medications for the Preferred Drug List?3
	How is the Preferred Drug List Developed?
	The Preferred Drug List is Subject to Change
	Why Do Some Medications Require Prior Authorization or Precertification? 4
	Why Do Some Medications Have Quantity Limits? . ,
	What is Step-Therapy?
	What are Generic Medications? 6
	How Can I Save Money on Prescriptions?6
	What is Aetna Rx Home Delivery?
	How Do I Contact Aetna Rx Home Delivery?
	What is Aetna Specialty Pharmacy?
Starting to	Preferred Drug List8
	Antineoplatic Agents · · · · · 8
	Blood Products - Modifiers - Volume Expanders
	.Cardiovascular System
	'Central Nervous System
	Dermatological Agents
	Endocrine System
	Gastrointestinal System
	Genitourinary System
	Immunological Agents
	Infections and Infestations 24
	Musculoskeletal System ,
	Opthalmic Agents
	Otic Agents
	Respiratory Tract Agents
	Presertification List
	9tep-Therapy List
	Quantity Limit List
	Index

www.aetna.com/formulary 1

What Pharmacy Benefits Plan Do I Have?

You are enrolled in a three-tier/open formulary plan.'

Open formulary means your pharmacy benefit covers medications that are on the Preferred Drug List (formulary). as well as many that are not. Your plan may not cover certain medications, even-though some are listed in this booklet, such as contraceprives, infertility medications, erectile dysfunction medications and diabetic supplies. Please see your plan documents for a complete description of your pharmacy benefit, or call the Member Services number on your ID card.

Three-tier means there are three copay tiers or levels for covered prescription medications. The three copay tiers are:

Copay Tier"	Type of Drug
Tier One (Low Copay)	Covered generics medications on the Preferred Drug List"
Tier Two (Middle Copay	Covered preferred brand-
Tier Three (High Copay)	Covered non-preferred generic of brand-name medications on the
	Preferred Drug List

Your plan may have a "mandatory generic cost-sharing requirement," which means that if yoll receive a brand-name medication when a generic medication is available, you will pay the difference in cost between the brand-name and generic medication, in addition to your copay.

For a summary of your pharmacy benefits plan, including copay amounts, please visit Aetna Navigator at www.aetna.com or call the Member Services number on' your ID card.

What is the Preferred Drug List?

The Preferred Drug List (also know as a formulary) is a list of medications selected by Aetna in consultation with a team of health care providers. Aetna will generally cover the drugs listed in our Preferred Drug List as long as the drug is medically necessary and plan rules are followed. For more information on the Preferred Drug List, please review your plan documents or call the Member Services number Listed on your ID card.

Drugs that appear on Aetna's Preferred Drug Lit have been chosen on the basis of **sound** medial data., safety and cost.

Your enrollment in an Aetna three-tierlopen formulary plan was based on information at the time of this mailing. If your pharmacy benefits plan changes, the copays and coverage of certain medications detailed in this booklet may no longer apply.

www.aetna.com/formulary

2

10.7

If your plan has copay levels based on a percentage of Aetna's negotiated charge with the participating pharmacy, this charge'does not include and is not reduced by any manufacturer rebate amounts Aetna receives from drug manufacturers. Also, in some cases, if you need to pay a percentage of the cost of a drug or an amount to meet a deductible, your costs may be higher for a preferred drug than they would be for a non-preferred drug.

^{***} If you are enrolled in a PPO plan, all covered generic medications are available at the lowest copay (tier one), regardless of whether they are on the Preferred Drug List. In most HMO plans, nori-preferred generic medications are available at the highest copay (tier three!.

- Both brand-name and generic medications are on Aetna's Preferred Drug List.
- All medications on the Preferred Drug list have been approved by the Food and Drug Administration (FDA) as safe and effective.
- The Preferred Drug List is updated on an ongoing basis and may be subject to change without prior notification.
- Many medications on the Preferred
 Drug List are subject to manufacturer
 rebate arrangements between Aetna and
 the manufacturer of those medications.

This Preferred Drug Guide is an abbreviated list of some of the most commonly prescribed drugs. Your pharmacy benefit may cover many more medications chat are not listed in this Preferred Drug Guide. However, certain medications listed in this booklet – such as contraceptives, infertility medications, erectile dysfunction medications and diabetic supplies – may not be covered by your particular plan. Please check out the Aetna website at www.aetna.com/formulary for a more complete listing of medications that may be covered by your plan.

It is important to note that you and your physician are responsible for making the final decision on your drug therapy. For a complete description of your pharmacy benefic see your plan documents or call the Member Services number on your ID card for further information.

Who Reviews Medications for the Preferred Drug List?

Aetna's Pharmaceutical and Therapeutics (P&T) Committee reviews available clinical literature for medications that have been approved by the FDA.

The P&T Committee also includes pharmacists and doctors who are employees of Aetna.

How is the Preferred Drug List Developed?

Our Pharmaceutical and Therapeutics (P&T) Committee is responsible for reviewing drugs for possible inclusion on our Preferred Drug Lists. Although the committee includes staff from Aetna, the majority of the members are practicing doctors and/or pharmacists who are chosen to represent various clinical specialties. All committee members must disclose any factors that may create a real or apparent conflict of interest or financial stake related to any of the manufacturers whose products are being considered in Preferred Drug Litterminations.

The P&T's clinical determinations are based on the strength of scientific evidence from literature and database searches from a number of sources and includes, but is not limited to: United States Pharmacopeia-Drug Information (USP-DI), American Hospital Formulary Service Drug Information (AHFS-DI),

www.aetna.com/formulary

3

DrugDex, Medline and other databases, including relevant findings of federal government agencies, the pharmaceutical manufacturers, medical professional associations, national commissions and peer-reviewed journals.

The P&T committee meets regularly to evaluate new drug indications and new clinical information on existing Preferred Drugs to verify that they continue to meet the criteria for safety, effectiveness, current use in therapy and overall value. Once the P&T completes its clinical review, Aetna conducts additional reviews of medications based on P&T's clinical determinations and information regarding overall value (including cost and manufacturer rebate arrangements) and other factors before a decision on Preferred Drug List status is made.

The Preferred Drug List is Subject to Change

Aetna periodically reviews our Preferred Drug List to make sure it meets the criteria for safety, effectiveness and overall value. The list is subject to change. Medications may be covered at a higher copayment and/or removed from the Preferred Drug List at any time.

As brand-name medications lose their patents and **generic** versions become available, **rhe** brand-name medication may be covered at a higher copayment. Medications likely to become available generically in 2006 are identified in **this** booklet with a symbol.

- The Preferred Drug List may change because the FDA approves many new medications throughout the year. Open formulary plans generally cover new FDA-approved medications before thy have completed Aetna's new drug review process. Depending on their plan, some members may pay a higher copayment, and the medication also may be subject to precertification or step-therapy requirements
- The Preferred Drug List also may change if a medication is withdrawn from the market or becomes available without a prescription. When an over-the-counter(OTC) equivalent becomes available, the prescription mediation may no longer be covered under many of Aetna's pharmacy benefits.

Why Do Some Medications-Require Prior Authorization or Precertification?

Precertification encourages the appropriate and cost effective use of medications by allowing coverage only when certain conditions are met.

- The precertification program is based upon current medical findings, FDA approved manufacturer labeling information, and cost and manufacturer rebate arrangements.
- If your plan includes our

 precertification program, your doctor
 must request authorization for themedication. If the request is approved,
 your doctor is notified and the
 medication will then be covered as

. www.aetna.com/formulary

1

the applicable copay under your plans
If the request is denied, you and your
doctor will be notified.

- Guide require prior authorization or precertification before they will be covered under some pharmacy benefits plans. For information on whether precertification applies to your plan, please refer to your plan documents or call the Member Services number on your ID card. Refer to pages 31—32 for further details on which medications require precertification.
- The medications requiring precertification are subject to change. Refer to our website at www.aetna.com/formulary for the most up to date information.

1

Why Do Some Medications Have Quantity Limits?

Quantity **limits** are **included** as part of our **precertification** program and are designed to help promote appropriate and efficient medication use and enhance patient **safety**.

Quantity **limits** are based on generally accepted **pharmaceutical** guidelines, **efficient** dosing **regimens** and dosing **recommendations**. Three types of **quantity** limits are in place. They are:

- Dose Efficiency Edits Limits coverage of prescriptions to one dose per day for drugs that are approved for once-daily dosing.
- Maximum Daily Dose –
 Informational message is sent to the

pharmacy if prescription lies outside recommended minimum and maximum doses,

Quantity limits over time – Limits coverage of prescriptions to a specific number of units per a defined amount of time.

Quantity limit medications may be covered for quantities up to those indicated. In order to receive coverage for amounts in excess of the quantity listed, the prescribing physician must request a medical exception. Refer to pages 35 – 40 for further details on which medications apply quantity limits.

The medications that have quantity limits are subject to change. Refer to our website at www.aetna.com/formulary for the most up-to-date information.

What is Step-Therapy?-

Step-thempy means you must first try
one or more "prerequisite" medications
before the step-thempy medication will
be covered. If your plan includes ourstep-thempy program, you need to try
one or more prerequisite medications
first before the "step-themapy" medication
will be covered under your pharmacybenefit.

- Prerequisite medications and their corresponding step-therapy medications are FDA-approved and are used to treat the same conditions
- If it is medically necessary, you can obtain coverage for a step therapy medication without trying a prerequisite medication first. In this

www.aetna.com/formulary

5

7 739

case, your doctor must request coverage for a step therapy medication as a medical exception. If the request is approved, your doctor will be notified and the medication will then be covered at the applicable copay under your plan. If the request is denied, you and your doctor will be notified

- Step therapy is based upon current medical findings, FDA approved manufacturer labeling information, and cost and manufacturer rebate arrangements.
- For information on whether steptherapy applies to your plan, please refer to your plan documents or call the Member Services number on your ID card.
- Refer to page 33 34 for further details on which medications require step therapy.

The medications requiring step-therapy are subject to change Refer to our website at www.aetna.com/formularyfor the most up to date information.

What-are Generic Medications?

Generic drugs are identical to brandname drugs in dosage, safety, strength, route of administration, quality, performance characteristics and intended use. Although generic drugs are chemically the same as their branded counterparts, they are typically sold . at .substantial discounts from the , branded price.

Generic medications have been

-approved by the FDA as safe and effective. They contain the same active ingredients in the same amounts as the brand-name products, although generics may be a different color, shape or size than brand-name products.

Your pharmacist can substitute a generic medication for a brand-name medication when filling your prescription when the generic is rated - by the FDA as equivalent and where substitution is permitted by law and by **your** doctor. ___

How Can I Save Money on Prescriptions?

Ask your doctor to consider prescribing medications on the Preferred Drug List whenever appropriate. Medications on the Preferred Drug List generally cost you less money with a lower copayment.

In many plans covered generic medications on the **Preferred Dug** List. are available at the lowest copay.

Ask your doctor or pharmacist whether generic medications are appropriate for you.

What is Aetna Rx Home Delivery?

Aetna Rx Home Delivery is our mail-order prescription service. Aetna Rx Home Delivery is an ideal way to obtain your medications that are taken regularly to treat a chronic condition such as arthritis, diabetes or heart disease.

www.aetna.com/formulary

These medications are delivered right to your dooc

How Do I Contact Aetna Rx Home Delivery?

For a specific question about the status of a prescription requested or filled by Aetna Rx Home Delivery:

Call 1-866-612-3862 Weekdays 7 a.m. - 11 p.m. ET Saturday 8 a.m. - 9:30 p.m. ET Sunday 8 a.m. - 6 p.m. ET

e di Paris

1.77

Or, check the **status** of your order **online** at www.aetnarxhomedelivery.com.

You may contact **Member** Services at the toll-free 800 number listed on the back of your ID card for questions about eligibility, benefits, copays, forms or other general information.

What is Aetna Specialty Pharmacy?

Aetna Specially Pharmacy is available to fill your specialty injectable medication needs. Some injectable medications, as well as ocher disease-specific drugs, require special handling, storage or shipping. These drugs are often referred to as specialty medications and are often used to treat certain conditions such as hemophilia, hepatitis and multiple sclerosis.

Aetna Specialty Pharmacy provides convenient mail-order services for specialty medications that are not always available at retail pharmacies. The

network abo offers educational and clinical support services to help members manage their medications and health condition.

Depending on your benefits plan, you may have a copay for specialty injectable medications. Please refer to your plan documents or contact Member Services at the number on your ID card for further information.

For more information on Aetna Specialty Pharmacy, call toll free at 1-866-782-2779 (ASRX) or visit www.AetnaSpecialtyPharmacy.com.

HERAPEUM ČLASSI ISI KEY UPBERGASE Eligipies menicalizatio (a)បុរាជាត្រាស់ ខេត្ត (ប្រជាព្យាធិប្បារិក្សា (ប្រជាព្យាធិប្បារិក្សា (ប្រជាព្យាធិប្បារិក្សា (ប្រជាព្យាធិប្បារិក a entraphism to the production of the second Contributions callege agains with a the CLE k → Brandiñame medication éxpected to. become available generically during the year After the generic medication becomes available, the branderian medication may be covered at a nigher copayment and/or removed from the Preferred Drug List MED - injectable medication that may be covered under the medical benefit PMED - Preferred injectable medication. that may be covered under the medical benefit

August 24, 2006

www.aetna.com/formulary

ABEL NAME	Copay Copay Copayity Dints Commission	LABEL NAME	Copay Level Quantity Limis Precent
Antineoplastic Age	onts	भारता विद्यासार हो हो हो है। इस्त्री के स्टब्स के स	9000000 00000 00 000 00 4'/(1(::1)11:11:11(6):5:2
		$_{1}=\{(c_{0})_{1},c_{1}\}_{1}^{2}$	
रवेत्वाची केव्हर्गर्ग मुर्ग		IRESSA	
CYTADREN		TARCEVA	
distanting assisting		Antineoplasiiks M	
ALKERAN	102	ACTIMMUNE	
CEENU		ALFERON N	MEGERAL
cyclophosphamide		HYDREA	
CYTOXAN		hydroxyurea	
HEXALEN		INTRON-A	VEDS EMES EVEN E
LEUKERAN		MATULANE	
MYLERAN		MYLOCEL	33 11 11
TEMODAR	2	PHOTOFRIN	MED
ា ម៉ាពីទៅទទៅពី		PROLEUKIN	
mercaptopurine		ROFERON-A	ME
methotrexate		TARGRETIN	
PURINETHOL		THERACYS	
TABLOID		TICE BCG	MED
TREXALL		UVADEX	
XELODA		VESANOID	2 4
្រាប់ក្រស់ស្រាស់ក្រាស់ប្រ		raileinoineenvike	speknikoskoe
The state of the latest st		leucovorin calcium	
ARIMIDEX		MESNEX	
AROMASIN		m Micheldions	
CASODEX	Harrist Street, Street	etoposide	
DEPO-PROVERA		VEPESID	
EMCYT			
EULEXIN		Blood Products - N	Modifiers -
FARESTON		Volume Expander	and the same of th
FASLODEX		Letter in Gentlin	化自由性性的 计记录的 化多种子 化二甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基
FEMARA flutamide	2	CEREDASE	
		CEREZYME	MINE NEW MINE
leuprolide LUPRON		ZAVESCA	
LYSODREN		Agenes orsania	eel whemis
		DROXIA	
MEGACE ES	CONTRACTOR OF CONTRACT COSTS CONTRACT CONTRACT CONTRACT CONTRACTOR CONTRACT	GOUMATIN/AMIGOA	60000000000000000000000000000000000000
megestrol		COUMADIN	
NILANDRON		warfarin	
		11. 11.11	
NOLVADEX	ACCURATION AND LESS AND ADDRESS OF THE ACCURATION AND ACCURATION A	ienatopoleidos	
tamoxifen		PROCRIT	2
TESLAC	3	ARANESP	2
ZOLADEX	MEDI	NEULASIA	2
Antineoplastic En	ymetinhibitors 🧦	Hematopoletic Mi	xtures
GLEEVEC	2 4 4	TRINSICON	2

5

	a Arraketosat Viktarik NALIA Lik		
		A Commence of the Commence of	
		:	
LABEL NAME	Copav (evel) Ouando Ilmite hevery Siep-	LABEL NAME	
ដូចរួនពេលនុយ្យា ំ ខ្មែ <u>ង</u> ន		Alphadistatilocker	
		TRANDATE	
ARIXTRA		1	
FRAGMIN	MEDIE	Amaphylaxis Thesi	
heparin sodium		EPIPEN	
INNOHEP		EPIPEN-JR	
		/કાણભાગામાં દિવસ	រប្រថា រយៈខេត្តកម្ពុជាខ្លែរ 📑
ម្មីត្រូវដូច្នេះ ខេត្ត		ATACAND	
AGGRENOX		AVAPRO	
AGRYLIN		BENICAR	
ANAGRELIDE		COZAÁR	
cilostazol		DIOVAN	
dipyridamole		MICARDIS	
PERSANTINE		TEVETEN	
PLAVIX #		/ល់ផងពីក្រុងក្រុម /ល្បី	HAVIET SAFVES
PLETAL		CARDURA	
TICLID		CATAPRES	
ticlopidine		CATAPRES-TTS	
Cardiovascular Sys	tem	clonidine	
र (द: १०१)। ।। छोड		doxazosin	
ACCUPRIL		guanabenz	
ACEON		guanfacine	
ALTACE		HYTRIN	
benazepril		methyldopa	
CAPOTEN		MINIPRESS	
captopril		prazosin	CONTROL OF STREET STREE
enalapril		reserpine	
fosinopril		TENEX	
lisinopril		terazosin	
LOTENSIN		響い こうけい もっちょ	
MAVIK		/Amiletrinydamicely	
MONOPRIL		ETHMOZINE	
PRINIVIL		/Antienthy/Ininfredit	yı•ı:-liJt;
guinapril		disopyramide	
UNIVASC		NORPACE	
VASOTEC		procainamide	
ZESTRIL		procainamide ER	
Agents to Priced	nomoguent	PROCANBID	
DEMSER		PRONESTYL	
DIBENZYLINE		PRONESTYL SR	
phentolamine	MEDITER	quinidine gluconate	
Alpha Beta Block	united in the second property of the second party of the second pa	quinidine sulfate	
COREG		Antian hytinnis i	vpe I+B# AB
labetalol		mexiletine	
1000 WIOI		THE AREA IN	reconstra socialisti pira el Welli. S

9

PAGE

1					
	2				
	a. E4		* . · · · · · · · · · · · · · · · · · ·		
LABEL NAME	Cobay Lyvell Organity Innits	192	LABEL NAME	Copal level Quantity Umits	湖岸
	essentato statuta d				
Amianiyilime 300	and the second second second second		Awanypasandye es Rominoan)0(1)012(1(1)11. J	
flecainide			LOTREL #		
propafenone			methyldopal		
RYTHMOL	3		hydrochlorothiazide		
RYTHMOL SR	3		metoprolol/		
TAMBOCOR			hydrochlorothiazide		
Angering to the Unit	eill		MICARDIS HCT		
amiodarone			MINIZIDE		
CORDARONE			MONOPRIL HCT		
PACERONE			PRINZIDE	3 1	
TIKOSYN			propranolol/		
/:milhy@silpiden()	Combination		hydrochlorothiazide		
ADVICOR			quinaretic		
VYTORIN			rauwolfial bendroflumethiazide		
Payrantantanty (mark)			TARKA		
		悪魯夢 海	TENORETIC		
ACCURETIC			TEVETEN HCT		
ALDORIL			TIMOLIDE		
ATACAND HCT atenolol/chlorthalidone			UNIRETIC		
			UNI-SERP		
AVALIDE			VASERETIC		
benazeprill hydrochlorothiazide			ZESTORETIC		
BENICAR HCT			ZIAC		
bisoprololi			ास्त्रह । अवर्ग (स्ट्रास्ट्रासी।	Granina de la composición dela composición de la composición de la composición de la composición de la composición dela composición dela composición dela composición de la composición de la composición de la composición de la composición dela composición de la composición de la composición dela composición dela composición dela composición dela composición dela composic	
hydrochlorothiazide	1				
CAPOZIDE			acebutolol atenolol		
captopril/					
hydrochlorothiazide			betaxolol bisoprolol fumarate		
CLORPRES	3300		KERLONE		
CORZIDE			LOPRESSOR		
DIOVAN HCT	22 4		metoprolol		
enalaprill			SECTRAL		
hydrochlorothiazide			TENORMIN		
ENDURONYL FORTE			TOPROL XL		
fosinopril/ hydrochlorothiazide			ZEBETA		
hydrolazine/			Bean Blocker Non		
hydrochlorothiazide			DETADACT		
HYZAAR	2 7				
INDERIDE			BETAPACE AF		
LEXXEL			BLOCADREN	3	
lisinopril/			CARTROL		
hydrochlorothiazide			CORGARD		
LOPRESS HCT			INDERAL	3.4	
LOTENSIN HCT	3		INDERAL LA		
					-

10

en e	deediakon kriilikh (46.4)		
	al III is		
	Oppay evel Manita Imita Recer Recer Recer		Copay Lievel Quantity Limits Limits Therent Step-
ABEL NAME	Copay Lavel Quantity Imits Prevent Step-	LABEL NAME	
តែន ដ្រែប្រែកែកែរប៉ូត្វដ		(भावितात अधिविधाः ५५०	The state of the s
INNOPRAN XL		PLENDIL	
LEVATOL		PROCARDIA	
nadolol		PROCARDIA XL	
pindolol		SULAR	
oropranolol		taztia XT	
sorine		TIAZAC	
sotalol AF		verapamil	
sotalol hcl		verapamil SR	
timolol maleate		- VERELAN	
វៀនេស៊ីដូចូមនេស៊ីសារ៉ានេ <i>ៈ</i>	SUSCIENTED REPORTS FIRST AND AND PAGE	VERELAN PM	
cholestyramine		म्बर्गास्त्राम् । त्याच्या । स्टब्स्ट्रिके	esimmotors :
COLESTID		acetazolamide	
prevalite		DIAMOX	
		methazolamide	
QUESTRAN WELCHOL		Carther Gyresides	Selection of the select
		digitek	
engling ploties	and the second contract of the second contrac	digoxin	
ADALAT CC		LANOXICAPS	
afeditab		LANOXIN	
CALAN		翻 to the control of	
CALAN SR		โลงกฤติกระบบ เลิกและ	
CARDENE		ALDACTAZIDE	
CARDENE SR		amiloride/	
CARDIZEM		hydrochlorothiazide	
CARDIZEM CD		DYAZIDE	
CARDIZEM LA		MAXZIDE	
cartia XT		MODURETIC	
COVERA-HS		spironolactonel hydrochlorothiazide	
DILACOR XR	差期影倒到周克	triamterenel	
dilt-CD	洲馬彭鄉到護護	hydrochlorothiazide	
diltia XT	一展期党准期商 萄	idigge Aragabidavel	
diltiazem CD		ANTARA	
diltiazem ER		gemfibrozil	
diltiazem extended		LOFIBRA	
release beads SR		LOPID	
DYNACIRC		TRICOR #	
DYNACIRC CR		TRIGLIDE	
felodipine		HIME GOARCOUGE	
ISOPTIN SR			
nicardipine		ALTOPREV	
nifedipine		CRESTOR	
nifedipine SR		LESCOL	
NIMOTOP #		LESCOL XL	
NORVASC		LIPITOR	

August 24, 2006

, e			
			Copay Level Quantif Limits Limits Present Therap
ABEL NAME		LABEL NAME	
]))/(६.(२७): {१६०)। विकास		n Mitteries (continue)) Sendoporeces representation per pest pest test pest
lovastatin		MONOKET	
MEVACOR			
PRAVACHOL		NITROBID	- G - H - H - H - H - H
PRAVIGARD		NITRO-DUR	
ZOCOR #		NITROGARD	
market de la companie		nitroglycerin	
aphyrodyne		nitroglycerin SL	
CAVERJECT		nitroglycerin SR	
CIAUS		NITROLINGUAL	
EDEX		nitroquick NITROSTAT	
LEVITRA			
MUSE		nitrotəb	
testomar-		nitro-time nitro-transderm	
VIAGRA		TANK TO THE PARTY OF THE PARTY	
ામાં લેવામાં (વાતીલવાના	1/21-2-19-12001	Rempheral Vasculla	
		papaverine ER	
ZETIA		papaverine EK para-time	
ल्डाः भागत्योद		VASODILAN	
bumetanide		### 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
BUMEX		1,00923 ប្រើខ្លាំជាព្រះ	
DEMADEX		ALDACTONE	
EDECRIN		amiloride	
furosemide		DYRENIUM	
LASIX		MIDAMOR	
torsemide		spironolactone	
សេខ សម្រាញ់ស្តែចខ្មាំច្រាច់	<u>(Emile)</u>	រួមមនុស្សមនុស្សមនុស្សមនុស្សមនុស្សមនុស្ស	ansion - land othern
LIPEX		Read to we four	TO THE STREET, BUT THE SEC
Miss (क्षाचीक्रफडबंगेह)	उद्गानिहास्त्रम् -	TRACLEER	
BIDIL		Sale inversions in a	માં લેવવેમાં
CADUET		/Ange groups (\$/AR/A	(5)
Masilin Asid Digity	et i vies	INSPRA	
NIASPAN		Thiarides and Tha	खाद्वीयार भागत्वसार स
THE RESERVE AND A STREET AND A		chlorothiazide	
Nitratesado		chlorthalidone	
amyl nitrite	and the second distribution and distribution	DIURIL	
DILATRATE SR		hydrochlorothiazide	
IMDUR		indapamide	
ISIVIO		LOZOL	
isochron		methychlothiazide	
ISORDIL		metolazone	
isosorbide dinitrate		MICROZIDE	
isosorbide mononitrate		NATURETIN	3.

······································			
		The second second	
	x Iğu tılığı		≥ Eu E
			Copay level Quam Imits
ABEL NAME		LABEL NAME	
inexiderand ilinexi	ienijalejinejiaj	ะเย่า ที่เจาในรถเลงแล้งเรื่อง	ivasii kwajolina
continued and a second		(compared a second	-
THALITONE		KLONOPIN	
ZAROXOLYN		KLONOPIN WAFER	
/asodilatojs:		Amidementa	diserviring and the state of th
hydralazine		ARICEPT	
minoxidil		ARICEPT ODT	
Central Nervous Syst	em	COGNEX	
તાલામાં કેઇ (લેલ્લ્લો) કો	the large section is an array was a section of principle coupling a	EXELON	
ANTABUSE		NAMENDA	
CAMPRAL		RAZADYNE	
		RAZADYNE ER	
alibe zaracinei 7en	CONTRACTOR SERVICES SEED SEED BEEN SERVICE.	केन्द्रमध्योदसम्बद्धीकाः/द	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
mirtazapine		LODOSYN	
mirtazapine ODT		Antilogian anaoilei /:	હાલું કહેલી છે. (સંસ્થૃો)
REMERON		AKINETON	
REMERON SOLUTAB	remist of safe	benztropine ""	
elle Andenfe	and the second s	KEMADRIN	
RILUTEK		trihexyphenidyl	
រុក្សារ៉ាន់ខិត្តាព្រះ		Antiperimental (4	a), i simililikais että
ADDERALL		COMTAN	
ADDERALL XR #		TASMAR	
amphetamine/		terrifogration of the let	
dextroamphetamine		amantadine	
DESOXYN		atamet	
DEXEDRINE		bromocriptine	
dextroamphetamine		carbidopallevodopa	
dextroamphetamine CR		carbidopallevodopa SR	
DEXTROSTAT		LARODOPA	
methamphetamine		MIRAPEX	
អ្នកជ្រើកចេះ) នាន់វិទ្យាតែជន	The state of the s	PARCOPA	
acetaminophen/salicylam	idė/	PARLODEL	
phenyltoloxamine		pergolide	
butalbital CPD		PERMAX	
butalbital/acetaminopher		REQUIP	2
butalbital/acetaminopher caffeine		SINEMET	
butalbitallaspirin/caffeine		SINEMET CR	
	 Introduced by the device the state of the device of 	STALEVO	
Anti-Carapleous Age		SYMMETREL	3 jij
XYREM		Antibarkinsonlan N	longamine Oxidas
Anticonvulsant « Be	nzodiażepine	Inhibitor * **	
clonazepam		ELDEPRYL	
DIASTAT		selegiline	

	»Haras Maras de La		
		2 1 .	
Ç.		•	Copay Coantity Emits The English
	Coppy Inveligentity Immits Immedia Step		Copay Level Ouant Timits Tree
LABEL NAME		LABEL NAME	
vizacention delejlejdetti	**************************************	Digenzajonnes	
Agente		clozapine	
CONCERTA		CLOZARIL	
FOCALIN		FAZACLO	三美選
FOCALIN XR		loxapine	
METADATE CD		SEROQUEL	
METADATE ER		ZYPREXA	
methylin		ZYPREXA ZYDIS	
METHYLIN CHEW/SOLN		(त्रेन्डाः) व विश्वविद्यात्रिक्षात्र	
methylin ER		GABITRIL	
methylphenidate		igyäginioine	
methylphenidate SR		phenytoin extended	
PROVIGIL		phenytoin sodium	
RITALIN		Continue de la constitución de l	
RITALIN LA		lithium carbonate	
RITALIN SR		lithium carbonate CR	
STRATTERA	The second secon	lithium citrate	
sensione estivione		LITHOBID	
BUTISOL SODIUM		ស្រីស្រី ដៅជាសាល់នេះ	Octobardon - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -
MEBARAL		MARPLAN	
phenobarbital		NARDIL	
SECONAL		PARNATE	
នធារជារបៈគេរប់(ទ		(કોઇલોઇસ્ક્રીએલ્ડો) વેર્કેટ	Charles and September of the second basis was the
RISPERDAL		MIGRANAL	
RISPERDAL CONSTA		Mis Psycholicaer	
RISPERDAL M		(/idi)(o)(o)((s) /a(d))	14444.49116
Benzoubazepines		ergoloid mesylate	
alprazolam		ORAP	
chlordiazepoxide		Misc Amilanxiety.	marketing therefore or send the world
clorazepate		Controlled to tention and personal property of the party	
diazepam		buspirone bol	
lorazepam		hydroxyzine hcl hydroxyzine pamoate	
oxazepam		meprobamate	
Buyrajahenones	AND ENGLISHED THE PROPERTY OF THE PARTY OF	18	
haloperidol		Mise Anticonvuls	
naloperaor		<u>carbamazepine</u>	
Carbamates		gabapentin	
FELBATOL		KEPPRA	
Combination Psyc	notherapeutics	LAMICTAL	
chlordiazepoxide/		lamotrigine	
amitriptyline		NEURONTIN primidone	
perphenazine/amitripty	yline 1	TEGRETOL	
. SYMBYAX		TEGRETOL	CONTRACTOR AND ACTION OF BEHAVE MAKE MINISTER.

14

	opay syal finits feed Seep	LABEL NAME
ABEL NAME	Copay Level Quantity Limits Limits Step- Step-	LABEL NAME 8º 6= 4 26
ที่เรา 7ราษ์เลือบั <i>ญ</i> ปัธิสู่ใ		Valuation (Granted)
TEGRETOL XR		msir Bis
TOPAMAX		ORAMORPH SR
TRILEPTAL		oxycodone SR
ZONEGRAN		OXYCONTIN CR
VISCO ATT LE DICESSO		oxyfast ####################################
Water Committee of the		OXYIR
bupropion		percolone management
bupropion SR		propoxyphene
maprotiline		tramadol
WELLBUTRIN		ULTRAM 3
WELLBUTRIN SR		(શુનારાજ્યા (વર્ગા)માં ભાગ
WELLBUTRIN XL		acetaminophen/codeine
វាទេ វត្តាមិទ្រសាយវាម	The second secon	ANEXSIA
GEODON #		aspirin/codeine
វត្តាវិជ្រាស់ (សូវវិគ្គ		butalbitallacetaminophen/
DESYREL	- 第二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十	caffeine/codeine
nefazodone		butalbitailaspirin/caffeine/
trazodone		codeine III III III III III III III III III I
		CAPITAL/CODEINE 3
មួយលោកស្នំផ្ទាល់មកអ		COMBUNOX
AVONEX		DARVOCET
BETASERON		DARVOCET-N 3
COPAXONE		DARVON COMPOUND
REBIF		FIORICET/CODEINE 3
denami zahones		FIORINAL/CODEINE SINGER
ACTIQ		hydrocodone/ Hydrocodone/
AVINZA		acetaminophen acetaminophen
codeine phosphate		hydrocodone/ibuprofen
codeine sulfate		LORCET
DARVON		LORCET PLUS
DARVON-N		LORCET-HD 3
DEMEROL		LORTAB
DILAUDID		MAXIDONE 3
DURAGESIC	工業運運運用開業	mèperidine/promethazine
fentanyl		_ meprozine
hydromorphone		NORCO 31 11 11
KADIAN		oxycodone/acetaminophen 1
levorphanol		oxycodonelaspirin 1
meperidine		pentazocine/
methadone		
methadose		Annual Personal Perso
morphine sulfate		PERCODAN 3
morphine sulfate CR		phrenilin/caffeine/codeine 1
MS CONTIN		propoxyphene/ acetaminophen
IVID CONTIN		acetáminophen 1 1 2 2 2 2

					h 1 m hay name (1 m hay name 1
				f :	
v'		8., €			
	Copa				Copay Copay Quanti Limits Trece Step
LABEL NAME	84		ğĒ.	LABEL NAME	OF DEED NO.
//elseote (eotijojileido)	Kiton			Gunolinone Denv	31//07
propoxyphene-N/				ABILIFY	海斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯
acetaminophen				Selective Serotonii	i Reuptake innibilos
REPREXAIN	3.			CELEXA	一种互联组员组织
ROXICET	3			citalopram	
SYNALGOS DC	3			fluoxetine	
TALACEN	3			fluvoxamine	
tramadol/acetaminophen				LEXAPRO	
TYLENOL/CODEINE	3		Y.	paroxetine	
TYLOX	3			PAXIL	
ULTRACET	3			PAXIL CR	
VICODIN	3			PEXEVA	主要是不可以的。
VICODIN ES	3			PROZAC	
vicodin HP				PROZAC WEEKLY	
VICOPROFEN	3		Y	RAPIFLUX	維羅塞維
VOPAC	3			SARAFEM	
XODOL	3.			ZCLOFT #	
ZYDONE	3			ិទ្ធសាល់រាជាស្រួលពីរ៉ាស់	
New could be reight die gr	ទ្រ			AMERGE	
butorphanol				AXERT	
pentazocine/naloxone				FROVA	
SUBOXONE	3			IMITREX #	
SUBUTEX	3			MAXALT	
TALWIN NX	3			MAXALT-MLT	
North and North Section	Hote			RELPAX	
AMBIEN #				ZOMIG	
chloral hydrate				ZOMIG ZMT	萨爾彭維 周爾爾薩
DORAL	3				ម្រើកូរីក្រេះអ៊ី(ឧបុភឌីវ៉េ(ឧបុភ
estazolam				Inhibitors: 33.55	hanaysacan askasacan sek esem dag esemb
flurazepam				CYMBALTA	
LUNESTA	3			EFFEXOR	
midazolam				EFFEXOR XR	
SONATA #	2			Succinimides *	
temazepam				CELONTIN	
triazolam				ethosuximide	
Phrenothiazines				ZARONTIN	
chlorpromazine	1			Thioxanthenes	
compro				thiothixene	
fluphenazine	120300			Tricyclic Agents 2	
perphenazine				amitriptyline	
prochlorperazine				amoxapine	
thioridazine	77.75			domipramine	
trifluoperazine	1				
	mm/ships-11	and the second second	market in the second		

16

e de la companya de	Water Server Land	ABBOLLATION			L-diff.		
			191 <u>0</u>				
i	Copay Level Quamity Ilmits			Copay			19
	Copay Copay Copan Cimits	Merell Merell Merell		Copay) je
LABEL NAME	89 65		LABEL NAME	OB C		E D	
and graite assemble stoom in	processus recitores		A Greation Lines Continu	et)			
SECRETARIAN PROPERTY OF THE PR			PLEXION SCT	3			
doxepin hcl			PLEXION TS	3		祖置	
imipramine hcl			prascion				
nortriptyline vanatrip			RETIN-A	3.0			
			RETIN-A MICRO	2			
Valjoketo/Akdid	enerane som		ROSAC	3-			
DEPAKOTE #	4		rosaderm				
DEPAKOTE ER			rosanil				4
DEPAKOTE SPRINKLE		超麗麗麗	ROSULA	33111			基礎
Dermatological Agent	ts		ROZEX	2			
7:(4)(4):701[0](4)			sodium sulfacetamine/				
ACCUTANE		医温度	sulfur				
AKNE-MYCIN			SOTRET				
amnesteem			SULFACET-R	3			
AVAR			sulfatol				
AVAR GREEN	3		SULFOXYL	3 1			翻覆
avar-E green			suphera				
AVITA		建型层置	tretinoin				
AZELEX	3		TRIAZ				
BENZACLIN	3		VANOXIDE-HC				
BENZAMYCIN			Z-CLINZ				
benzoyl peroxide			ZODERM				
claravis		建新聞園	লোটনাল্ডা ৰ নিটোলে				
clenia			gentamicin				
clindamax			mupirocin				
clindamycin			द्वारातीयम्बद्धाः । । इत्तरातीयम्बद्धाः ।				
DIFFERIN	2		ciclopirox				
DUAC			clotrimazole/				
erythromycin			betamethasone				
erythromycin/			econazole				
benzoyl peroxide			ERTACZO	- 2			
ethexderm			EXELDERM	- 3			
isotretionoin			hydrocortisone/clioquino		757		
KLARON			hydrocortisone/iodoquin				
METROCREAM #			ketoconazole				
METROGEL	2 /		LOPROX CREAM/LOTION	V			
METROLOTION	2		SUSPENSION	3			
metronidazole	3		LOPROX GEL/SHAMPOO				
NORITATE	CONTRACTOR DE L'ANGELES		LOTRISONE	-3			
NUOX			NAFTIN				
panoxyl			nystatin				
panoxyl AQ			nystatin/triamcinolone				
PLEXION CLOTH	3		OXISTAT	3		+	
PLEXION EMULSION			PENLAC				gastas

17

August 24, 2006

		3			*		Ø.		
	Copay			herap	LABEL NAME	Copay	Quant Limits	1000	tep-
ABEL NAME	Links and the sa			15102					ALC: C
មារដែលមិនដែល នៃម	nellgn	gar Lda	310		(៥០)ដែលទាយសាល់ កូរ៉ាឡែម៉ា	1 S. Martinia (1)	(IVIVE	W	
obice and the second					CLOBEX	2			
CARAC	3				CLODERM	3			
EFUDEX	3		-		CORDRAN	3			2.4
FLUOROPLEX	3 1.02.9			91412 1941	desonide			-	
fluorouracil	3				desoximetasone			墨麗	
LEVULAN KERA	2				diflorasone	(T1)			
PANRETIN SOLARAZE	3			######################################	; DIPROLENE AF	3	40.04		
TARGRETIN	2				fluocinolone acetonide				
			Table 1		fluocinonide				
មានប្រជាព្យាក្រុង			瓣菌		fluticasone				
prudoxin					HALOG	2			
ZONALON					hydrocortisone				
नित्तीक्रमान्यकः ।					hydrocortisone butyrate				₩.
8-MOP	3			.	hydrocortisone valerate				H
AMEVIVE	MED		到道		hydrocortisone/pramoxine	4			
anchralin 3					lacticare/hydrocortisone				1_
DOVONEX	3				lidocaine/hydrocortisone	1			
DRITHO-SCALP	3				LUXIQ	- 4			
OX\$ORALEN-UL	3				mometasone				
PSORIATEC	2		劉簋		OLUX	12			
RAPTIVA	MED				triamcinolone				
SORIATANE	2-				ULTRAVATE				
TAZORAC	2				lamenoneidelleibe-	:ଓ(କାନ	7	00 e	a)
/សារតែដែលពីក្រៅជាងសំរៀ	iets M				ALDARA	2			
CAPITROL	3				ELIDEL	2			
OVACE	3				PROTOPIC	-2			
ROSULA NS	3				Kernolynes/Ambrid	otics			
SEBIZON	3			32123 31133	podocon				
selenium sulfide					podofilox				
sulfacetamide sodium					lioial Affesthelies I	487281			
/अस्प्राची श्रावनीको					cocaine hcl				
DENAVIR	3								
ZOVIRAX					lidocaine				
ច្រៅដូចមាល់ប្រទេស	ical				lidocaine/prilocaine LIDODERM	2		H	
alclometasone									. Z
amcinonide					Rosacea Agents				
augmented					FINACEA	3	T CONTROL TO		
betamethasone	1				Scabicides & Pedicul				
betamethasone					EURAX	3			
diproprionate					lindane	300			
betamethasone valerate					permethrin				
clobetasol.				14:	sulfurated lime solution	1			
clobevate		Balania B				\$45.ZU			WÓ

ADEL MARKE	evel evel mits neo-	LABEL
ABEL NAME		1 Fa.,
Endocrine System		Cont
<u>্যার্টাটের টোগকেন্টার্টাটির</u>	difference and the	crysell
GLYSET		CYCL
PRECOSE		DEMIL
empogens esse		DESO
ANDRODERM		enpre
ANDROGEL #		ESTRO
danazol		junel
FIRST-TESTOSTERONE		junel
STRIANT		junel
TESTIM		junel
testosterone		kariva
Anning Saning	Acced Digition West	leena
STARLIX		lessin
ក្រុងព្រះត្រូវដូវទេ(៤១ហិសិន	Hillion.	LEVLI
AVANDAMET		LEVLI levon
GLUCOVANCE		LO/O
glyburide/metformin		LOES
METAGLIP		LOES
eministrate de la piente		LOES
methimazole		LOES
propylthiouracil		low-c
TAPAZOLE		lutera
ibueride		micro
FORTAMET		micro
GLUCOPHAGE		micro
GLUCOPHAGE XR		micre
metformin		MIRC
metformin SR		MOE
RIOMET		mon
Combination Contr	ज्ञात्वा <u>रायः ।</u>	neco
Transdermal	and the second second and the second	neco
ORTHO EVRA		neco
Combinetion Contr	नारक्रारिएइड - Vaginal	necc
NUVARING		NOR
(Gamiaina lone (o)els		NOR
ALESSE		NOR
apri		nort
aranelle		nort
aviane		nort
BREVICON		oge
		ORT

+ 50, 7	
	8 2 5 0 6
LABEL NAME	
มะรู้วิได้รายใหล่ที่ได้เกียว)	continued) = 2 = 2
cryselle	
CYCLESSA	
DEMULEN 1/35	
DEMULEN 1/50	
DESOGEN ,	
enpresse	
ESTROSTEP FE	
junel 1,5/30	
Junel 1/20	
junel FE 1,5/30	
junel FE 1/20	
kariva	
leena	
i lessina LEVLEN	
LEVLITE	
levora	
LO/OVRAL	
LOESTRIN 1.5/30	
LOESTRIN 1/20	
LOESTRIN FE	
LOESTRIN FE 1.5/30	
low-ogestrel	
lutera	
microgestin 1.5/30	
microgestin 1/20	
microgestin FE 1.5/30	
microgestin FE1/20	
MIRCETTE	
MODICON 0.5/35	
mononessa	
necon 0.5/35	
necon 1/35	
necon 1/50	
necon 10/11	
necon 7/7/7	
NORDETTE	
NORINYL 1+35	
NORINYL 1+50 nortrel 0.5/35	
nortrel 1/35	
nortrel 7/7/7	
ogestrel ORTHO TRI-CYCLEN	
OKINO IN-CYCLEN	

V+		Distributed of the life of		n.trakan	AAUNise Daaraa	- Alia	dia D	Ļ
			1 7 7					- Marie
					à	Į I	la	
	중의 문원	B 国際		Copay	Limits	8		
LABEL NAME	Copay Level Quantity	華展	LABEL NAME	89	35	4	۲E	
(પ્રાથમાં મામેલાન પાક કર્યુ	onnogi)		ស្រែត្រីស្នង នៃប្រើស្រាន់ នៃ ខេត្ត	invedia				
ORTHO TRI-CYCLEN LO			PRECISION Q-I-D TEST					1
ORTHO-CEPT	3 7		STRIPS	2				ĺ
ORTHO-CYCLEN	3 7	H	PRECISION SOF-TACT					į.
ORTHO-NOVUM 1/35			TEST STRIPS	. 2				į
ORTHO-NOVUM 1/50	3 /		PRECISION XTRA KETONE			H		ŝ
ORTHO-NOVUM 10/11	6 11 72		TEST STRIPS	2				1
ORTHO-NOVUM 7/7/7			PRECISION XTRA TEST STRIPS	2				Ä
OVCON 50	3		TEST STRIPS					İ
OVCON-35	13. 7		(all other brands)	3				2
OVRAL	200		Emerge cyacontrace	7 77 25 2			銀線	i i
portia	1 7		PLAN B	11227 E0580 H				
previfem								
reclipsen			dainemen (complication	COMMONSTRATES IN	watersal ex	est kasti f	katenyi lepiy	
SEASONALE			ACTIVELLA	3				
solia			CUMARA PRO	3	4			Æ
sprintex			COMBIPATCH		/			ŧ.
TRI-LEVLEN			ESTRATEST	9.		4.		1
trinessa	1 /		ESTRATEST HS	3				I
TRI-NORINYL	3 /		FEMHRT	3				₫
TRIPHASIL		到問題到	PREFEST	1 2				噩
tri-previfem			PREMPHASE	13				ŧ
tri-sprintec	i Z		PREMPRO	3				益
trivora		到面测度	syntest D.S.					Ħ.
velivet		鐵川川鉄	syntest H.S.					I
YASMIN	基础影		(4) <u>((4)</u>					á
zovia1/35E			ALORA		W.1			
zovia1/50E			CENESTIN		1			Ħ
. Djeloetic (Othicas			CLIMARA	-13	7			
GLUCAGON	MED		ESCLIM	3	7			
PROGLYCEM	2		ESTRACE	3	7			124
विशिव्या आगुनी (क			ESTRADERM	2 :	7			
: alcohol swabs	NG		estradiol		7			Ħ
B & D INSULIN SYRINGE			ESTRASORB	3				
gauze pad	NC L		ESTROGEL	3				Ħ
INSULIN SYRINGES			estropipate					Ħ
(all other brands)	3		gynodiol		7			
ONE TOUCH BASIC/			MENEST	2	7			
PROFILE/ONE TOUCH	1 2		MENOSTAR	3	7			Ħ
TEST STRIPS			OGEN	3	es a contract Transport			
ONE TOUCH FAST TAKE TEST STRIPS	2 12 1		ortho-est					
ONE TOUCH SURE STEE			PREMARIN	3	7			Ħ
TEST STRIPS	2		VIVELLE	2:	7			
ONE TOUCH ULTRA TES	ST THE STATE OF TH		VIVELLE-DOT		7			ö
STRIPS	2		VIVELLE-DOT	- 2	-33.408			

20

	aturul Juruliakhaba	nii.	
		4	
	e de la Companya de		gil∄ili⊎⊟
·,			Gopay Level Quantite Limits Recent
ABEL NAME		LABEL NAME	
		tinsulm (Carinoed).	androsprenski britisticki česti test isest
CONAL F		NOVOLIN 70/30	
POLLISTIM		NOVOLIN N	
FOLLISTIM AQ	DIVISATE SECTION OF SEC	NOVOLIN R	
BRAVELLE	PMID III	NOVOLOG	201
REPRONEX		NOVOLOG MIX 70/30	
MENOPUR	DAISM SERVED SERVED SERVED	Jinedin Senstiring?	Medic i
ទៀបថ្មាសារាស្រែរប្រស		ACTOS	
bubbli-pred		AVANDIA	
CELESTONE		Megiliinide/Aribiog	STREET, THE PARTY OF THE CALLSON
cortisone AC		CANTARANTA CAMBANA CAM	
dexamethasone		PRANDIN	
ENTOCORT EC	菱川翼列門	: असेरिकारी जात्त्र किन्नोरी	
hydrocortisone		CARNITOR	
methylpred		CYSTADANE	
ORAPRED		HECTOROL	
prednisolone		ORFADIN	2 4
prednisone		SENSIPAR	
	Control Building Control	ZEMPLAR	
GENOTROPIN		Whiteleter it (our	PARTHERINAL MANAGEMENT CONTRACT WITH MANY
HUMATROPE		fludrocort	
MORDITROPIN		The state of the s	
NUTROPIN		Rosterio Phintery	Parameter (Contract Contract C
NUTROPIN AQ		DDAVP	
SAIZEN		desmopressin	
SEROSTIM		🚆 (પ્રાપ્ટ) સ્થાન (૧૦) માટલ	រាមប្រភពព័ន្ធក្រៅពី(ម
TEV TROPIN		medroxyprogesterone	
		progesterone	
		DEPO-PROVERA	
SOMAVEDT		Prografili (00s	
(Stanish day) watel	electionical	camila	
GEREF		eriin	
lingulin es es Es		jolivette	
HUMALOG		nora-be	
HUMALOG MIX 75/25		NOR-OD	
HUMULIN 50/50		ORTHO MICRONOR	
HUMULIN 70/30		OVRETTE	
HUMULIN L		THE CO.	
HUMULIN N		Progestifis **	anderestern contacts con red as
HUMULIN R	22 11 11 11 11 11	medroxyprogesterone	1
HUMULIN U		acetate	
ILETIN II LENTE		norethindrone acetate	
ILETIN II NPH		PROMETRIUM	
ILETIN II RG		Sulfonylureas 2	
LANTUS	12.	AMARYL	3

•	8			
:	dopay level Quantity	2 5 1		Copay Level Quantit Imits Mecen
			LABEL NAME	Copay level limits freed Step
ABEL NAME			100	
illi mayjukeals (domini	2 1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.	egiu carsi sono ancesi le	- Antispasinione (s - clidinium/chlordiazepo	
chlorpropamide				
glimepiride			12,000,000	
glipizide			hyoscyamine CR	
glipizide ER			propanthelin	
glipizide XL			SYMAX DUOTAB	
glyburide			^ symax-SL	
glyburide micronized			symax SR	
glycron			Photesanic And Chi	DAUTES
tolazamide			CREON	
tolbutamide			KU-ZYME	
inymetaminend			KU-ZYME-HP	
ARMOUR THYROID	正洲語	調器器體	lipram	
BIO-THROID			lipram CR	
levethroid			☐ lipram PN	
levothyroxine			lipram UL	
Levisyl			- pancrelipase	
SYNTHROID			ULTRASE	多数 医阻阻阻
THYROLAR			- ULTRASE MT	
UNITHROID			VIOKASE	224
		超麗麗羅	- Pigeshredaryine	CHARLES CHARLES CHI COL
Gastrointestinal Sys	tem		Application of the last of the	
callegicación dante	16(0)11(4)		• digex	
ANZEMET		建富量	pancreatin	
KYTRIL	2012112-1-1-1		ाताहरू का जानक	zing Agents as had
ZOFRAN	200		URSO 250	
ZOFRAN ODT			URSŐ FORTE	
· · · · · · · · · · · · · · · · · · ·			ursodiol	
/engements:/Amili	ioineele		lisi/Antiallergy/Ag	នៅវិសី" នៃ
maldemar			GASTROCROM	
MENI-D	9		(g) Shimilan (s)	N221000000 SCHOOL SEE 139 EM
TRANSDERM				
SCOPOLAMINE			metoclopramide hcf	
trimethobenzamide			if /27/amagionists	
Antiemetics Miscell	aneous		AXID	
tebamide			cimetidine	
/Antiperistalfic Age	nts # Feb		famotidine	
diphenoxylate/atropine			nizatidine	
paregoric			PEPCID	
			PEPCID RPD	
Antispasmodies			ranitidine	
belladonna aklaloids			TAGAMET	
belladonna alkaloids/	Shill.		ZANTAC	- 30 10 12 17
opium			inflammatory Bo	wel Agents
belladonna alkaloids/			ASACOL	-22 F/Z-15 E
phenobarbital			ASACUL	

22

August 24, 2006

				y '		
	2		a		1	
	copay evel Quantific	2 5	lera Tera		Copay Level	imits Sep
ABEL NAME	Copa evel	Similar Times	8 <u>=</u>	LABEL NAME	896	
((Isiminia) (iliy bowel	Agents		T M	Broston Bung Inhibit		
AZULFIDINE	. 3 v	Actual Control of the Control		PRILOSEC	100-99-19-79-79-79-6	
AZULFIDINE ENTABS	1.3 mily	A 100 (100)		PROTONIX	Page Cambridge	
CANASA	the trace (didd states			ZEGERID	3	
COLAZAL	3 - 1 •	-1-5-1 -1		Read Combinations		
DIPENTUM	3			hc pramoxine		
mesalamine				lidazone		
PENTASA				lidocaine/hydrocortisone	1	
REMICADE	PMED			វុស្មេរ៉ូវ៉ា សម្រេញវិស្ត្		
ROWASA (enema only)		4 1 1 1 1 1 1 1 1 1		hydrocortisone acetate		三田田田
sulfasalazine sulfasalazine ER	101111111111111111111111111111111111111			proctocream hc		
sulfazine en				proctosert	1	
sulfazine EC	The state of the s			proctosol		
1 1				proctosol hc		
હિલ્ફાહિ /ક(હેઇ)લિંક	en e		223 2233	हैंगान्सकार है।अस्तिमान्।		
lactulose				រូវភេទម៉ាលី ភេពឆ្នាំណូម		
mieneval Spywist	and comme		44	EMEND		
colocort				(dira bruge-140ste)		
CORTIFOAM				The state of the s		
PARTIE BOVIE SALE	rome ui	S) Vitte		misoprostol		
LOTRONEX	9			શિલ્ફ ઉપલક્ષણ ઉછે.	Mariona	emunin pand never sand
ZELNORM	3	酮乙氧		HELIDAC		
exagne Combinelli	57.			PREVPAC	2	
COLYTE				Genitourinary Syste	m	
GOLYTELY	3			(લામાં)માં હાલાલા ક્રેમોમાં છે.		ie nies
HALFLYTELY	3			URELLE		
NULYTELY	3			urimar T		
peg 3350			IE SE	urin D/S		
trilyte				uriseptic		
Mise Anti-Liker				uro blue	12.1	
sucralfate				urogesic blue		
Mistellaheous Laxa	ilvae ka	eneral siti ek		UTA	34	
glycolax				Cysilnosis/Agleine		2000 PAR 2001 PAR 1
	2			CONTRACTOR AND MAINTAINS AND ASSESSMENT OF THE PROPERTY OF THE		
KRISTALOSE lactulose	A			CYSTAGON		
MIRALAX	3			intesilital (eyattis <i>)</i>	igents:	encontrol end general and
polyethylene glycol	100			DMSO		
				ELMIRON	233	
हित्ताता कातपुर <u>त्रका</u> नु				RIMSO	3.	
ACIPHEX	2 .			Phosphate Binders		
NEXIUM	1.3	$Y \mid Y$	14	FOSRENOL	2	
omeprazole				PHOSLO	2	
PREVACID	2	4 		RENAGEL	2	
PREVACID SOLUTAB	2	414			andluni	

		Mantalia Mantalia		24.1	Į.	NEW			
		₽		à					ď
	e e e					Copa	Quant	e e	ğ
LABEL NAME	89	85) l	i j	LABEL	NAME	ŬΞ	OB	31 (2)	
អ្នកម្មាស់ ស្រាវិទីសិស្សិស្សិស្សិស្សិស្សិស្សិស្សិស្សិស្សិស	Section 1			Vadina	i Estro gens				
AVODART	3			ESTRAC	E VAGINAL	3			
FLOMAX	2			ESTRING	ā	3:::			
PROSCAR #	33			FEMRIN		3 -			
UROXATRAL	2			PREMA	RIN VAGINAL	3 -			
Urinary Arraidesis at				VAGIFE		3-			
phenazopyridine hcl				Vagin	Haogestus		ninamisecoud case		
-				CRINO		3			
ម្រាក់កេត្ត សម្រើជាផ្នែរ៉ូប្រែ		क्रस्टान्स्य सर्व	जन्म छन	PROCH		3			
MACROBID	3			PROGE	STERONE VAGINAL	3			
methenamine hippurate				lmmui	nological Agent	s			
methenamine mandelate	1			interest de la constantina della constantina del	e zintelilängan	7.			
MONUROL	3			THALO					
nitrofurantoin					inaildoi n ain i	1000	3		
nitrofurantoin monohydra macrocrystal	Te .			AZASA				2000	
UREX has been been provided				1177					
the state of the s			100 G	CELLCI	prine	- 3			
เมินโยโซ - พ.ม.สายสมดัง	116			cyclosp					
bethanechol				cyclose	orine modified				
DETROL				gengra					
DETROL LA	3			IMURA		3			
DITROPAN	## 3			MYFO		3			
DITROPAN XL #	3			NEOR/		3			
ENABLEX				PROGE	RAF	2			
flavoxate				RAPAN	MUNE	3			
hyoscyamine				SANDI	MMUNE	3.			
hyospaz oxybutynin				infed	ions and Infest	ations			
OXYTROL	2			in Amer					
SANCTURA	3			YODO		2			
URECHOLINE	3			Table .	NAME OF TAXABLE PARTY OF TAXABLE PARTY OF TAXABLE PARTY OF TAXABLE PARTY.				
URISPAS	3			Section Control of the Control of th	ज् <u>र</u> ीप्रत्वसंबंध				
VESICARE	12			neom					#
Vagjiral/Amidinediy	CHARACTE			TOBI	omycin	3		ilit	
	3			20000					
CLEOCIN VAGINAL					dillins // etg				
clindamax	3			amoxi		3.4			
METROGEL VAGINAL	3			AMO)					
nystatin vaginal				ampic	RMOX	· 3			
TERAZOL	3			princi					
terconazole				trimo					
tioconazole									***
ZAZOLE	3				elmintic	1			***
- ALULE				mebe	ndazole	a la		223 (12)	.6335.E

COMMONWEALTH REGISTER

1 / 1			e e e e e e e e e e e e e e e e e e e	
	Copay Level Ouantity	2 6 . 6		opay evel Quantity Imits Recent
ABEL NAME	Copay Level Quan		LABEL NAME	Copay Lavel Outan Clinins Step:
encistazondorekt	(1)	ee en 100 eeu 1010 eeu	/www.catovnelette	
RIFAMATE			FUZEON	
RIFATER	3	翻貫貫翻譯	HIVID	
antifulogals			INVIRASE	
ANCOBON			KALETRA #	
BIO-STATIN			LEXIVA	
GRIFULVIN V	- 9		NORVIR	
GRIS-PEG			RESCRIPTOR	
LAMISIL #			RETROVIR	
nystatin			REYATAZ	
anhoemial -		erect izer civil Isaaca (Sist	SUSTIVA	
ARALEN			TRIZIVIR	
chloroquine			TRUVADA	
DARAPRIM			VIDEX	
hydroxychloroquine sui	fate 1		VIDEX EC	
LARIAM	10.0		VIRACEPT	
mefloquine			VIRAMUNE	
primaquine			VIREAD	
quinerva			ZERIT	
quinine sulfate			ZIAGEN	
Manalaria Root			វីមេម៉ែត (និវិកម៉ានេ	diens.
FANSIDAR			REBETRON	
MALARONE			Avalenciny (die	
		開西羅 開 題	azithromycin	
कारकारला जनसङ्ख्या	Edena.	50760 202 E285 20646 bb2	ZITHROMAX	
ethambutol			ZMAX	
isoniazid			(Georgio Julius)	
MYAMBUTOL	2 2) National Control	
pyrazinamide			cefadroxil	
rifampin			cephalexin DURICEF	
/Amijo ovozost /agi		and the second second second	PANIXINE	
ALINIA	32			
MERRON	2		PORTON DESCRIPTION OF THE PROPERTY OF THE PROP	Zigii (steprepetito); Angresia massa di seria 1886
/Amilia (ઇઇ) (કોર્ક			cefacior	
AGENERASE			cefaclor ER	
APTIVUS	3 3		CEFTIN	
COMBIVIR	2		cefuroxime	
CRIXIVAN	2		CEFZIL	Commission Commission and Commission of the Comm
didanosine delayed re			RANICLOR	
EMTRIVA	⊞2			and Generation
EPIVIR	2		CEDAX	
EPIVIR HBV	2		cefpodoxime	
EPZICOM.	- 3			2
FORTOVASE	2		SPECTRACEF	2

			i.		
	Copay Evel Quamity	Adeletti 1607 1708	LABEL NAME	Copay evel ouantity	
ABEL NAME	piloteliteral municipal (Calabasas) dispersión				
के हिन्दु सामित्र होते हैं। स्ट्रीतिक स्ट्राह्म स्ट्रीतिक स्ट्रीतिक स्ट्रीतिक स्ट्रीतिक स्ट्रीतिक स्ट्रीतिक स्ट्रीतिक स्ट्रीतिक स्ट्रीतिक	(៩៨៧៦៤)ព្រ		Hepatitis Agents (co		
on gred - all			PEG-INTRON	3	
SUPRAX	3		REBETOL	1	
VANTIN	3		ribasphere ribavirin		
ត្រូវប្រហែលមួយ 🖟 🚎	and the second s	soul HAZI card sättä:			
BIAXIN	3		រដ្ឋមេលាម «វិបាមមេ		
BIAXIN XL	2		acyclovir		
clarithromycin			EAMVIR	2	競兵選 顧問報題
វត្តិ ម៉ាងចូងមេន	- como como Residio	taga dani sani yasin	VALTREX ZOVIRAX	3	
CYTOVENE #	2				國盟盟國
gançiclovir			imideralistice (4:	and the local	
VALCYTE	22		DIFLUCAN	3	
iniditonyib.			(all other strengths)	111111111111111111111111111111111111111	
DYNABAC		園園園園	DIFLUCAN 150 mg fluconazole		
องนั้นหอนพบกับร้อง รัง			(all other strengths)		
ees.			fluconazole 150 mg		经 间量量
erythrocin			itraconazole		
erythromycin			ketoconazole		
erythromycin delayed			SPORANOX		
release particles			VFEND		
erythromycin ethylsuccina			ារមានមន្ត /ខ្មែរម		
PCE			FLUMADINE		
regregation		an each training result branch	RELENZA		
GEOCILLIN			rimantadine		
វារស់សម្រាលវិហា <u>ម</u> ្			TAMIFLU		ZEE
AVELOX	2.				
AVELOX ABC	2	1克爾羅麗	Kerolides KETEK		
CIPRO	3				
CIPRO XR			រម្មហ្លស់ចាពី៤		
ciprofloxacin			dapsone		
FACTIVE			langoramide:		
FLOXIN			clindamycin		
LEVAQUIN			Mise Zini Jinasi W		
MAXAQUIN			LORABID	2	
NOROXIN	43		metronidazole		
ofloxacin			metronidazole SR		
TEQUIN	3		NEBUPENT	2	
Repătitis Agents			trimethoprim	11	
BARACLUDE	3 7		XIFAXAN	3	
COPEGUS	3		Natural Penicillins		
HEPSERA	2				F14, 276 (25)
INFERGEN	3 3		penicillin VK veetids	1	
PEGASYS	2		veetias		

26

	skituitaa urus. N	nadsalsalseuesselb ü		V. Mielskie	School de la company de la
4 4			4		
	12	l i i l			
				Copas	India India Step
LABEL NAME	8 <u>4</u> 6		LABEL NAME	OH (
(એ સ્ટ્રુપ્ટ) (હેમાં આપ્યોને	geriariya) alabi	II 34 36 16 16 16 16 16 16 16 16 16 16 16 16 16	(គា្ន៧៣០ ដែញទៀតចាំនៅ	anniniei	
ZYVOX	2:		fortical		
Pandiline ondinatio			FOSAMAX	2	
amoxicillin/K clavulanate		esenes	FOSAMAX PLUS D	2	
AUGMENTIN	3 1		MIACALCIN NASAL	3	82561 666 61 624 6666 86661 666 61 616 6266
AUGMENTIN ES	3		SKEUD		
AUGMENTIN XR			(बक्तरन्त्रीवर्गमन्त्राचीस्थित)	ens	ज्ञानक राज्या रहा स्टब्स स्टिस्ट
।:लेक्स्मीक्रस्य व्यक्तिक	Property March	PER CHICAGO SERVICE CONTROL SCALE	baclofen		
dicloxacillin sodium	調盟 顯		carisoprodol		
सुक्षात्री हो (लोडू : १५४म) इ.स.हे.	ALTER IN		chlorzoxazone		
VIRAZOLE	(100.2		cyclobenzaprine hcl methocarbamol		
			orphenadrine ER		
इंगानिकानिका		H 55 H 111 H	SKELAXIN	112	
sulfadiazine			tizanidine		
sulfisoxazole			(વેનામાં માર્ગ કોલા (કોલા) વૃત્	THE STATE OF	Serfender annal enn anna landa
adminations of	Secretary story	कार क्षेत्र कार्य प्रस्थात स्था	probenecid/colchicine		
ADOXA	3				
DECLOMYCIN			शिल्ब काल के अल्लाह		
demeclocycline			DANTRIUM		
doxy-caps			(១៨គឺ (១០៣០០៣៨៩)		क्रांस्ट व करने छन्न स्टान स्टान
doxycycline hyclate doxycycline monohydrate			RIDAURA		
DYNACIN			(6[9]1]		(Annabias) Engle (10) Engle (2005)
MINOCIN			allopurinol		
minocycline			colchicine		
MONODOX	3		કિલ્લામાં કિલ્લામાં	Modula	OK
tetracycline			EVISTA	2	
Musculoskeletal Sys	tom		Misteration (se	midneri	(0)15
			carisoprodol/aspirin	蕭繼	
/Antimyasticanic /Age			carisoprodol/aspirin/		
MESTINON			codeine		
pyridostigme			orphenadrine cpd		
/amii តែឧបក្រស់ប្រ/Amii	บครอบอาห	इसकारी रकता सम्बद्ध सम्बद्धाः जीव	orphenadrinelaspirinl caffeine		
RHEUMATREX			orphengesic		
Anni anderelighas Me)itolefo)itos		orphengesic forte	1	
Amilionles .	- 100 - 1 000 110	essen san sand esseel de	INS/Alibbs		
HUMIRA	3		ARTHROTEC	3	
Caldum Regulators			CELEBREX	3	
ACTONEL	harden and the second		DAYPRO	3.	
ACTONEL with CALCIUM			diciotenac		
BONIVA	And the second second second second		diclofenac potassium	1	
DIDRONEL	3		diclofenac sodium XR	3	
FORTEO	2		etodolac		


27

August 24,2006

		- L			L			2			A
	8	Ĕ,	Ł		18		8-	置的	ŧ		æ
	Copay	Quamit Imits	ופכפו		Įĕ	k safalin Nakilak	Copa	Ouant	¥	9	2
LABEL NAME	V.	OΞ	8	ý	严	LABEL NAME	보니	0=	4	50	
NS/AIDG/(Grimmai)	men mu					Opthalmic Agents					
etodolac ER	3					/រប់ខ្មែលមួយ /រប់ខ្មែរ ទ					
fenoprofen	1					ALPHAGAN P	2	Harkette o			
flurbiprofen						brimonidine					
ibuprofen		9 8				dipivefrin	100				t
indomethacin	1 -2					IOPIDINE	3				
indomethacin ER	1					PROPINE					
ketoprofen *	1	8	2			S. market and the second secon			1		
ketoprofen ER	3					្រុះខ្មែន មៀត្រង្គបាននេះ (ឲ្យបញ្ជាំ	Califolic	500000000		4 C.	響
ketorolac	1	7				betaxolol					
LODINE XL	3					& BETIMOL	3		4		¥
				H		BETOPTIC-S	112				H
MOBIC	3				4	carteolol					
1100,011,1410111	3				鐵貫	COSOPT	2				
NAPRELAN	3				4	ISTALOL		200			
naproxen						levobunolol					
ORUVAIL ER	3					metipranolol					
oxaprozín	3					OPTIPRANOLOL	9.3	2			
piroxicam						timolol					
PONSTEL	3					timolol maleate ophth	1				
PREVACID NAPRAPAC	-3		M			(Mining)					
RELAFEN			Н			carboptic					
sulindac					-	ISO CARBACHOL	113				
TOLECTIN	3					ISOPTO CARPINE	3				
tolmetin sodium	3	7				PHOSPHOLINE	3				
TORADOL ORAL		Y.				pilocar	1				
VOLTAREN	3					pilocarpine					
VOLTAREN XR	Pirk to the state of					PILOPINE HS					
Parintina Synthesis	Inhib	100			翻	piloptic					
ARAVA	3					REV-EYES	3				
leflunomide						200					
Salitylates						Miss Objections					
amigesic						ACULAR					
aspirin CR	1.1					ACULAR LS	3				H
aspirin CR EC				H		ACULAR PF	3				4
choline/magnesium						akorn balanc					
salicylates						ALAMAST	3		H		H
diflunisal						ALOCRIL			H		4
mst 600	1					ALOMIDE	2		H		
salflex	1.1					AZOPT	2		H		
salsalate						bal salt			H		
tricosal	1					cromolyn sodium ophth	1		H		
zero-order						ELESTAT	31		Н		
Soluble:Tumor Necro	sis Fa	ctor	Re	er	itd	EMADINE	3		Ш		
Agents			饠		虁	flurbiproten	1				
ENBREL	MED				117	OPTIVAR	2				

28

	sersiste k	prosession and the second		
the first of the control of				
	le.			
	9-1 E E	l 5 LE	, <u>, , , , , , , , , , , , , , , , , , </u>	Gopay Level Ouantity Imits Present Step-
LABEL NAME	copay avel		LABEL NAME	
Medical Control of the St	emerume eman (ii) ;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;		(वृत्तीकृश्यक्तीत्ताः अस्ताति (वृ	(i.e., 115.17.1)
PATANOL			HMS	
TRUSOPT	2		LOTEMAX	
VOLTAREN	2		neomycin/polymyxin/	
XIBROM	3.		bacitracin/hydrocortiso	
ZADITOR	2		neomycin/polymyxin/ dexamethasone	
Constitution Zaidali		el segli padi kanani min	neomycin/polymyxin/	
Carlotte Street Colorania Control of the Coloran Color			hydrocortisone	
bacitracin bacitracin/neomycin/			poly-dex	
polymyxin			POLY-PRED	
bacitracin/polymyxin			PRED-G	
ciprofloxacin			PRED-G S.O.P	
erythromycin			prednisolone	
gentamicin			sulfacetamide sodium/	
neomycin/bacitracin/		超超層型型	prednisolone	
polymyxin			TOBRADEX	
neomycin/polymyxin/			VEXOL	
gramicidin ophth			២០១៤២២៤៣៩១២	
ofloxacin			LUMIGAN	
polymyxin B/trimethop	rim 1		TRAVATAN	
QUIXIN	3 6		XALATAN #	
sulfacetamide sodium	opth I 🖽		Otic Agents	2006年1月1日 1日本
tobramycin			The second secon	
trifluridine			(anganianiania	THE COURT OF THE PARTY AND THE PARTY HAS
triple antibiotic			FLOXIN OTIC	
VIGAMOX			(Pite (Pontone Hore)	200 PD 01 PD
ZYMAR		葡萄萄葡萄	antipyrine/benzocaine	
(ច្រុះតែងគ្រាខៅព្យាមេរិ	(១ភូមិស្រី១៤)៖		CIPRO HC	
RESTASIS			CIPRODEX	
(១)ក្រុងទៀតថ្ងៃស៊ី	Tit.		COLY-MYCIN-S	
ak-pred			cortomycin	
ALREX			neamycin/polymyxin/ hydrocortisone	
bacitracin/polymyxin/				
neomycin/hydrocor	tisone 1		Respiratory Tract A	Agents
BLEPHAMIDE S.O.P.	3 4		Am teisimmetije. Mo	।(जुल्बे(स्थाः /:४४४)(क्ल <mark>िस</mark>
dexacidin			WOLAID.	
dexamethasone phos	phate t		Antiastingatics 4	niidiolineelis
dexamethasone/			ATROVENT	
neomycin/polymyxi			ATROVENT HFA	
dexasol	1		ipratropium	
dexasporin			SPIRIVA	
fluorometholone			Antihistamines 2	
fluor-op				
FML-S	3		chlorpheniramine ER	



30

www.aetna.com/formulary

PAGE

网络四种手术 网络证

Precertification List

iffekareunggass	PREGER	TIFICATION DRUG(ภ /
Acne Products	ACCUTANE amnesteem AVITA PR ≥ 36 yr ol claravis	RETIN-A MICRO gel RETIN-A PR ≥ 36 yr d SOTRET tretinoin PR ≥ 36 yr	old
	isotretiņoin		
Agents for Gauther Disease	ZAVESCA		<u> </u>
Anti-Cataplectic Agents	XYREM	/	
Antihistamines - Non-Sedating	ALLEGRA ALLEGRAD CLARINEX	CLARINEX REDITAS CLARINEX-D fexofenadine	SEMPREX-D ZYRTEC ZYRTEC-D
Antifungals - Topical	PENLAC NAIL LACQUE	R . /	
Antimalarial (covered for active treatment only - not covered for prophylactic treatment)	ARALEN chloroquine DARAPRIM FANSIDAR	hydroxyghloroquine LARIAM MAYARONE melloquine	PLAQUENIL primaquine
Antineoplastic Enzyme Inhibitors	GLEEVEC	RESSA	TARCEVA
Antineoplastics Misc.	WITRON-A	ROFERON-A	
Attention-Deficit/Hyperactivity Disorder Agents	PNOVIGIL		a State
Blood Clotting Factor VIIa	NOVOCEVEN		
Blood Clotting Factor VIII	ADVATE ALPHANATE HELIXATE FS HEMOFIL M	HUMATE-P HYATE:C KOATE-DVI KOGENATE FS	MONARC-M MONOCLATE-I RECOMBINATE REFACTO
Blood Clotting Factor IX	ALPHANINE SD BEBULIN VH	BENEFIX MONONINE	PROFILNINE PROPLEX T
FluoroquinolonesPR ≤ 10 yr old	AVELOX CIPRO CIPRO XR ciprofloxacin	FACTIVE FLOXIN LEVAQUIN MAXAQUIN	NOROXIN ofloxacin TEQUIN ZAGAM
Growth Hormone	GENOTROPIN HUMATROPE NORDITROPIN NUTROPIN	NUTROPIN AQ PROTROPIN SAIZEN SEROSTIM	TEV-TROPIN ZORBTIVE
Hepatitis Agents	INFERGEN PEG-INTRON	PEGASYS	REBETRON
Imidazole-Related Antifungals	DIFLUCAN fluconazole	itraconazole LAMISIL TAB	SPORANOX VFEND
Immune Globulin	IV IMMUNE GLOBUL	N(IVIG)	
Intestinal Cholesterol Absorption Inhibitors	ZETIA		
Irritable Bowel Syndrome (IBS) Agents	LOTRONEX	ZELNORM	
Oxazolidinones	ZYVOX		

THERAPEUTIC CLASS	PRECEI	RIFICATION DRUG	3(5)
Prostatic Hypertrophy Agents (PR for females only)	AVODART . CASODEX	FLOMAX PROSCAR	OROXATRAL
Metabolic Modifiers	ORFADIN		.,
NSAID's	CELEBREX	PREVACIO NAPRAP	AC
Pulmonary Hypertension	TRACLEER REVATIO	VENTAVIS	<u> </u>
Proton Pump Inhibitors	ACIPHEX NEXIUM opreprazole	PREVACID PRILOSEC	PROTONIX ZEGERID
Respiratory Syncytial Virus	SYNAGIS		
Serotonin-Norepinephrine Reuptake Inhibitors	CYMBALTA	EFFEXOR XR	1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1
Tetracyclines PR ≤ 8 yr old	ADÖXA DECLOMYCIN demeclocycline doxycycline	DYNACIN MINOCIN minocycline MONODOX	tetracycline VIBRATAB
Typhoid	VIVOTIF BERNIA EC	# in the	na wa

his in the

Step-Therapy I	ist
----------------	-----

			RECOUNTED PRERECULTY F
THERAREUTIC GLASS	STEP-THER/	PY DRUG	DRUG(S)
cne Products	ACCUTANE		isotretinoin
CE Inhibitars	ACCUPRIL		quinapril
	ACCURETIC		quinapril/hctz
. \	CAPOTEN		captopril
\	CAPOZIDE		captopril/hctz /
\ '	LOTENSIN		benazapril /
	LOTENSIN HCT		benazapril/nctz
	MONOPRIL		fosinopri
\	MONOPRIL HCT		fosinopril/hctz
	PRINIVIL	ZESTRIL	lisinopril
	PRINZIDE	ZESTORETIC	lis/nopril/hctz
Y	VASERETIC		/enalapril/hctz
	VASOTEC		enalapril
	ATACAND	AVAPRO /	COZAAR and DIOVAN
AngiotensIn II Receptor		/	DIOVAN HCT and HYZAAR
Antagonist	ATACAND HCT		TAZORAC
Antipsoriatics	68X6ALX	_pemgline _	
Attention-Deficit1	Desoxyn \ Pegannn	RITALIN LA RITALIN SR	Any one of: methylphenidate SR, ADDERALL X
Hyperactivity Disorder Agents	FOCALIN	R_ALIN SR	METADATE CO-METADATE RR.
Ageno	FOCALIN XR	STRATTERA	
Biguanides	GLUCOPHAGE	$\overline{}$	metformin
	GLUCOPHASE	XL \	metformin SR
Calcium Blockers	ADALAT /	PROCARDIA	nifedipine
	ADALAT CC	PROCARDIA	XL nifedipine extended release
	CALAN	ISOPTIN	verapamil
	CALAN SR	ISOPTIN SR	verapamil extended release
	COVERA-HS	VERELAÑ	<u>\</u>
	ARDENE		nicardipine
	CARDIZEM	DILACOR	diltiazem
	CARDIZEM CD	TIAZAC	dilijazem extended release
	DILACOR XR	* -	
H-2 Antagonists	AXID		nizatidine
	PEPCID		Suspension = ZANTAC syrup
			Tablet or Chewable = famotidine
	TAGAMET		cimetidine
	ZANTAC		ranitidine
HMG CoA Reductase	ALTOPREV	MEVACOR	lovastatin, LESCOL LESCOL XL,
Inhibitors/	CADUET	PRAVACHOL	VYTORIN and ZOCOR
	CRESTOR LIPITOR	PRAVIGARD	
Inflormations Bourd Agent		DENEAGA	sulfasalazine or ASACOL
Inflammatory Bowel Agent	NOVOLIN 70/2	PENTASA	RELION 70/30 HUMULIN 70/30
Insulin			HUMULIN N
	NOĀOTĪN N	r <u>elion n</u>	
	NOVOLIN R	RÉLION R	HUMULIN R
Misc. Anticonvulsants	NEURONTIN		gabapentin

Ste	p-T	her	ару	List
-----	-----	-----	-----	------

			REQUIRED PREREQUISITE
THERAPEUTIC CLASS	STERATHER	APY DRUG	DRUG(S)
Misc. Antidepressants1 Selective Sero tonin Reupake (nhibitors/ Serotonin-Norepinephrine Reuptake (nhibitors	CELEXA CYMBALTA DESYREL EFFEXOR EFFEXOR XR	PROZAC PROZAC WEEKLY REMERON REMERON	Any one of: bupropion, bupropion SB, citalopram, fluoxetine, paroxetine, mirtazapine, trazodone
	LEXAPRO LUVOX PAXIL PAXIL CR PEXEVA -LUVOX	SOLUTAB WELLBUTRIN WELLBUTRIN SR WELLBUTRIN XL ZOLOFT	fluvoxaynine
	SARAFEM		PAXIL/CR
Narcotic Combinations	ANEXSIA LORCET LORCET HD	MAXIDONE NORCO VICODIN ES	<i>hydr</i> ocodonelacetaminophen
1 . 1	LORCET PLUS LORTAB	vicodin hp ZYDONE	
	COMBUNOX CAPITALX ODE TYLENOL 33	INE	Any oxycodone combinations codeine/acetaminophen
· 新州 · · · · · · · · · · · · · · · · · ·	VOPAC (C)	∖TBVCET	propoxyphene-N/acetaminophen
	DARVON DARVON COIY	X	propoxyphene/aspirin/caffeine
	DURAGESIC/ FIORICET/COD	EINE	fentanyl patch butalbitallacetaminophen/caffeine/ codeine
	FIORINAL/COD MEPERGAN FO		butalbital/aspirin/caffeine/codeine meperidine/promethazine
	OXYCET PERCOCET	ROXICET TYLOX	oxycodone/acetaminophen
	PERCODAN TALACEN		ox codone/aspirin peniazocine/acetaminophen
	ULTRAM VICOPROFEN WYGESIC		tramadol hydrocodone/ibuprofen propoxyphege/acetaminophen
Nasal Steroids	NASACORT A		FLONASE and WASONEX
NSAID's	MOBIC	NAPRELAN	Use of two (2) preferred generic NSAID's
Platelet Aggregation Inhibitors	PLETAL		cilostazol
Posterior Pituitary	DDAVP		desmopressin
Proton Pump Inhibitors	NEXIUM PRILOSEC	PROTONIX ZEGERID	ACIPHEX and PREVACID
Urinary Antispasmodics	DETROL DETROL LA	DITROPAN XL SANCTURA	Any one of: ENABLEX, VESICARE, OXYTROL

Quantity Limit List

	OUANTITY LUI	AIT DRUG	QUANTITY LIMIT(S)
ACE inhibitors	ACCUPRIL	quinapril	5 mg, 10 mg and 20 mg = 1 tablet/day
	ACEON		2 mg and 4 mg = 1 tablet/day
	ALTACE		1.25 mg, 2.5 mg and 5 mg =
			1 capsule/day
	CAPOTEN	captopril	12.5 mg, 25 mg and 50 mg = 3 tablets/day
	LOTENSIN	benazepril	5 mg, 10 mg, and 20 mg = 1 tablet/day
	MAVIK		1 mg and 2 mg = 1 tablet/day
	MONOPRIL	fosinopril	10 mg and 20 mg ≈ 1 tablet/day
	PRINIVIL	ZESTRIL	2.5 mg. 5 mg, 10 mg, 20 mqand
	lisinopril		30 mg = 1 tablet/day
	UNIVASC		7.5 mg = 1 tablet/day
	VASOTEC	enalapril	2.5 mg, 5 mg and 10 mg = 1 tablet/da
Acne Products	ACCUTANE	isotretinoin	10 mg, 20 mg, and 40 mg =
,	4		30-day supply
Amphetamines	ADDERALL		5 mg, 7.5 mg, 10 mg, 12.5 mg. 15 mg
	amphetamine/de	ktro-	and 30 mg = 2 tablets/day
	amphetamine.		.20.mg.=.3 tablets/day
185 F 186 8 18 18 18 18 18	ADDERALL XI?.		All = 2 capsules/day
	DESOXYN	dextrostat	All strengths 1 tablets/day
•	dextroamphetam		
	DEXEDRINE		
	DEXEDRINE CR		All strengths = 3 capsules/day
	dextroamphetam	ine CR	
Angiotensin II Receptor	ATACAND		4 mg. 8 mg and 16 mg = 1 tablet/day
Antagonist	ATACAND HCT		16-12.5 mg = 1 tablet/day
9 0e.	AVALIDE		150-12.5 mg = 1 tablet/day
	AVAPRO		75 mg and 150 mg = 1 tablet/day
	BENICAR	***********	5 mg and 20 mg = 1 tablet/day
	BENICAR HCT		20-12.5.mg = .1 tablet/day
	COZAAR	***********	.25.mg and 50 mg = 1. tablet/day.
	DIOVAN		40 mg, 80 mg and 160 mg = 1 capsule or tablet/day
	DIOVANUIOT		
	DIOVAN HCT		80-12.5 mg = 1 tablet/day
	HYZAAR		50-12.5 mg =' I tablet/day
	MICARDIS		20 mg and 40 mg = 1 tablet/day
	MICARDIS HCT	*******	40-12.5 mg = 1 tablet/day
	TEVETEN	<u> </u>	400 mg = 2 tablets/day
Antihistamines-	ALLEGRA		30 mg and 60 mg= 2 tablets/day
Non-Sedating	fexofenadine	*******	180 mg = 1 tablet/day
	ALLEGRA-D		12 hour = 2 tablets/day
	1		24 hour = 1 tablet/day
	L	~~~~~~~~~~~~	
	CLARINEX		5 mg = 1 tablet/day Syrup = 10 ml/day

www.aetna.com/formulary

Quantity Limit List

THERAPEUTIC CLASS	QUANTITY LIMIT DRUG	QUANTITY LIMIT(S)
Antihistamines -	CLARINEX REDITAB	2.5 mg and 5 mg= 1 tablet/day
Non-Sedating	CLARINEX-D	24 hour = 1 tablet/day
(continued)	SEMPREX-D	4 capsules/day
(continued)	ZYRTEC	5 mg and 10 mg = 1 tablet or
		chewable/day
		5 mg/5 ml syrup = 10 ml/day
	ZYRTEC-D	2 tablets/day
Antihyperlipidemic	ADVICOR	All strengths = 2 tablets/day
Combinations	VYTORIN	All strengths = 1 tablet/day
Attention-Deficit/	CONCERTA	18 mg = 3 tablets/day;
Hyperactivity	1	27 mg, 36 mg and 54 mg =
Disorder Agents		2 tablets/day
	FOCALIN	2.5 mg, 5 mg and 10 mg = 2 tablets/day
	FOCALIN XR	All strengths = 1 capsule/day
	METADATE CD	10 mg = 1 capsule/day
	No. of the second second	20 mg = 3 capsules/day
		30.mg ≈ 2.capsulesiday
	WETAOATE ER RITALIN	5 mg, 10 mg and 20 mg= 3 tabletsiday
	methylin RITALIN SR	Comprehense of the state of the
	methylin ER methylphenidate	
•	methylphenidate SR	
	METHYLIN chewable	2.5 mg, 5 mg and 10 mg = 6 tabletsiday
	and solution	5 mg/5 ml solution = 60 ml/day
en e		11.0mg/ 5.ml.solution = 30.ml/day
	PROVIGIL	100 mg and 200 mg = 2 tabletsiday
the first was been seen to be a first	RITALIN LA	10 mg, 20 mg, 30 mg and 40 mg =
		.2.capsules/day
	STRATTERA	All strengths = 2 capsules/day
Benzisoxazoles	RISPERDAL	4 mg = 4 tabletslday
	RISPERDAL M	All other strengths = 2 tablets/day
Calcium Blockers	ADALAT CC	30 mg = 1 tabletiday
	nifedical <i>XL</i>	60 mg = 2 tablets/day
	nifedipine SR	1 × 8
	PROCARDIA XL	
**	CALAN SR ISOPTIN SR	
		180 mg = 2 tablets/day
	CARDIZEM CO taztia XT	120 mg = 1 capsule/day
	CARDIZEM LA TIAZAC	180 mg = 3 capsules/day
	cartia XT DILACOR XR	
	diltia XT	
	diltiazem extended	
	release beads SR	
	diltiazem SR	

THERAPEUTICE BASSENS	QUANTITY LIV	IT DRUG	OVANTITY-LIMIT(S)
Calcium Biockers	COVERA-HS	1	180 mg = 2 tablets/day
(continued)	NORVASC		25 mg and 5 mg = 1 tablet/day
(continuou)	PLENDIL		25 mg and 5 mg = 1 tablet/day
	SULAR	1	10 mg and 20 mg = 1 tablet/day
		}	30 mg = 2 tablets /day
	verapamil SR		120 mg = 1 capsule or tablet/day
	VERELAN SR	_].	180 mg = 2 capsules or tablets/day
4	VERELAN PM		100 mg = 1 capsule/day
			200 mg = 2 capsules/day
Calcium Regulators	ACTONEL		$35 \text{ mg} \approx 4 \text{ tablets/28-day} \text{ supply}$
_	ACTONEL with CA	LCIUM	· · · ·
	BONIVA		150 mg = 3 tablets/90-day supply.
			2.5 mg = 1 tablet/day
•	FOSAMAX		35 mg = 4 tablets/28-day supply
	ł		70 mg = 4 tablets/28-day supply 70 mg/75 ml solution = 4 doses
	1.	- 1	(75ml each)/28-day supply increments
	FOGANAN DIVIS D		4 tablet/28-day supply
	FOSAMAX PLUS D All (except SEASO)		Limit = 1.4 tablets/day or 28-day supply
Combinations OC's		FAZACLO	12.5 mg = 1 tablet day
Dibenzapines	CLOZARIL		25 mg = 1 tabletoday
	ÇEOZAME		100 mg = 9 tablets/day
	SEROQUEL		25 mg = 6 tablets/day
	SENOGOLE		100 mg = 3 tablets/day
			200 mg = 4 tablets/day
			300 mg = 2 tablets/day
· · · · · · · · · · · · · · · · · · ·	SYMBYAX		All strengths = 1 tablet/day
	ZYPREXA		2.5mg = 2 tablets/day
	ZYPREXA ZYDIS		All other strengths = 1 tablet/day
Estrogens	ALORA	VIVELLE	All strengths = 8 patches/28 day supply
	COMBIPATCH	VIVELLE-	教练 文章
	ESCLIM	DOT	
	ESTRADERM		
	CENESTIN	GYNODIOL	All strengths = 1 tablet/day
	ESTRACE	MENEST	
	<i>estradiol</i> ESTRATAB	PREMARIN	
	CLIMARA	estradiol	,
	CLIMARA	estracioi patch	This are rights = 4 parties 20-gay supply
, .	PRO WEEKLY	MENOSTAR]
Hepatitis Agents	BARACLUDE	WILL TOO IT W	All strengths = 1 tablet/day, soln =
ricpatitis Agents	DANACEODE		20 ml/day
HMG CoA Reductase	ALTOPREV		All strengths = 1 tablet/day
Inhibitors	CADUET		All strengths = 1 tablet/day
**	CRESTOR		All strengths = 1 tablet/day

www.aetna.com

37

Quantity Limit List

THERAPEUTICE (PASS	QUANTITY LIMIT DRUG	QUANTITY LIMIT(S)
HMG CoA Reductase	LESCOL	All strengths = 2 tab~&+~
Inhibitors	LESCOL XL	80 mg = 1 tablet/day
(continued)	LUPITOR	All strengths = 1 tablet/day
(**************************************	MEVACOR lovastatin	All strengths = 2 tablets/day
	PRAVACHOL	All strengths = 1 tablet/day
	FRAVIGARD	All strengths = 1 tablet/day
	ZOCOR	/Al strengths = 1 tablet/day
Imidazole-Related Antifungals	DIFLUCAN fluconazole	150 mg only = 1 dose/30-day supply
Influenza Agents	RELENZA	1.treatments (units)/year.
	TAMIFLU	1 treatments (20 capsules)/year
Intestinal Cholesterol Absorption Inhibitors	ZETIA	10 mg = 1 tablet/day
Inflammatory Bowel	ASACOL	400 mg = 12 tablets/day
Agents	AZULFIDINE sulfazine	500 mg = 12 tablets/day
	AZULFIDINE sulfazine	
	ENTABS entab	
	sulfasalazine	And the second s
the state of the s	CANASA ROWASA	500 mg = 3 suppositories/day 1000 mg = 1 suppository/day
	COLAZAL	750 mg = 9 capsules/day
en e	DIPENTUM	250 mg = 12 capsules/day
	PENTASA	250 rng = 20 capsules/day
Leukotriene 11	ACCOLATE	10 mg and 20 mg = 2 tablets/day
Leukotrierie	SINGULAIR	4 rng granules = 1 granule/day
	SINGULAIN	10 mg = 1 tablet/day
		4 mg and 5 mg chewable ≈ 1 tabletIday
Migraine Products	MIGRANAL	4 kits/30-day supply
5-HT3 Receptor	ANZEMET.	Total quantity any strength =
Antagonists		5.tablets/30-day.supply
	KYTRIL	1 mg = 10 tablets/30-day supply Liquid = quantity > 5 bottles/
	70FDAN	30-day supply
	ZOFRAN ZOFRAN ODT	4 mg and 8 mg = 12 tablets/ 30-day supply
	ZOFRAN OD I	24 mg = 5 tablets/30-day supply
		Liquid = 1 bottle (50 ml)/30-day supply
Misc. Antidepressants	bupropion	75 mg = 6 tablets/day
mad, Antidoprocodino	WELLBUTRIN	1.00 mg = 6 tablets/day
	bupropion SR	100 mg, 150 mg and 200 mg =
	budeprion	2 tablets/day
	WELLBUTRIN SR	
	maprotiline	25 mg = 1 tablet/day
		50 mg = 2 tablets/day
**	i .	75 mg = 3 tablets/day

38

www.aetna.com

atalakvasetilleresvastille	QUANTITY LIMITARUS	TQUANTINALIMIT(S)
Mix. Antipsychotics	GEODON	All strength ≈ 2 capsules/day
Mix. Anticonvulsants	gabapentin NEURONTIN GABARONE	
	LYRICA	All strengths = 3 capsules/day
Narcotic Agonists	ACTIQ	All strengths = 6 lollipops/day
	butorphanol nasal STADOL NS	
	COMBUNOX	Limit = 4 tablets/day
	DURAGESIC	20 patches/30-day supply
	fentanyl patch	
	ketorolac TORADOL	20.tablets/30-day_supply
	oxycodone SR	Quantitiesup to a total dosage of
	OXYCONTIN CR	320 mg/day or 120 tablets/
	ALIDEN	30-day supply
Non-Barbiturate	AMBIEN	5 mg = 2 tablets/day 10.mg = 1 tablet/day
Hypnotics	AMBIEN CR	6.25 'hg and 12.5 mg = 1 tablet/day
	LUNESTA	All strengths = 1 tablet/day
	SONATA	5 mg = 4 tablets/day
	SUMAIA	10 mg = 2 tablets/day
NSAID's	(CELEBREX	100 mg = 60 capsules/30-day supply
isomo s		200 mg = 30 capsules/30-day supply
		400 mg = 60 capsules/30-day supply
Prostatic Hypertrophy Agents	AVODART	0.5 mg = 1 capsule/day
Quinolinone Derivatives	ABILIFY	All strengths = 1 tablet/day Solution = 30 ml/day
Selective Serotonin	CELEXA citalopram	10 mg, 20 mg and 40 mg = 1 tablet/day
Reuptake Inhibitors	fluoxetine RAPIFLUX	10 mg = I tablet/day
	PROZAC	20 mg= 4 tablewday
.*	1	40 mg = 2 tablewday
		Liquid 20 mg/5 ml = 10 ml/day
	L .,	Weekly = .4.tablets/28-day supply
	fluvoxamine	25 mg and 50 mg = 1 tablet/day 100 mg = 3 tablets/day
	LEXAPRO	5 mg, 10 mg and 20 mg = 1 tablet/day
	LEXAPRO	5.mg/5.ml solution = 20.ml/day
	paroxetine PEXEVA	10 mg and 20 rng = 1 tablet/day
	PAXIL	30 mg and 40 mg = 2 tablewday
		Suspension 10 mg/5 ml = 30 ml/day
	SARAFEM	10 mg= 1 tablet/day
		20 mg= 2 tablets/day
	ZOLOFT	25 mg = 1 tablet/day
	1	50 mg = 1 1/2 tablewday
		100 mg = 2 tablets/day
	I	Liquid = 10 ml/day

www.aetna.com

Quantity Limit List

THERAREUMERASSEE	QUANTITY LI	MIT DRUG	QUANTITY LIMIT(S)
Serotonin- Norepinephrine Reuptake Inhibitors	EFFEXOR		25 mg and 100 mg = 3 tablets/day 37.5 mg = 4 tablets/day 50 mg = 6 tablets/day 75 mg = 5 tablets/day
Serotonin Agonists	AMERGE		Total quantity any strength = 9 tablet9 30-day supply
	AXERT		All strengths = 6 tablets/30-day supply
	FROVA		2.5 mg = 9 tablets/30-day supply
	IMITREX	:	Nasal = 6 sprays/30-day supply Injection = 2 kits/30-days or 10 vial9 30-day supply
	MAXALT	· ·	Tablets (All strengths) = 18 tablet9 30-day supply Total quantity any strength = 12 tablets/
	MAXALT MLT	-	30-day supply
	RELPAX	· .	20 mg = 12 tablets/30-day supply 40 mg = 6 tablets/30-day supply
	ZOMIG ZOMIG ZMT		2.5 mg = 12 tablets/30-day supply 5 mg = 6 tablets/30-day supply
Substance P/Neurokinin	EMEND		Nasal = 6 sprays/30-day supply 80 mg and 125 mg = 5 tablets/
1 (NK1) Receptor			30-day supply
Antagonist			80 mg/125 mg combo pack= 2 package (6 tablets)/30-day supply
Proton Pump inhibitors	ACIPHEX NEXIUM	PREVACID SOLUTAR PROTONIX	All strengths = 1 tablet or capsule/day
	omedrazole PREVACID	LUGIQUE	
	ZEGERID		20 mg and 40 mg packets = . 1 packet/day
Ulcer Therapy Combinations	HELIDAC	PREVPAC	1pack/day for 14-days

40

经未通过的 化

Index

#	ALKERAN · · · · · · · · · · · · · 8	ARMOUR THYROID22
# 8-MOP	ALLEGRA 30, 31, 35	AROMASIN8
u-14101 .	ALLEGRA-D 30, 31, 35	ARTHROTEC
<u>A</u>	allopurinol 27	ASACOL 22, 33. 38
ABILIFY 16, 39	ALOCRIL 28	ASMANEX30
ACCOLATE 30.38	ALOMIDE	<i>aspirin CR</i> 28
ACCUNEB30	ALORA	aspirin CR EC28
ACCUPRIL 9, 33, 35	ALPHAGAN P	aspirin/codeine 15
ACCURETIC 10, 33	ALPHANATE,	ASTELIN NASAL 30
ACCUTANE 17, 31, 33, 35	ALPHANINE SD	asthmanefrin 30
acebutolol , 10	alprazolam	ATACAND9, 33, 35
35 و	ALREX 29	ATACAND HCT 10. 33. 35
acetaminophen/codeine 15	ALTACE 9 35	atamet
acetaminophen/salicylamide/	ALTOPREV 11, 33.37	atenolol 10
phenyltoloxamine 13	ALUPENT	atenolol/chlorthalidone 10
acetazolamide 11	amantadine	ATROVENT29
acetylcyst 30	AMARYL 21	ATROVENT HFA 29
ACIPHEX 23, 32, 34, 40	AMBIEN	ATROVENT NASAL30
ACTIMMUNE	AMBIEN CR	augmented betamethasone 18
ACTIQ	amcinonide	AUGMENTIN 27
	AMERGE	AUGMENTIN ES
ACTONEL 27, 37	AMEVIVE	AUGMENTIN XR
ACTONEL with CALCIUM 27, 37	amigesic	AVALIDE 10, 33, 35
, , , , ,	amiloride	AVANDAMET19
28	amiloride/hydrochlorothiazide 11	AVANDIA21
ACULAR LS . 28-	•	AVAPRO 9 , 33 , 35
ACULAR LS 28 ACULAR PF 28	aminophylline	AVAR weeks
acvclovir	amitiabilita	AVAR GREEN
	amitriptyline	avar-E green 17
ADALAT CC	amnesteem ,	AVELOX, 26. 31.
ADDERALL	amoxapine16	AVELOX ABC26
ADDERALL XR 13, 35 ADDERALL XR 13, 33, 35	arnoxicillin	aviane
ABBXA::	amoxicillin/K clavulanate 27	AVINZA 15
ADVAIR DISKUS 3 0	AMOXIL 24	AVITA
ADVATE 31	ampnetamine i	AVODART 24, 32, 39
ADVICOR	dextroamphetamine 13, 35	AVONEX 15
AEROBID30	ampicillin 24	AXERT 16.40
AEROBID-M30	amyl nitrite12	AXID
afeditab	ANAGRELIDE	AZASAN 24
AGENERASE	ANCOBON	azathioprine24
AGGRENOX 9	ANDRODERM19	AZELEX
AGRYLIN , 9	ANDROGEL 19	azithromycin 25
airet 30	ANEXSIA 15, 34	AZMACORT
AKINETON	ANTABUSE	AZOPT28
AKNE-MYCIN	ANȚARA · · · · · · · · · · · · · · · · 1	AZULFIDINE 23. 38
akorn balanc · · · · · · · 28	anthralin18	AZULFIDINE ENTABS 23. 38
ak-pred	antipyrinelbenzocaine 29	_
. ALAMAST	ANZEME1	<u>B</u>
albuterol	aphyrodyne	B & D INSULIN SYRINGES 20
albuterol HFA30	<i>apri</i>	bacitracin 29
alclometasone 18	APTIVUS 25	bacitracin/neomycin/
alcohol swabs 20	ARALEN	polymyxin29
ALDACTAZIDE · · · · · · 11	aranelle · · · · · 19	bacitracinlpolymyxin 29
ALDACTONE	ARANESP 8	bacitracin/polymyxin/neomycin/
ALDARA18	ARAVA 28	hydrocortisone 2
ALDORIL · · · · · · · · 10	ARICEPT13	baclofen 2
ALESSE 19	ARICEPT ODT 13	BACTROBAN NASAL 3
ALFERON N 8	ARIMIDEX 8	bal salt2
ALINIA25	ARIXTRA9	BARACLUDE
	-	
	www.aetna.com/formulary	4

Index

		abla aliana ancidal
	butorphanol16	chlordiazepoxide/
BECONASE AQ 30	butorphanol nasal 39	amitriptyline : 14
belladonna aklaloids 22	c	chloroquine 25 • 31
belladonna alkaloids/opium . 22		chlorothiazide 12
halladanna alkalaida/	CADUET 13 22 27	chlorpheniramine ER 29
belladonna alkaloids/	CADUET 12, 33, 37 CALAN 11, 33	
phenobarbital22	CALAN SR 11-33-36	chlorpromazine 16
benazapril	CALAN SR	chlorpropamide 22
33		chlorthalidone 12
benazapril/hctz9. 33 benazepril9. 35	CAMPRAL	chlorzoxazone 27
	CAPITAL/CODEINE 23, 38	cholestyramine11
benazepril/	CAPITAL/CODERINE 13, 34	choline/magnesium salicylates 28
hydrochlorothiazide 10	CAPITROL	
BENEFIX 31	EAPOTEN	CIALIS
BENICAR 9, 35	CAPOZIDE 10, 33	.cìclopirox 17
BENICAR HCT 10, 35	captopril 9, 33, 35	cilostazol 9. 34
BENZACLIN 17	Captoprii 9, 33, 33	cimetidine 22, 33
DENTALAVENI 17	captopril/hctz33	CIPRO 26. 31
BENZAMYCIN 17 benzoyl peroxide 17 benztropine 13	captopril/hydrochlorothiazide 10	CIPRO HC 29
penzoyi peroxide	CARAC	CIPRO XR
DCI)20Opina	carbamazepine14	
betamethasone diproprionate 18	carbidopallevodopa13	CIPRODEX 29
betamethasone valerate 18 BETAPACE 10	carbidopallevodopa SR13	ciprofloxacin 26. 29. 31
BETAPACE	· · · · · · · · · · · · · · · · · · ·	citalopram 16. 34,39
BETAPACE AF	carboptic	claravis
BETASERON.	CARDENE	claravis
	CARDENE SR	CLARINEX 30.31. 35
betaxolol 10, 28	CARDIZEM	CLARINEX REDITAB 30, 31. 36
bethanechol24	CARDIZEM CD 11, 33, 36 -	CLARIEVE NEDITAD 30, 31, 30
BETIMOL 28 BETOPTIC-5. 28	CARDIZEM LA	CLARINEX-D 30, 31, 36
BETOPTIC-528	CARDURA 9	*ClarithromyCin
BIAXIN	carisoprodol 27	clenia17
BIAXIN XL	carisoprodoltaspirin 27	CLEOCIN VAGINAL2 4
BIDIL	carisoprodol/aspirin/codeine 27	clidinium/chlordiazepoxide 22
BIO-STATIN 25	CARNITOR	CLIMARA
BIO-THROID	carteolol 28	CLIMARA PRO 20
bisoprolol fumarate 10	cartia XT	CLIMARA PRO WEEKLY 37
bisoprolol/hydrochlorothiazide 10	CARTROL	clindamax 17. 24
BLEPHAMIDE S.O.P 29	CARIROL	clindamycin 17, 26
BLOCADREN 10	CATAPRES9	clobetasol
BONIVA 27, 37	CATABBES TTS	clobevate18
DDAVELLE 21	CATAPRES-TTS 9	CLOBEX 18
BRAVELLE	CAVERJECT 12	
BREVICON19	CEDAX	CLODERM18
brimonidine	CEENU8	clomipramine16
bromocriptine	cefaclor	clonazepam13
bubbli-pred 21	cefacior ER	clonidine
budeprion 38	cefadroxil	ciorazepate 14
bumetanide 12	cefpodoxime 25	CLORPRES 10
BUMEX	CEFTIN 25	clotrimazole/betamethasone . 17
bupropion 15, 34, 38	cefuroxime25	clozapine
bupropion SR 15, 34, 38	CEFZIL	CLOZARIL
buspirone		
butalbital CPD	CELEBREY 37 32 30	
butalbital/acetaminophen13	CELEBREX 27, 32, 39	cocaine hcl 18
	CELEBREX 27, 32, 39 CELESTONE 21	cocaine hcl
	CELEBREX 27, 32, 39 CELESTONE 21 CELEXA 16, 34, 39	cocaine hcl
butalbital/acetaminophen/	CELEBREX 27, 32, 39 CELESTONE 21 CELEXA 16, 34, 39 CELLCEPT 24	cocaine hcl
butalbital/acetaminophen/ caffeine 13	CELEBREX 27, 32, 39 CELESTONE 21 CELEXA 16, 34, 39 CELLCEPT 24 CELONTIN 16, 20, 37	cocaine hcl. 18 codeine phosphate 15 codeine sulfate 15 , codeine/acetaminophen 34 COGNEX 13
butalbital/acetaminophen/ caffeine	CELEBREX 27, 32, 39 CELESTONE 21 CELEXA 16, 34, 39 CELLCEPT 24 CELONTIN 16, 20, 37 cephalexin 25	cocaine hcl. 18 codeine phosphate 15 codeine sulfate 15 , codeine/acetaminophen 34 COGNEX 13 COLAZAL 23, 33, 38
butalbital/acetaminophen/ caffeine	CELEBREX 27, 32, 39 CELESTONE 21 CELEXA 16, 34, 39 CELLCEPT 24 CELONTIN 16, 20, 37 cephalexin 25 CEREDASE 8	cocaine hcl. 18 codeine phosphate 15 codeine sulfate 15, codeine/acetaminophen 34 COGNEX 13 COLAZAL 23, 33, 38 colchicine 27
butalbital/acetaminophen/ caffeine	CELEBREX 27, 32, 39 CELESTONE 21 CELEXA 16, 34, 39 CELLCEPT 24 CELONTIN 16, 20, 37 cephalexin 25 CEREDASE 8 CEREZYME 8	cocaine hcl. 18 codeine phosphate 15 codeine sulfate 15 , codeine/acetaminophen 34 COGNEX 13 COLAZAL 23, 33, 38 colchicine 27 COLESTID 11
butalbital/acetaminophen/ caffeine	CELEBREX 27, 32, 39 CELESTONE 21 CELEXA 16, 34, 39 CELLCEPT 24 CELONTIN 16, 20, 37 cephalexin 25 CEREDASE 8 CEREZYME 8 cesia 19	cocaine hcl. 18 codeine phosphate 15 codeine sulfate 15 , codeine/acetaminophen 34 COGNEX 13 COLAZAL 23, 33, 38 colchicine 27 COLESTID 11 colocort 23
butalbital/acetaminophen/ caffeine	CELEBREX 27, 32, 39 CELESTONE 21 CELEXA 16, 34, 39 CELLCEPT 24 CELONTIN 16, 20, 37 cephalexin 25 CEREDASE 8 CEREZYME 8 cesia 19 chloral hydrate 16	cocaine hcl. 18 codeine phosphate 15 codeine sulfate 15 , codeine/acetaminophien 34 COGNEX 13 COLAZAL 23, 33, 38 colchicine 27 COLESTID 11 colcocort 23 COLY-MYCIN-S 29
butalbital/acetaminophen/ caffeine	CELEBREX 27, 32, 39 CELESTONE 21 CELEXA 16, 34, 39 CELLCEPT 24 CELONTIN 16, 20, 37 cephalexin 25 CEREDASE 8 CEREZYME 8 cesia 19	cocaine hcl. 18 codeine phosphate 15 codeine sulfate 15 , codeine/acetaminophen 34 COGNEX 13 COLAZAL 23, 33, 38 colchicine 27 COLESTID 11 colocort 23

COMBIPATCH 20, 37	DEMULEN 1/50 19 .	DIOVAN HCT 10.33,35
COMBIVENT 30	DENAVIR 18	DIPENTUM
COMBIVIR · · · · · 25	DEPAKOTE	diphenoxylatelatropine 22
COMEUNOX15, 34, 39	DEPAKOTE ER	dipivefrin 28
compro	DEPAKOTE SPRINKLE 17	DIPROLENE AF 18
COMTAN	DEPO-PROVERA 8. 21	dipyridamole
CONCERTA14. 33.36	desipramine16	disopyramide
COPAXONE	desmopressin · · · · · · 21 34	DISPERMOX 24
COPEGUS .:	DESOGEN · · · · · · · · · 19	DITROPAN 24
CORDARONE10	desonide	DITROPAN XL
CORDRAN18	desoximetasone · · · · · · · 18	DMSO
COREG	DESOXYN 13, 33, 35	DORAL
CORTIFOAM 23	DESYREL	DOVONEX 18. 33
cortisone AC 21	DETROL LA	doxazosin9
cortomycin	dexacidin · · · · · 29	doxepin hcl 17
CORZIDE 10	dexamethasone21	doxy-caps27
COSOPT	dexamethasone phosphate 29	doxycycline 32
COUMADIN8	dexamethasone/neomycin/	doxycycline hydate 27
COVERA-HS 11.33. 37	polymyxin 29	doxycycline monohydrate 27
COZAAR 9. 33. '35	dexasol · · · · · · 29	DRITHO-SCALP 18
CREON	devasorio · · · · · · · · · · · · · · · · · · ·	DROXIA 8
CRESTOR11, 3 3 7 dexchlorpheniramine30 DUAC		
CRINONE	DEXEDRINE 13, 35	DUONEB 30
CRIXIVAN	DEXEDRINE CR	DURAGESIC 15, 34, 39
cromolyn sodium nebulizer 30 cromolyn sodium ophth 28	dextroamphetamine - 13, 35	DURICEF 25
cromolyn sodium ophth 28	dextroamphetamine CR - 13, 35	DYAZIDE Company of Automating the
cryselle 19	dextrostat	DYNABAC
CYCLESSA 19	DEXTROSTAT 13	DYNACIN
cyclobenzaprine hcl 27	DIAMOX	DYNACIRC11
cyclophosphamide 8	DIASTAT13	DYNACIRC OR11
cýclosporine	diazepam·····14	DYRENIUM 12
cyclosporine modified 24 CYMBALTA 16, 32, 34	DIBENZYLINE 9	<u>E</u>
	diclofenac 27	e.e.s
cyproheptadine · · · · · · · 30	diclofenac potassium,27	econazole
CYSTADANE	diclofenac sodium XR27	EDECRIN
CYTADREN8	dicloxacillin sodium 27	EDEX12
	didanosine delayed relase 25	EFFEXOR 16.34, 40
CYTOVENE	didanosine delayed relase	EFFEXOR XR16. 32. 34
Б		EFUDEX18
D	diflorasone	ELDEPRYL13
danazol 19	DIFLUCAN 26, 31, 38	ELESTAT 28
DANTRIUM	diflunisal	ELIDEL18
: dapsone	digex	ELMIRON
DARAPRIM 25, 31	digitek 11 digoxin 11	EMADINE
DARVOCET	DILACOR	EMCYT 8
DARVOCET-N 15, 34 DARVON	DILACOR XR 11.33. 36	EMEND
DARVON COMPOUND 15, 34		ENABLEX
DARVON-N	DILAUDID	enalanril 9 33 35
DAYPRO	dilt-CD	enalapril9, 33, 35 enalapril/hctz33
DDAVP	diltia XT	enalaprillhydrochlorothiazide 10
DECLOMYCIN 27, 32	diltiazem	ENBREL
. DEMADEX	diltiazem CD II	ENDURONYL FORTE 10
demeclocycline 27. 32	diltiazem ER	enpresse 19
DEMEROL	diltiazem extended release	ENTOCORT EC
DEMSER9	beads SR	EP!PEN9
DEMULEN 1/35 19	DIOVAN	EPIPEN-JR9
· · ·		
	www.aetna.com/formulary	43

PAGE 2609⁴

&___*****

Index

EPIVIR 25	FIDRICETICODEINE 15, 34	GENOTROPIN 21 31
EPIVIR HBV · · · · · · · · · · · · 25	FIORINAUCODEINE · · · · 15: 34	gentamicin 17. 29
EPZICOM	FIRST-TESTOSTERONE 19	GEOCILLIN 26
ergoloid mesylate 14	flavoxate · · · · · · · · 24	GEODOPJ 15. 39
errin 21	flecainide · · · · · · · · 10	GEREF 21.
ERTACZO 17	FLOMAX 24, 32	GLEEVEC 8, 31
erythrocin 26	FLONASE 30. 34	glimepiride · · · · · · · · · · 22
erythromycin 17, 26, 29	FLOVENT 30	alipizide · · · · · · · · · · · 22
erythromycin delayed release	FLOVENT HFA	glipizide ER · · · · · · · · 22
particles 26	FLOVENT ROTADISC 30	glipizide XL
erythromycinethylsuccinate 26	FLOXIN 26. 31	GLUCAGOM 20
erythromycin/benzoyl peroxide. 17	FLOXIN OTIC	GLUCAGON
	fluconazole 26, 31.38	
ESCLIM 20, 37		GLUCOPHAGE XL
estazolam 16	fludrocort 21	GLUCOPHAGE XR · · · · · 19
ESTRACE	FLUMADINE 26	GLUCOVANCE
ESTRACE VAGINAL24	flunisolide	glyburide
ESTRADERM 20,37	fluocinolone acetonide 18	glyburide micronized · · · · · · 22
estradiol 20, 37	fluocinonide:	alvhuride/metformin · · · · · · 19
estradiol patch37	fluorometholone 29	glycolax · · · · · · · 23
ESTRASORB 20	fluor-op 29	glycron. · · · · · · · · · · 22
ESTRATAB 37	FLUOROPLEX18	GLYSET · · · · · · · · · 19
ESTRATEST20	fluorouracil	GLYSE1 19
ESTRATEST HS 20	fluoxetine 16. 34 39	GOLYTELY 23 GONAL-F 21
ESTRING24	fluphenazine	GONAL-F 21
		GRIFULVIN V
ESTROGEL 20	flurazepam16	GRIS-PEG25
estropipate 20	flurbiprofen	guanabenz
やESTROSTEP FE		guanfacine
ethambutol25	fluticasone 18	GYNAZOLE-1
ethexderm 17	fluvoxamine 16, 34, 39	
CUICXUCIIII	110000000000000000000000000000000000000	aumodial
	FML-S	guantacine 9 GYNAZOLE-1 24 gynodiol 20 GYNODIOL 27
ETHMOZINE9	FML-S	gynodiol. 20 GYNODIOL
ethosuximide	FML-S29 FOCALIN 14.33,36	GYNODIOL37
ETHMOZINE 9 ethosuximide 16 etodolac 27	FML-S	H
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 2 8	FML-S 29 FOCALIN 14.33,36 FOCALIN XR 14, 33, 36 FOLLISTIM 21	H HALFLYTELY
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 2 8 etoposide 8	FML-S 29 FOCALIN 14.33,36 FOCALIN XR 14, 33,36 FOLLISTIM 21 FOLLISTIM AQ 21	H HALFLYTELY
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 2 8 etoposide 8 EULEXIN 8	FML-S 29 FOCALIN 14.33,36 FOCALIN XR 14,33,36 FOLLISTIM 21 FOLLISTIM AQ 21 FORADIL 30	H HALFLYTELY 23 HALOG 18 haloperidol. 14
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 2 8 etoposide 8 EULEXIN 8 EURAX 18	FML-S 29 FOCALIN 14.33,36 FOCALIN XR 14,33,36 FOLISTIM 21 FOLISTIM AQ 21 FORADIL 30 FORTAMET 19	H HALFLYTELY 23 HALOG 18 haloperidol 14 hc pramoxine 23
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 2 8 etoposide 8 EULEXIN 8 EURAX 18 EVISTA 27	FML-S	H HALFLYTELY 23 HALOG 18 haloperidol 14 hc pramoxine 23 HECTOROL 21
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 2 8 etoposide 8 EULEXIN 8 EURAX 18 EVISTA 27 EVOXAC 30	FML-S 29 FOCALIN 14.33,36 FOCALIN XR 14,33,36 FOLLISTIM 21 FOLLISTIM AQ 21 FORADIL 30 FORADIL 30 FORTAMET 19 FORTEO 27 fortical 27	H HALFLYTELY 23 HALOG 18 haloperidol. 14 hc pramoxine. 23 HECTOROL 21 HELIDAC 23 40
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 2 8 etoposide 8 EULEXIN 8 EURAX 18 EVISTA 27 EVOXAC 30 EXELDERM 17	FML-S	H HALFLYTELY 23 HALOG 18 haloperidol 14 hc pramoxine 23 HECTOROL 21 HELIDAC 23, 40 HFI IXATE FS 31
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 2 8 etoposide 8 EULEXIN 8 EURAX 18 EVISTA 27 EVOXAC 30	FML-S 29 FOCALIN 14.33,36 FOCALIN XR 14,33,36 FOLLISTIM 21 FOLLISTIM AQ 21 FORADIL 30 FORTAMET 19 FORTEO 27 fortical 27 FORTOVASE 25 FOSAMAX 27,37	H HALFLYTELY 23 HALOG 18 haloperidol 14 hc pramoxine 23 HECTOROL 21 HELIDAC 23, 40 HELIXATE FS 31 HEMOFIL M 31
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 2 8 etoposide 8 EULEXIN 8 EURAX 18 EVISTA 27 EVOXAC 30 EXELDERM 17 EXELON 13	FML-S	H HALFLYTELY 23 HALOG 18 haloperidol 14 hc pramoxine 23 HECTOROL 21 HELIDAC 23, 40 HELIXATE FS 31 HEMOFIL M 31
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 2 8 etoposide 8 EULEXIN 8 EURAX 18 EVISTA 27 EVOXAC 30 EXELDERM 17 EXELON 13	FML-S	# HALFLYTELY 23 HALOG 18 haloperidol. 14 hc pramoxine. 23 HECTOROL 21 HELIDAC 23,40 HELIXATE FS 31 hEMOFIL M 31 heparin sodium 9
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 2 8 etoposide 8 EULEXIN 8 EURAX 18 EVISTA 27 EVOXAC 30 EXELDERM 17 EXELON 13 F 26, 31	FML-S	# HALFLYTELY 23 HALOG 18 haloperidol. 14 hc pramoxine. 23 HECTOROL 21 HELIDAC 23,40 HELIXATE FS 31 hEMOFIL M 31 heparin sodium 9
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 2 8 etoposide 8 EULEXIN 8 EURAX 18 EVISTA 27 EVOXAC 30 EXELDERM 17 EXELON 13 F 26, 31 famotidine 22, 33	FML-S	H HALFLYTELY 23 HALOG 18 haloperidol 14 hc pramoxine 23 HECTOROL 21 HELIDAC 23, 40 HELIXATE FS 31 HEMOFIL M 31 heparin sodium 9 HEPSERA 26 HEXALEN 8
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 2 8 etoposide 8 EULEXIN 8 EURAX 18 EVISTA 27 EVOXAC 30 EXELDERM 17 EXELON 13 F 26, 31 famotidine 22, 33 FAMVIR 26	FML-S	H HALFLYTELY 23 HALOG 18 haloperidol 14 hc pramoxine 23 HECTOROL 21 HELIDAC 23, 40 HELIXATE FS 31 HEMOFIL M 31 heparin sodium 9 HEPSERA 26 HEXALEN 8 HIVID 25
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 2 8 etoposide 8 EULEXIN 8 EURAX 18 EVISTA 27 EVOXAC 30 EXELDERM 17 EXELON 13 F 26, 31 famotidine 22, 33 FAMVIR 26 FANSIDAR 25, 31	FML-S	# HALFLYTELY 23 HALOG 18 haloperidol 14 hc pramoxine 23 HECTOROL 21 HELIDAC 23, 40 HELIXATE FS 31 HEMOFIL M 31 heparin sodium 9 HEPSERA 26 HEXALEN 8 HIVID 25 HMS 29
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 2 8 etoposide 8 EULEXIN 8 EURAX 18 EVISTA 27 EVOXAC 30 EXELDERM 17 EXELON 13 F 26, 31 famotidine 22, 33 FAMVIR 26 FANSIDAR 25, 31 FARESTON 8	FML-S	H HALFLYTELY 23 HALOG 18 haloperidol 14 hc pramoxine 23 HECTOROL 21 HELIDAC 23, 40 HELIXATE FS. 31 HEMOFIL M 31 heparin sodium 9 HEPSERA 26 HEXALEN 8 HIVID 25 HMS 29 HUMALOG 21
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 2 8 etoposide 8 EULEXIN 8 EURAX 18 EVISTA 27 EVOXAC 30 EXELDERM 17 EXELON 13 F 26, 31 famotidine 22, 33 FAMVIR 26 FANSIDAR 25, 31 FARESTON 8 FASLODEX 8	FML-S	H HALFLYTELY 23 HALOG 18 haloperidol 14 hc pramoxine 23 HECTOROL 21 HELIDAC 23, 40 HELIXATE FS. 31 HEMOFIL M 31 heparin sodium 9 HEPSERA 26 HEXALEN 8 HIVID 25 HMS 29 HUMALOG 21
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 2 8 etoposide 8 EULEXIN 8 EURAX 18 EVISTA 27 EVOXAC 30 EXELDERM 17 EXELON 13 F 26, 31 famotidine 22, 33 FAMVIR 26 FANSIDAR 25, 31 FARESTON 8 FASLODEX 8	FML-S	H HALFLYTELY 23 HALOG 18 haloperidol 14 hc pramoxine 23 HECTOROL 21 HELIDAC 23,40 HELIXATE FS 31 HEMOFIL M 31 heparin sodium 9 HEPSERA 26 HEXALEN 8 HIVID 25 HMS 29 HUMALOG MIX 75/25 21 HUMALOG MIX 75/25 21 HUMATE-P 31
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 28 etoposide 8 EULEXIN 8 EURAX 18 EVISTA 27 EVOXAC 30 EXELDERM 17 EXELON 13 F 26, 31 famotidine 22, 33 FANVIR 26 FANSIDAR 25, 31 FARESTON 8 FASLODEX 8 FAZACLO 14, 37	FML-S	H HALFLYTELY 23 HALOG 18 haloperidol 14 hc pramoxine 23 HECTOROL 21 HELIDAC 23,40 HELIXATE FS 31 HEMOFIL M 31 heparin sodium 9 HEPSERA 26 HEXALEN 8 HIVID 25 HMS 29 HUMALOG MIX 75/25 21 HUMALOG MIX 75/25 21 HUMATE-P 31
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 28 etoposide 8 EULEXIN 8 EURAX 18 EVISTA 27 EVOXAC 30 EXELDERM 17 EXELON 13 F 26, 31 famotidine 22, 33 FAMVIR 26 FANSIDAR 25, 31 FARESTON 8 FASLODEX 8 FAZACLO 14, 37 FELBATOL 14	FML-S	H HALFLYTELY 23 HALOG 18 haloperidol 14 hc pramoxine 23 HECTOROL 21 HELIDAC 23, 40 HELIXATE FS 31 HEMOFIL M 31 heparin sodium 9 HEPSERA 26 HEXALEN 8 HIVID 25 HMS 29 HUMALOG MIX 75/25 21 HUMALOG MIX 75/25 21 HUMATE-P 31 HUMATROPE 21, 31
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 28 etoposide 8 EULEXIN 8 EURAX 18 EVISTA 27 EVOXAC 30 EXELDERM 17 EXELDERM 13 F 26, 31 famotidine 22, 33 FAMVIR 26 FANSIDAR 25, 31 FARESTON 8 FAZACLO 14, 37 FELBATOL 14 felodipine 11	FML-S	H HALFLYTELY 23 HALOG 18 haloperidol 14 hc pramoxine 23 HECTOROL 21 HELIDAC 23, 40 HELIXATE FS. 31 HEMOFIL M 31 heparin sodium 9 HEPSERA 26 HEXALEN 8 HIVID 25 HMS 29 HUMALOG MIX 75/25 21 HUMATE-P 31 HUMATROPE 21, 31 HUMIRA 27
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 2 8 etoposide 8 EULEXIN 8 EURAX 18 EVRAX 27 EVOXAC 30 EXELDERM 17 EXELDERM 17 EXELON 13 F 26, 31 famotidine 22, 33 FANSIDAR 25, 31 FARESTON 8 FASLODEX 8 FAZACLO 14, 37 FELBATOL 14 felodipine 11 FEMARA 8	FML-S	### HALFLYTELY 23 HALOG 18 haloperidol 14 hc pramoxine 23 HECTOROL 21 HELIDAC 23,40 HELIXATE FS 31 heparin sodium 9 HEPSERA 26 HEXALEN 8 HIVID 25 HMS 29 HUMALOG 121 HUMALOG MIX 75/25 21 HUMALOG MIX 75/25 21 HUMATE-P 31 HUMATE-P 31 HUMATE-P 31 HUMATROPE 21,31 HUMIRA 27 HUMIRA 27 HUMIRA 27 HUMIN 50/50 21
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 2 8 etoposide 8 EULEXIN 8 EURAX 18 EVISTA 27 EVOXAC 30 EXELDERM 17 EXELON 13 F 26, 31 famotidine 22, 33 FANSIDAR 25, 31 FARESTON 8 FASLODEX 8 FAZACLO 14, 37 FELBATOL 14 felodipine 11 FEMHRT 20	FML-S	## HALFLYTELY 23 HALOG 18 haloperidol. 14 hc pramoxine. 23 HECTOROL 21 HELIDAC 23, 40 HELIXATE FS 31 HEMOFIL M 31 heparin sodium 9 HEPSERA 26 HEXALEN 8 HIVID 25 HMS 29 HUMALOG 21 HUMALOG MIX 75/25 21 HUMATE-P 31 HUMATROPE 21, 31 HUMIRA 27 HUMULIN 50/50 21 HUMULIN 70130 21, 33
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 28 etoposide 8 EULEXIN 8 EURAX 18 EVISTA 27 EVOXAC 30 EXELDERM 17 EXELON 13 F 26, 31 famotidine 22, 33 FAMVIR 26 FANSIDAR 25, 31 FARESTON 8 FASLODEX 8 FASLODEX 8 FAZACLO 14, 37 FELBATOL 14 felodipine 11 FEMARA 8 FEMHRT 20 FEMRING 24	FML-S	## HALFLYTELY 23 HALOG 18 haloperidol 14 hc pramoxine 23 HECTOROL 21 HELIDAC 23, 40 HELIXATE FS 31 HEMOFIL M 31 heparin sodium 9 HEPSERA 26 HEXALEN 8 HIVID 25 HMS 29 HUMALOG 21 HUMATE-P 31 HUMATROPE 21, 31 HUMATROPE 21, 31 HUMIRA 27 HUMULIN 50/50 21 HUMULIN 50/50 21 HUMULIN 70130 21, 33 HUMULIN L 21
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 28 etoposide 8 EULEXIN 8 EURAX 18 EVISTA 27 EVOXAC 30 EXELDERM 17 EXELON 13 F 26, 31 famotidine 22, 33 FAMVIR 26 FANSIDAR 25, 31 FARESTON 8 FASLODEX 8 FASLODEX 8 FAZACLO 14, 37 FELBATOL 14 felodipine 11 FEMARA 8 FEMHRT 20 FEMRING 24 fenoprofen 28	FML-S	# HALFLYTELY 23 HALOG 18 haloperidol 14 hc pramoxine 23 HECTOROL 21 HELIDAC 23, 40 HELIXATE FS 31 HEMOFIL M 31 heparin sodium 9 HEPSERA 26 HEXALEN 8 HIVID 25 HMS 29 HUMALOG MIX 75/25 21 HUMATE-P 31 HUMATROPE 21, 31 HUMATROPE 21, 31 HUMIRA 27 HUMULIN 70130 21, 33 HUMULIN L 21 HUMULIN N 21, 33
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 28 etoposide 8 EULEXIN 8 EURAX 18 EVISTA 27 EVOXAC 30 EXELDERM 17 EXELON 13 F 26, 31 famotidine 22, 33 FAMVIR 26 FANSIDAR 25, 31 FARESTON 8 FASLODEX 8 FAZACLO 14, 37 FELBATOL 14 felodipine 11 FEMARA 8 FEMHRT 20 FEMRING 24 fenoprofen 28 fentanyl 15	FML-S	H HALFLYTELY 23 HALOG 18 haloperidol 14 hc pramoxine 23 HECTOROL 21 HELIDAC 23, 40 HELIXATE FS 31 HEMOFIL M 31 heparin sodium 9 HEPSERA 26 HEXALEN 8 HIVID 25 HMS 29 HUMALOG 21 HUMALOG MIX 75/25 21 HUMATE-P 31 HUMATE-P 31 HUMATROPE 21, 31 HUMULIN 70130 21, 33 HUMULIN N 21, 33
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 28 etoposide 8 EULEXIN 8 EURAX 18 EVISTA 27 EVOXAC 30 EXELDERM 17 EXELON 13 F 26, 31 famotidine 22, 33 FAMVIR 26 FANSIDAR 25, 31 FARESTON 8 FASLODEX 8 FAZACLO 14, 37 FELBATOL 14 felodipine 11 FEMARA 8 FEMHRT 20 FEMRING 24 fenoprofen 28 fentanyl 15 fentanyl patch 34, 39	FML-S	## HALFLYTELY 23 HALOG 18 haloperidol 14 hc pramoxine 23 HECTOROL 21 HELIDAC 23, 40 HELIXATE FS 31 HEMOFIL M 31 heparin sodium 9 HEPSERA 26 HEXALEN 8 HIVID 25 HMS 29 HUMALOG MIX 75/25 21 HUMATE-P 31 HUMATE-P 31 HUMATROPE 21, 31 HUMULIN 70130 21, 33 HUMULIN 1 21 HUMULIN N 21, 33 HUMULIN 1 21
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 28 etoposide 8 EULEXIN 8 EURAX 18 EVISTA 27 EVOXAC 30 EXELDERM 17 EXELON 13 F 26, 31 famotidine 22, 33 FAMVIR 26 FANSIDAR 25, 31 FARESTON 8 FASLODEX 8 FAZACLO 14, 37 FELBATOL 14 felodipine 11 FEMARA 8 FEMHRT 20 FEMRING 24 fenoprofen 28 fentanyl patch 34, 39 fexofenadine 31, 35	FML-S 29 FOCALIN 14.33,36 FOCALIN XR 14,33,36 FOLLISTIM 21 FOLLISTIM AQ 21 FORADIL 30 FORTAMET 19 FORTEO 27 fortical 27 FORTOVASE 25 FOSAMAX 27,37 FOSAMAX PLUS D 27,37 fosinopril 9,33,35 fosinopril/hydrochlorothiazide 10 FOSRENOL 33 fosinopril/hydrochlorothiazide 10 FOSRENOL 23 FRAGMIN 9	H HALFLYTELY 23 HALOG 18 haloperidol. 14 hc pramoxine. 23 HECTOROL 21 HELIDAC 23, 40 HELIXATE FS. 31 HEMOFIL M 31 heparin sodium 9 HEPSERA 26 HEXALEN 8 HIVID 25 HMS 29 HUMALOG MIX 75/25 21 HUMALOG MIX 75/25 21 HUMATE-P 31 HUMATE-P 31 HUMATE-P 31 HUMATROPE 21, 31 HUMIRA 27 HUMULIN 70130 21, 33 HUMULIN L 21 HUMULIN N 21, 33 HUMULIN N 21, 33 HUMULIN N 21, 33 HUMULIN U 21 HYATE:C 31
ETHMOZINE 9 ethosuximide 16 etodolac 27 etodolac ER 28 etoposide 8 EULEXIN 8 EURAX 18 EVISTA 27 EVOXAC 30 EXELDERM 17 EXELON 13 F 26, 31 famotidine 22, 33 FAMVIR 26 FANSIDAR 25, 31 FARESTON 8 FASLODEX 8 FAZACLO 14, 37 FELBATOL 14 felodipine 11 FEMARA 8 FEMHRT 20 FEMRING 24 fenoprofen 28 fentanyl 15 fentanyl patch 34, 39	FML-S	## HALFLYTELY 23 HALOG 18 haloperidol 14 hc pramoxine 23 HECTOROL 21 HELIDAC 23, 40 HELIXATE FS 31 HEMOFIL M 31 heparin sodium 9 HEPSERA 26 HEXALEN 8 HIVID 25 HMS 29 HUMALOG MIX 75/25 21 HUMATE-P 31 HUMATE-P 31 HUMATROPE 21, 31 HUMULIN 70130 21, 33 HUMULIN 1 21 HUMULIN N 21, 33 HUMULIN 1 21

44

www.aetna.com/formulary

hydralazine/		LEUKERAN
hydrochlorothiazide 10	isosorbide dinitrate 12	LEVAQUIN · · · · · · · · 26. 31
HYDREA8	isosorbide dinitrate 12	LEVAQUIN
hydrochlorothiazide 12	,	LEVITRA · · · · · · · · · 12
hydrocodonel	isotretinoin	LEVIEN
acetaminophen 15, 34	isoxsuprine	LEVLITE · · · · · · · · · · · · · · · · · · ·
hydrocodone/ibuprofen . 15,34	ISTALOL	levobunolol 28
hydrocortisone 18, 21	itraconazole 26. 31	levora······19
hydrocortisone acetate 23	IV IMMUNE GLOBULIN (IVIG) 31	levorphanol 15
hydrocortisone butyrate 18	IN IMMONE GLOBOLIN (IV)O) . 31	levothroid22
hydrocortisonevalerate 18 hydrocortisone/clioquinol 17	<u>J</u>	levothyroxine · · · · · · 22
hydrocortisoneliodoquinol 17	jolivette	levotnyroxine · · · · · · · · · · · · · · · · · 22 levoxyl · · · · · · · · · · · · 22
hydrocortisone/pramoxine 18	junel 1/20	LEVULAN KERA · · · · · · 18
hydromorphorie 15		LEXAPRO 16,34, 39
hydroxychloroquine 31	junel FE 1.5/3019	LEXIVA
hydroxychloroquine sulfate	junel FE 1/20 19	LEXXEL10
hydroxyurea8	K	lidazone
hydroxyzine hcl 14	KADIAN	lidocaine
hydroxyzine pamoate 14	KALETRA	lidocaine/hydrocortisone . 18.23
hyoscyamine 22, 24	karlva	lidocaine/prilocaine 18
hyoscyamine CR	KEMADRIN	LIDODERM 18
hyospaz	KEPPRA	lindane18
HYTRIN 9	KERLONE	LIPEX12
HYZAAR 10, 33, 35	KETEK 26	LIPITOR 11, 33, 38
_		
	ketoconazole 17.26 ketoprofen 28	lipram
ibuprofen 28	ketoprofen IR	lipram PN
ILETIN II LENTE	ketorolac 28, 39	lipram UL22
ILETIN II NPH 21	KLARON 17	lisinopril
ILETIN II RG	KLONOPIN 13	lisinopril/hctz
IMDUR12	KLONOPIN WAFER 13	lisinopril/hydrochlorothiazide . 10
imipramine hcl	KOATE-DVI	lithium carbonate 14
IMITREX 16, 40	KOGENATE FS	lithium carbonate CR 14
IMURAN 24	KRISTALOSE 23	lithium citrate 14
indapamide	KU-ZYME 22	LITHOBID 14
INDÉRAL	KILTYNAE LID	
INBERIOLE 18	KYTRIL'	LOONE XL
	L	LODOSYN
indomethacin 28 indomethacin ER 2 8	Inhetalal O	LOESTRIN 1.5/30 19
INFERGEN 26, 31	labetalol 9 lacticare/hydrocortisone 18	LOESTRIN 1/2019
INNOHEP9	lactulose 23	LOESTRIN FE
INNOPRAN XL	LAMICTAL · · · · · · · · · · · · 14	LOESTRIN FE 1.5/30 19
INSPRA 12	LAMISIL	LOFIBRA
INSULIN SYRINGES20	LAMISIL TAB	LOPID
INTAL,	lamotrigine14	LOPRESS HCT10
INTRON-A 8. 31	LANOXICAPS · · · · · · · 11	LOPRESSOR 10
INVIRASE25	LANOXIN 11	LOPROX CREAM/LOTION/
IOPIDINE · · · · · · · · · 28	LANTUS21	SUSPENSION
ipratropium 29, 30	LARIAM	LOPROX GEL/SHAMPOO 17
IRESSA 8, 31	LARODOPA13	LORABID · · · · · · · · · 26
ISMO12	LASIX 12	lorazepam 14
ISO CARBACHOC28	leena 19	LORCÉT 15, 34
isochron 12	leflunomide 28	LORCET HD 34
isoetharine 30	LESCOL 11, 33, 38	LORCET PLUS······15. 34
isoniazid25	LESCOL XL 11, 33, 38	LORCET-HD
ISOPTIN	lessina	LORTAB 15. 34
ISOPTIN SR 11, 33, 36	leucovorin calcium 8	LOTEMAX29
·		
	www.aetna.com/formulary	45

www.aetna.com/formulary

. 3

Index

1.025NGN 0.33.3E	METAGLIP 19	MIRAPEX
LOTENSIN 9. 33. 35		
LOTENSIN HCT10. 33	metaproterenol nebulizer30	MIRCETTE
LOTREL	metaproterenol tab/syrup 30	mirtazapine 13.34
LOTRISONE17	metformin 19,33	mirtazapine ODT 13
LOTRONEX	metformin SR····· 19. 33	misoprostol 23
lovastatin 12. 33. 38	methadone	MOBIC
LOVENOX 9	methadose · · · · · · · · · 15	MODICON 0.5/35 19
	methamphetamine	MODURETIC
low-ogestrel 19	methamphetamine13	
loxapine14	methazolamide 11	momrtasone 18
LOZOL	methenamine hippurate 24	MONARC-M
LUMIGAN 29	methenamine mandelate 24	MONOCLATE-P 31
LUNESTA 16. 39		MONODOX 27. 32
	methimazole 19	
LUPRON8	methocarbamol 27	MONOKET
lutera	methotrexate8	mononessa · · · · · · · 19
LUVOX	methychlothiazide 12	MONONINE
LUXIQ		MONOPRIL 9.33.35
	methyldopa 9	
LYRICA	methyldopal	MONOPRIL HCT 10. 33
LYSODREN8	hydrochlorothiazide 10	MONUROL24
37	methylin	morphine sulfate OR, 15
<u>M</u>	METHYLIN chewable and 14, 36	morphine sulfate OR 15
24	IVIETA LINI CHEWADIE and	MS CONTIN 15
3E 34	solution	M2 COM11N · · · · · · 15
maldemar 25, 31	mathulin FR 14 36	msir 15
maigemar 22	mothyinhonidata 14,36	msir
maprotiline 15, 38 MARPLAN 14 MATULANE 8	metrypremidate	MUCOMYST30
MARPIAN 14	methyiphenidate SR · 14, 33, 36	mugirocin
MATI II ANE 8	methylpred21	MUSE 12
O DE	metipranolol	
MAVIK 4. 4. 3. 3. 4. 4. 4. 9. 35.	metipranolol 28 metoclopramide hcf 22 metolazone /2	MIVAMBUTO: Programme 25
MAXAIR AUTOHALER 30°	metoclopramide hcl	MYFORTIC24
MAXALT	metolazone	MYLERAN 8
MAXALT MLT	metoprolol10	MYLOCEL
MAXAQUIN 26, 31	metoprolol/	MYLOCEL 8
14. NOONE 45 34	hydrochlorothiəzide 10	N
MAXIDONE		nabumetone
MAXZIDE.,		
MEBARAL 14	METROGEL 17	nadolol
mebendazole 24	METROGEL VAGINAL 24	NAFTIN 17
meclofenamate sodium 28 .	METROLOTION	NAMENDA
mediorenamote sociali	metronidazole 17 26	NADDELANI 10 24
medroxyprogesterone acetate 21		NAPRELAN
medroxyprogesterone	metronidazole SR26 MEVACOR12, 33, 38	naproxen
progesterone	MEVACON	NARDIL
mefloquine 25, 31	mexiletine · · · · · 9	NASACORT AQ 30, 34
MEGACE	MIACALCIN NASAL 27	NASAREL
MEGACE ES	MICARDIS 9, 35	
IVIEGACE ED		
		NASONEX
megestrol 8	MICARDIS HCT 10, 35	NATURETIN
megestrol 8	MICARDIS HCT 10, 35 microgestin 1.5/30 19	NATURETIN 12 NEBUPENT 26
megestrol	MICARDIS HCT 10, 35 microgestin 1.5/30 19	NATURETIN 12 NEBUPENT 26
megestrol 8 MENEST 20, 37 MENI-D 22	MICARDIS HCT 10, 35 microgestin 1.5/30 19 microgestin 1/20 19	NATURETIN 12 NEBUPENT 26 necon 0.5135. 19
megestrol 8 MENEST 20, 37 MENI-D 22 MENOPUR 21	MICARDIS HCT 10, 35 microgestin 1.5/30 19 microgestin 1/20 19 microgestin FE 1.5/30 19	NATURETIN 12 NEBUPENT 26 necon 0.5135 19 necon 1/35 19
megestrol 8 MENEST 20, 37 MENI-D 22 MENOPUR 21	MICARDIS HCT 10, 35 microgestin 1.5/30 19 microgestin 1/20 19 microgestin FE 1.5/30 19 microgestin FE1/20 19	NATURETIN 12 NEBUPENT 26 necon 0.5135 19 necon 1/35 19 necon 1/50 19
megestrol 8 MENEST 20, 37 MENI-D 22	MICARDIS HCT 10, 35 microgestin 1.5/30 19 microgestin 1/20 19 microgestin FE 1.5/30 19 microgestin FE1/20 19 micronefrin 30	NATURETIN 12 NEBUPENT 26 necon 0.5135 19 necon 1/35 19
megestrol 8 MENEST 20, 37 MENI-D 22 MENOPUR 21 MENOSTAR 20, 37 MEPERGAN FORTIS 34	MICARDIS HCT 10, 35 microgestin 1.5/30 19 microgestin 1/20 19 microgestin FE 1.5/30 19 microgestin FE1/20 19	NATURETIN 12 NEBUPENT 26 necon 0.5135 19 necon 1/35 19 necon 1/50 19 necon 10/11 19
megestrol 8 MENEST 20, 37 MENI-D 22 MENOPUR 21 MENOSTAR 20, 37 MEPERGAN FORTIS 34 meperidine 15	MICARDIS HCT 10, 35 microgestin 1.5/30 19 microgestin 1/20 19 microgestin FE 1.5/30 19 microgestin FE1/20 19 micronefrin 30 MICROZIDE 12 MIDAMOR 12	NATURETIN 12 NEBUPENT 26 necon 0.5135. 19 necon 1/35 19 necon 1/50 19 necon 10/11 19 necon 7/7/7 19
megestrol 8 MENEST 20, 37 MENI-D 22 MENOPUR 21 MENOSTAR 20, 37 MEPERGAN FORTIS 34 meperidine 15 meperidine/promethazine 15, 34	MICARDIS HCT 10, 35 microgestin 1.5/30 19 microgestin 1/20 19 microgestin FE 1.5/30 19 microgestin FE1/20 19 micronefrin 30 MICROZIDE 12 MIDAMOR 12	NATURETIN 12 NEBUPENT 26 necon 0.5135. 19 necon 1/35 19 necon 1/50 19 necon 10/11 19 necon 7/7/7 19 nefazodone 15
megestrol 8 MENEST 20, 37 MENI-D 22 MENOPUR 21 MENOSTAR 20, 37 MEPERGAN FORTIS 34 meperidine 15 meperidine/promethazine 15, 34 meprobamate 14	MICARDIS HCT 10, 35 microgestin 1.5/30 19 microgestin 1/20 19 microgestin FE 1.5/30 19 microgestin FE1/20 19 micronefrin 30 MICROZIDE 12 MIDAMOR 12 midazolam 16	NATURETIN 12 NEBUPENT 26 necon 0.5135. 19 necon 1/35 19 necon 1/50 19 necon 10/11 19 necon 7/7/7 19 nefazodone 15 neomycin 24
megestrol 8 MENEST 20, 37 MENI-D 22 MENOPUR 21 MENOSTAR 20, 37 MEPERGAN FORTIS 34 meperidine 15 meperidine/promethazine 15, 34 meprobamate 14 MEPRON 25	MICARDIS HCT 10, 35 microgestin 1.5/30 19 microgestin 1/20 19 microgestin FE 1.5/30 19 microgestin FE1/20 19 micronefrin 30 MICROZIDE 12 MIDAMOR 12 midazolam 16 MIGRANAL 14, 38	NATURETIN 12 NEBUPENT 26 necon 0.5135. 19 necon 1/35 19 necon 1/50 19 necon 10/11 19 necon 7/7/7 19 nefazodone 15 neomycin 24 neomycin/bacitracin/
megestrol 8 MENEST 20, 37 MENI-D 22 MENOPUR 21 MENOSTAR 20, 37 MEPERGAN FORTIS 34 meperidine 15 meperidine/promethazine 15, 34 meprobamate 14 MEPRON 25	MICARDIS HCT 10, 35 microgestin 1.5/30 19 microgestin 1/20 19 microgestin FE 1.5/30 19 microgestin FE1/20 19 micronefrin 30 MICROZIDE 12 MIDAMOR 12 midazolam 16	NATURETIN 12 NEBUPENT 26 necon 0.5135. 19 necon 1/35 19 necon 1/50 19 necon 10/11 19 necon 7/7/7 19 nefazodone 15 neomycin 24 neomycin/bacitracin/
megestrol 8 MENEST 20, 37 MENI-D 22 MENOPUR 21 MENOSTAR 20, 37 MEPERGAN FORTIS 34 meperidine 15, 34 meprobamate 14 MEPRON 25 meprozine 15	MICARDIS HCT 10, 35 microgestin 1.5/30 19 microgestin 1/20 19 microgestin FE 1.5/30 19 microgestin FE1/20 19 micronefrin 30 MICROZIDE 12 MIDAMOR 12 midazolam 16 MIGRANAL 14, 38 MINIPRESS 9	NATURETIN 12 NEBUPENT 26 necon 0.5135 19 necon 1/35 19 necon 1/50 19 necon 10/11 19 necon 7/7/7 19 nefazodone 15 neomycin 24 neomycin/bacitracin/polymyxin 29
megestrol 8 MENEST. 20, 37 MENI-D 22 MENOPUR 21 MENOSTAR 20, 37 MEPERGAN FORTIS 34 meperidine 15 meperidine/promethazine 15, 34 meprobamate 14 MEPRON 25 meprozine 15 mercaptopurine 8	MICARDIS HCT 10, 35 microgestin 1.5/30 19 microgestin 1/20 19 microgestin FE 1.5/30 19 microgestin FE1/20 19 micronefrin 30 MICROZIDE 12 MIDAMOR 12 midazolam 16 MIGRANAL 14, 38 MINIPRESS 9 minitran 12	NATURETIN 12 NEBUPENT 26 necon 0.5135 19 necon 1/35 19 necon 1/50 19 necon 10/11 19 necon 7/7/7 19 nefazodone 15 neomycin 24 neomycin/bacitracin/ polymyxin 29 neomycin/polymyxin/bacitracin/
megestrol 8 MENEST. 20, 37 MENI-D 22 MENOPUR 21 MENOSTAR 20, 37 MEPERGAN FORTIS 34 meperidine 15 meperidine/promethazine 15, 34 meprobamate 14 MEPRON 25 meprozine 15 mercaptopurine 8 mesalamine 23	MICARDIS HCT 10, 35 microgestin 1.5/30 19 microgestin 1/20 19 microgestin FE 1.5/30 19 microgestin FE 1.5/30 19 microgestin FE1/20 19 micronefrin 30 MICROZIDE 12 MIDAMOR 12 midazolam 16 MIGRANAL 14, 38 MINIPRESS 9 minitran 12 MINIZIDE 10	NATURETIN 12 NEBUPENT 26 necon 0.5135 19 necon 1/35 19 necon 1/50 19 necon 10/11 19 necon 7/7/7 19 nefazodone 15 neomycin 24 neomycin/bacitracin/ polymyxin 29 neomycin/polymyxin/bacitracin/ hydrocortisone 29
megestrol 8 MENEST. 20, 37 MENI-D 22 MENOPUR 21 MENOSTAR 20, 37 MEPERGAN FORTIS 34 meperidine 15 meperidine/promethazine 15, 34 meprobamate 14 MEPRON 25 meprozine 15 mercaptopurine 8 mesalamine 23 MESNEX 8	MICARDIS HCT 10, 35 microgestin 1.5/30 19 microgestin 1/20 19 microgestin FE 1.5/30 19 microgestin FE 1.5/30 19 microgestin FE 1/20 19 micronefrin 30 MICROZIDE 12 MIDAMOR 12 midazolam 16 MIGRANAL 14, 38 MINIPRESS 9 minitran 12 MINIZIDE 10 MINOCIN 27, 32	NATURETIN 12 NEBUPENT 26 necon 0.5135. 19 necon 1/35 19 necon 1/50 19 necon 10/11 19 necon 7/7/7 19 nefazodone 15 neomycin 24 neomycin/bacitracin/ polymyxin 29 neomycin/polymyxin/bacitracin/ hydrocortisone 29 neomycin/polymyxin/
megestrol 8 MENEST. 20, 37 MENI-D 22 MENOPUR 21 MENOSTAR 20, 37 MEPERGAN FORTIS 34 meperidine 15 meperidine/promethazine 15, 34 meprobamate 14 MEPRON 25 mercaptopurine 15 mesalamine 23 MESNIEX 8 MESTINON 27	MICARDIS HCT 10, 35 microgestin 1.5/30 19 microgestin 1/20 19 microgestin FE 1.5/30 19 microgestin FE1/20 19 micronefrin 30 MICROZIDE 12 MIDAMOR 12 midazolam 16 MIGRANAL 14, 38 MINIPRESS 9 minitran 12 MINIZIDE 10 MINOCIN 27, 32 minocycline 27, 32	NATURETIN 12 NEBUPENT 26 necon 0.5135. 19 necon 1/35 19 necon 1/50 19 necon 10/11 19 necon 7/7/7 19 nefazodone 15 neomycin 24 neomycin/bacitracin/ polymyxin 29 neomycin/polymyxin/bacitracin/ hydrocortisone 29 neomycin/polymyxin/ dexamethasone 29
megestrol 8 MENEST. 20, 37 MENI-D 22 MENOPUR 21 MENOSTAR 20, 37 MEPERGAN FORTIS 34 meperidine 15 meperidine/promethazine 15, 34 meprobamate 14 MEPRON 25 mercaptopurine 15 mesalamine 23 MESNIEX 8 MESTINON 27	MICARDIS HCT 10, 35 microgestin 1.5/30 19 microgestin 1/20 19 microgestin FE 1.5/30 19 microgestin FE1/20 19 micronefrin 30 MICROZIDE 12 MIDAMOR 12 midazolam 16 MIGRANAL 14, 38 MINIPRESS 9 minitran 12 MINIZIDE 10 MINOCIN 27, 32 minocycline 27, 32 minoxidil 13	NATURETIN 12 NEBUPENT 26 necon 0.5135. 19 necon 1/35 19 necon 1/50 19 necon 10/11 19 necon 7/7/7 19 nefazodone 15 neomycin 24 neomycin/bacitracin/ polymyxin 29 neomycin/polymyxin/bacitracin/ hydrocortisone 29 neomycin/polymyxin/ dexamethasone 29
megestrol 8 MENEST. 20, 37 MENI-D 22 MENOPUR 21 MENOSTAR 20, 37 MEPERGAN FORTIS 34 meperidine 15 meperidine/promethazine 15, 34 meprobamate 14 MEPRON 25 meprozine 15 mercaptopurine 8 mesalamine 23 MESNEX 8 MESTINON 27 METADATE CD 14, 33, 36	MICARDIS HCT 10, 35 microgestin 1.5/30 19 microgestin 1/20 19 microgestin FE 1.5/30 19 microgestin FE1/20 19 micronefrin 30 MICROZIDE 12 MIDAMOR 12 midazolam 16 MIGRANAL 14, 38 MINIPRESS 9 minitran 12 MINIZIDE 10 MINOCIN 27, 32 minocycline 27, 32 minoxidil 13	NATURETIN 12 NEBUPENT 26 necon 0.5135. 19 necon 1/35 19 necon 1/50 19 necon 10/11 19 necon 7/7/7 19 nefazodone 15 neomycin 24 neomycin/bacitracin/ polymyxin 29 neomycin/polymyxin/bacitracin/ hydrocortisone 29 neomycin/polymyxin/ dexamethasone 29 neomycin/polymyxin/gramicidin
megestrol 8 MENEST. 20, 37 MENI-D 22 MENOPUR 21 MENOSTAR 20, 37 MEPERGAN FORTIS 34 meperidine 15 meperidine/promethazine 15, 34 meprobamate 14 MEPRON 25 mercaptopurine 15 mesalamine 23 MESNIEX 8 MESTINON 27	MICARDIS HCT 10, 35 microgestin 1.5/30 19 microgestin 1/20 19 microgestin FE 1.5/30 19 microgestin FE1/20 19 micronefrin 30 MICROZIDE 12 MIDAMOR 12 midazolam 16 MIGRANAL 14, 38 MINIPRESS 9 minitran 12 MINIZIDE 10 MINOCIN 27, 32 minocycline 27, 32	NATURETIN 12 NEBUPENT 26 necon 0.5135. 19 necon 1/35 19 necon 1/50 19 necon 10/11 19 necon 7/7/7 19 nefazodone 15 neomycin 24 neomycin/bacitracin/ polymyxin 29 neomycin/polymyxin/bacitracin/ hydrocortisone 29 neomycin/polymyxin/ dexamethasone 29

46

www.aetna.com/formulary

Sec. 2.176

neomycin/polymyxin/	NUTROPIN 21, 31	oxycodonelaspirin
hydrocortisone29	NUTROPIN AQ	OXYCONTIN CR 15, 39
NEORAL	NUVARING19	oxyfast
NEULASTA	nystatin 17, 25	OXYIR
NEURONTIN 14, 33, 39	nystatin vaginal 24	OXYTROL24, 34
NEXIUM	nystatin/triamcinolone 17	P
NIASPAN	0	PACERONE
nicardinine	ofloxacin	pancreatin 22
nifedical XL	OGEN	nancrelipase
nifedinine	ogestrel 19	PANIXINE
nifedinine extended release 33	OLUX	panoxyl
nifedipine SR 11, 36	omenrazole 23, 32, 40	panoxyl AQ
NII ANDRON 8	OMNICEF	PANRETIN 18
NIMOTOP11	ONE TOUCH BASIC/PROFILE/	papaverine ER
nitrek	ONE TOUCH II TEST STRIPS: 20	para-time
NITROBID12	ONE TOUCH FAST TAKE	PARCOPA
NITRO-DUR	TEST STRIPS20	paregoric
nitrofurantoin	ONE TOUCH SURE STEP	PARNATE
nitrofurantoin monohydrate	TEST STRIPS	paromomycin24
macrocrystal	ONE TOUCH ULTRA TEST	paroxetine 16, 34, 39
nitroglycerin	STRIPS	PATANOL
nitroglycerin SL	OPTIVAR28	PAXIL
nitroglycerin SR	ORAMORPH SR15	PAXIL CR 16, 34
NITROLINGUAL12	ORAP14	PCF
nitroquick	CRAPRED	nog 3350
NITROSTAT	ORFADIN	PEGASYS
nitrotab	orphenadrine cpd 27	PEG-INTRON
nitro-time	orphenadrine ER 27	pemoline
nitro-transderm	orphenadrine/aspirin/caffeine . 27	penicillin VK20
nizatidine 22, 33	orphenaesic 27	PENLAC
NOLVADEX8	orphengesic forte27	PENLAC NAIL LACQUER 31
nora-be 21	ORTHO EVRA19	PENTASA 23, 33, 38
NORCO	ORTHO MICRONOR21	pentazocine/ acetaminophen15, 34
NORDETTE	ORTHO TRI-CYCLEN 19	16
NORDITROPIN 21, 31	ORTHO TRI-CYCLEN LO 20	
norethindrone acetate 21	ORTHO-CEPT20	
NORINYL 1+35	ORTHO-CYCLEN	
NORINYL 1+50	7 ORTHO-NOVUM 1/35 20	
NOROXIN	1 ORTHO-NOVUM 1/50 20	nercolone
NORPACE	9 ORTHO-NOVUM 10/11 20	pergolide
NOR-QD	1 ORTHO-NOVUM 7/7/7 20	D PERMAX
nortrel 0.5/35	9 ORUVAIL ER 2	B permethrin18
nortrel 1/351	9 OVACE	8 perphenazine
nortrel 7/7/7	9 OVCON 50	0 perphenazine/amitriptyline 14
nortrintvline	7 OVCON-35	O PERSANTINE9
NORVASC	1 OVRAL	0 PEXEVA 16, 34, 39
NORVASC3	7 OVRETTE	
NORVIR	.5 oxaprozin	8 phenazopyridine hcl24
NOVOLIN 70/30 21, 3	13 oxázepam	4 phenobarbital
NOVOLIN N 21,	3 OXISTAT	
NOVOLIN R 21, 3	33 OXSORALEN-UL	
NOVOLOG	21 oxybutynin	
NOVOLOG MIX 70/30	21 OXYCÉT	
NOVOSEVEN		PHOTOFRIN 8
NULYTELY	23 oxycodone/ 17 acetaminophen15, 3	
NUOX	i/ acetaininopiien	per se manufactura de la compactica de l
	www.aetna.com/formulary	47

PAGE

www.aetna.com/formulary

Index

pilocar 28	procainamide ER 9	quinidine sulfate 9
pilocarpine. 28	PROCANBID 9	quinine sulfate 25
pilocarpine	PROCARDIA	OUIXIN 29
PILOPINE HS 28	PROCARDIA XL 11, 33, 36	QVAR30
piloptic 28	PROCERTIFIED 34	
pindolol	PROCHIEVE24	R
piroxicam 28	prochlorperazine 16	RANICLOR
PLAN B	PROCRIT 8	ranitidine
PLAQUENIL	proctocream hc 23	RAPAMUNE
PLAQUEINIL ,	proctosert	RAPAMUNE 16 20
PLAVIX9	proctosol23	RAPIFLUX
PLENDIL	proctosol hc23	RAPTIVA18
PLETAL 9, 34	PROFILNINE	rauwolfial
PLEXION CLOTH	PROGESTERONE VAGINAL 24	bendroflumethiazide 10
PLEXION EMULSION 17		RAZADYNE13
PLEXION SCT	PROGLYCEM 20	RAZADYNE ER
PLEXION T5	PROGRAF24	REBETOL
podocon	PROLEUKIN 8	REBETRON 25, 31
podofilox	promethazine 30	REBIF
podomox	promethegan30	KEDIF
poly-dex 29	PROMETRIUM21	reclipsen
polyethylene glycol 23	PRONESTYL 9	RECOMBINATE31
polymyxin B/trimethoprim 29	PRONESTYL SR9	REFACTO
POLY-PRED 29	PRONESTIL Sh	RELAFEN 28
PONSTEL 28	propafenone 10	RELENZA
oportia20	propanthelin	RELION 70/3033
PRANDIN	PROPINE	RELION N
PRANDIN	PROPLEX T 31	RELION R
prascion	100	RELION R
PRAVACHOL	propoxyphene/	RELPAX 16, 40
PRAVACHOL 12, 33, 38 PRAVIGARD 12, 53, 30	acetaminophen 15, 34	REMERON 13, 34
prazosin	acetaninophen.	REMERON SOLUTAB 13, 34
PRECISION Q-I-D TEST STRIPS. 20	propoxypricitedapiiiii	REMICADE
PRECISION SOF-TACT TEST		RENAGEL
STRIPS	propoxyphene-N/	REPREXAIN
PRECISION XTRA KETONE	acetaminophen	REPRONEX 21
TEST STRIPS	propranolol	REQUIP
1EST STRIPS	propranolol/	RESCRIPTOR25
PRECISION XTRA TEST STRIPS 20	h. deneblarathiazida 10	RESCRIPTOR
PRECOSE 19	10	reserpine
PRED-G		RESTASIS 29
PRED-G S.O.P	DDOTONIV 22 22 34 40	RETIN-A 17, 31
prednisolone 21, 29	PROTOPIC	RETIN-A MICRO 17, 31
prednisone2	1 11010110	RETROVIR
PREFEST 20		REVATIO
	PROVENTIL HFA 30	
DDENADINI 20 3	7	REV-EYES 28
PREMARIN	PROVIGIL 14, 31, 36	REV-EYES
PREMARIN	PROVIGIL	REYATAZ
PREMARIN 20, 3 PREMARIN VAGINAL 2 PREMPHASE 2	PROVIGIL	REYATAZ
PREMARIN	PROVIGIL	REYATAZ
PREMARIN	PROVIGIL	REYATAZ 25 RHEUMATREX 27 RHINOCORT AQ 30, 34 ribasphere 26
PREMARIN 20, 3 PREMARIN VAGINAL 2 PREMPHASE 2	PROVIGIL 14, 31, 36 PROZAC 16, 34, 39 PROZAC WEEKLY 16, 34 prudoxin 18 PSORIATEC 18	REYATAZ 25 RHEUMATREX 27 RHINOCORT AQ 30, 34 ribasphere 26 ribavirin 26
PREMARIN	PROVIGIL 14, 31, 36 PROZAC 16, 34, 39 PROZAC WEEKLY 16, 34 Prudoxin 18 PSORIATEC 18 PULMICORT RESPULES 30	REYATAZ 25 RHEUMATREX 27 RHINOCORT AQ 30, 34 ribasphere 26 ribavirin 26 RIDAURA 27
PREMARIN	PROVIGIL 14, 31, 36 PROZAC 16, 34, 39 PROZAC WEEKLY 16, 34 Prudoxin 18 PSORIATEC 18 PULMICORT RESPULES 30 PULMICORT TURBUHALER 30	REYATAZ 25 RHEUMATREX 27 RHINOCORT AQ 30, 34 ribasphere 26 ribavirin 26 RIDAURA 27 RIFAMATE 25
PREMARIN	PROVIGIL 14, 31, 36 PROZAC 16, 34, 39 PROZAC WEEKLY 16, 34 Prudoxin 18 PSORIATEC 18 PULMICORT RESPULES 30 PULMICORT TURBUHALER 30 PURINETHOL 8	REYATAZ 25 RHEUMATREX 27 RHINOCORT AQ 30, 34 ribasphere 26 ribavirin 26 RIDAURA 27 RIFAMATE 25
PREMARIN	PROVIGIL 14, 31, 36 PROZAC 16, 34, 39 PROZAC WEEKLY 16, 34 PROZAC WEEKLY 16, 34 PRORIATEC 18 PULMICORT RESPULES 30 PULMICORT TURBUHALER 30 PURINETHOL 8 PYTAZINAMIDE 25	REYATAZ 25 RHEUMATREX 27 RHINOCORT AQ 30, 34 ribasphere 26 ribavirin 26 RIDAURA 27 RIFAMATE 25 rifampin 25 DIFATER 25
PREMARIN 20, 3° PREMARIN VAGINAL 2. PREMPHASE 2. PREMPRO 2. PREVACID 23, 32, 34, 4 PREVACID NAPRAPAC 28, 3 PREVACID SOLUTAB 23, 4 prevalite 1 previfem 2 PREVPAC 23, 4	PROVIGIL	REYATAZ 25 RHEUMATREX 27 RHINOCORT AQ 30, 34 ribasphere 26 ribavirin 26 RIDAURA 27 RIFAMATE 25 rifampin 25 RIFATER 25
PREMARIN	PROVIGIL 14, 31, 36 PROZAC 16, 34, 39 PROZAC WEEKLY 16, 34 PROZAC WEEKLY 16, 34 PROZAC WEEKLY 16, 34 PROVIGIL 18 PSORIATEC 18 PULMICORT RESPULES 30 PULMICORT TURBUHALER 30 PURINETHOL 8 PYRIZINAMIDE 25 PYRIZINAMIDE 25 PYRIZINAMIDE 27	REYATAZ 25 RHEUMATREX 27 RHINOCORT AQ 30, 34 ribasphere 26 ribavirin 26 RIDAURA 27 RIFAMATE 25 rifampin 25 RIFATER 25 RILUTEK 13
PREMARIN	PROVIGIL 14, 31, 36 PROZAC 16, 34, 39 PROZAC WEEKLY 16, 34 PROZAC WEEKLY 16, 34 PROZAC WEEKLY 16, 34 PROVIGIL 18 PROVIGIL 18 PROVIGIL 18 PROVIGIL 19 P	REYATAZ 25 RHEUMATREX 27 RHINOCORT AQ 30, 34 ribasphere 26 ribavirin 26 RIDAURA 27 RIFAMATE 25 rifampin 25 RIFATER 25 RILUTEK 13 rimantadine 26
PREMARIN 20, 3' PREMARIN VAGINAL 2- PREMPHASE 2- PREVACID 23, 32, 34, 4 PREVACID NAPRAPAC 28, 3 PREVACID SOLUTAB 23, 4 prevalite 1 previfem 22 PREVPAC 23, 4 PRILOSEC 23, 32, 34, 4 primaquine 25, 3 primidone 1	PROVIGIL 14, 31, 36 PROZAC 16, 34, 39 PROZAC WEEKLY 16, 34 PROZAC WEEKLY 16, 34 PROZAC WEEKLY 16, 34 PROVIGIT 18 PSORIATEC 18 PULMICORT RESPULES 30 PULMICORT TURBUHALER 30 PURINETHOL 8 PURINETHOL 8 PURINETHOL 9 PURINETHOL 9 PURINETHOL 9 PURINETHOL 25 PURINETHOL 25 PURINETHOL 25 PURINETHOL 25 PURINETHOL 30 PURINETHOL 36 PROZAC 16, 34, 39 PROZAC 36, 34, 39 PROZAC 36, 36, 36, 36 PROZAC 36 PROZAC 36, 36 PROZAC 36 PROZAC 36, 36 PROZAC 36, 36 PROZAC 36 PROZAC 36, 36 PROZAC 36 PROZAC 36, 36 PROZAC 36 PROZA	REYATAZ 25 RHEUMATREX 27 RHINOCORT AQ 30, 34 ribasphere 26 ribavirin 26 RIDAURA 27 RIFAMATE 25 rifampin 25 RIFATER 25 RILUTEK 13 rimantadine 26 RIMSO 23
PREMARIN 20, 3' PREMARIN VAGINAL 2- PREMPHASE 2- PREVACID 23, 32, 34, 4 PREVACID NAPRAPAC 28, 3 PREVACID SOLUTAB 23, 4 prevalite 1 previfem 22 PREVPAC 23, 4 PRILOSEC 23, 32, 34, 4 primaquine 25, 3 primidone 1	PROVIGIL 14, 31, 36 PROZAC 16, 34, 39 PROZAC WEEKLY 16, 34, 39 PROZAC WEEKLY 16, 34 PROJATEC 18 PSORIATEC 18 PULMICORT RESPULES 30 PULMICORT TURBUHALER 30 PURINETHOL 8 POURINETHOL 25 pyridostigme 27 Q QUESTRAN 11 4 quinapril 9, 33, 35	REYATAZ 25 RHEUMATREX 27 RHINOCORT AQ 30, 34 ribasphere 26 ribavirin 26 RIDAURA 27 RIFAMATE 25 rifampin 25 RIFATER 25 RILUTEK 13 rimantadine 26 RIMSO 23 RIOMET 19
PREMARIN 20, 3' PREMARIN VAGINAL 2- PREMPHASE 2- PREVACID 23, 32, 34, 4 PREVACID NAPRAPAC 28, 3 PREVACID SOLUTAB 23, 4 prevalite 1 previfem 22 PREVPAC 23, 4 PRILOSEC 23, 32, 34, 4 primaquine 25, 3 primidone 1 principen 22	PROVIGIL 14, 31, 36 PROZAC 16, 34, 39 PROZAC WEEKLY 16, 34 PROZAC WEEKLY 16, 34 PROZAC WEEKLY 16, 34 PROVIGIT 18 PSORIATEC 18 PULMICORT RESPULES 30 PULMICORT TURBUHALER 30 PURINETHOL 8 PURINETHOL 9 PURINETHOL 9 PURINETHOL 25 pyridostigme 27 PURINETHOL 9 PURINETHOL	REYATAZ 25 RHEUMATREX 27 RHINOCORT AQ 30, 34 ribasphere 26 ribavirin 26 RIDAURA 27 RIFAMATE 25 rifampin 25 RIFATER 25 RILUTEK 13 rimantadine 26 RIMSO 23 RIOMET 19 RISPERDAL 14, 36
PREMARIN 20, 3 PREMARIN VAGINAL 2 PREMPHASE 2 PREMPRO 23, 32, 34, 4 PREVACID NAPRAPAC 28, 3 PREVACID SOLUTAB 23, 4 prevalite 1 previfem 2 PREVPAC 23, 32, 34, 4 primaquine 25, 3 primidone 1 principen 2 PRINIVIL 9, 33, 3	PROVIGIL 14, 31, 36 PROZAC 16, 34, 39 PROZAC WEEKLY 16, 34, 39 PROZAC WEEKLY 16, 34 PROJATEC 18 PSORIATEC 30 PULMICORT TURBUHALER 30 PURINETHOL 8 POURINETHOL 9 PURINETHOL 25 pyridostigme 27 Q QUESTRAN 11 Quinapril 9, 33, 35 quinapril/hctz 33	REYATAZ 25 RHEUMATREX 27 RHINOCORT AQ 30, 34 ribasphere 26 ribavirin 26 RIDAURA 27 RIFAMATE 25 rifampin 25 RIFATER 25 RILUTEK 13 rimantadine 26 RIMSO 23 RIOMET 19 RISPERDAL 14, 36 RISPERDAL CONSTA 14
PREMARIN 20, 3' PREMARIN VAGINAL 2' PREMPHASE 2' PREMPRO 23, 32, 34, 4 PREVACID NAPRAPAC 28, 3' PREVACID SOLUTAB 23, 4 PREVACID SOLUTAB 23, 4 PREVACID SOLUTAB 23, 4 PREVPAC 23, 4 PRILOSEC 23, 32, 34, 4 PRILOSEC 23, 32, 34, 4 PRILOSEC 25, 3 PRILOSEC 27, 32, 34, 4 PRINCIPE 25, 3 PRINCIPE 10, 3' PRINIVIL 9, 33, 3 PRINZIDE 10, 3'	PROVIGIL 14, 31, 36 PROZAC 16, 34, 39 PROZAC WEEKLY 16, 34, 39 PROZAC WEEKLY 16, 34 PROZAC WEEKLY 16, 34 PSORIATEC 18 PULMICORT RESPULES 30 PULMICORT TURBUHALER 30 PURINETHOL 8 PURINETHOL 8 PURINETHOL 25 pyridostigme 27 Q QUESTRAN 11 Quinapril 9, 33, 35 quinapril/hctz 33 quinaretic 11	REYATAZ 25 RHEUMATREX 27 RHINOCORT AQ 30, 34 ribasphere 26 ribavirin 26 RIDAURA 27 RIFAMATE 25 rifampin 25 RIFATER 25 RILUTEK 13 rimantadine 26 RIMSO 23 RIMSO 23 RIOMET 19 RISPERDAL 14, 36 RISPERDAL CONSTA 14
PREMARIN 20, 3 PREMARIN VAGINAL 2 PREMPHASE 2 PREMPRO 23, 32, 34, 4 PREVACID NAPRAPAC 28, 3 PREVACID SOLUTAB 23, 4 prevalite 1 previfem 2 PREVPAC 23, 32, 34, 4 primaquine 25, 3 primidone 1 principen 2 PRINIVIL 9, 33, 3	4 PROVIGIL 14, 31, 36 PROZAC 16, 34, 39 PROZAC WEEKLY 16, 34, 39 PROZAC WEEKLY 16, 34 PYSORIATEC 18 PULMICORT RESPULES 30 PULMICORT TURBUHALER 30 PURINETHOL 8 POURINETHOL 8 POURINETHOL 9 PURINETHOL 9 PURINETHOL 9 PURINETHOL 9 PURINETHOL 9 PURINETHOL 30 PURINETHOL 30 PURINETHOL 30 PURINETHOL 30 PURINETHOL 35 PURINETHOL 35 PURINETHOL 36 PROZAC WEEKLY 16, 34 PROZAC 34, 36 PROZAC WEEKLY 16, 34 PROZAC 34, 36 PROZAC WEEKLY 16, 34 PROZAC 34, 39 PROZAC WEEKLY 16, 34 PROZAC WEEKLY 18, 34 PULMICORT TURBUHALER 30 PURINETHOL 30 PURIN	REYATAZ 25 RHEUMATREX 27 RHINOCORT AQ 30, 34 ribasphere 26 ribavirin 26 RIDAURA 27 RIFAMATE 25 rifampin 25 RIFATER 25 RILUTEK 13 rimantadine 26 RIMSO 23 S RIOMET 19 B RISPERDAL 14, 36 O RISPERDAL CONSTA 14 F RISPERDAL M 14, 36

www.aetna.com/formulary

RITALIN LA 14, 33. 36	SUBOXONE 16	terazosin
RITALIN SR 14, 33, 36	SUBUTEX	terbutaline
ROFERON-A 8, 31	sucralfate23	terconazole
ROSAC17	SULAR	TESLAC
rosaderm······· 17	sulfacetamide sodium · · · · · 18 sulfacetamide sodium opth 29	TESTIM
rosanil	sulfacetamide sodium/	testomar · · · · · · · 12
ROSULA NS 18	prednisolone 29	testosterone 19
ROWASA 23, 38	SULFACET-R 17	tetracycline
ROXICET 16. 34	sulfadiazine	TNETEN
ROZEX 17	sulfasalazine 23.33.38	TEVETEN HCT10
RYTHMOL 10	sulfasələzine ER 23	TEV-TROPIN 21.31
RYTHMOLSR10	sulfatol17	THALITONE 13
.5	sulfazine	THALOMID24
SAIZEN 31 salflex 28	sulfazine entab	theocap
	sulfisoxazole27	theochron
salsalate28 SANCTURA24, 34	SULFOXYL	THERACYS 8
	sulfurated lime solution 18	thioridazine
SANDIMMUNE24	sulindac 28	thiothixene 16
SARAFEM 34, 39	suphera 17	THYROLAR
E 20, 37	SUPRAX	TIAZAC
SEBIZON	30311VA Z3	TICE BCG 8
SECTRAL	SYMAX DUOTAB	TICLID9
selegiline	symax 5L	ticlopidine
selenium sulfide	symax SR	TIKOSYN 10 TILADE 30 TIMOLIDE 10
SEMPREX D 30, 31, 36	SYMMETREL	TRACLIDE 10
SENSIPAR	SYNAGIS 32 SYNALGOS DC 16	timolol
SEKEAEMI DIZKOZ	SYNALGOS DC 16	timolol11
		unioloi
SEROQUEL14,37	syntest D.S. 20	
SEROQUEL	syntest D.S. 20	timolol maleate ophth
SEROQUEL 14,37 SEROSTIM 21,31 SINEMET 13		timolol maleate ophth 28 tioconazole 24
SEROQUEL 14,37 SEROSTIM 21,31 SINEMET 13 SINEMET CR 13	syntest D.S. 20 syntest H.S. 20 SYNTHROID 22 T	timolol maleate ophth 28 tioconazole 24 tizanidine
SEROQUEL 14,37 SEROSTIM 21,31 SINEMET 13 SINEMET CR 13 SINGULAIR 30,38	syntest D.S. 20 syntest H.S. 20 SYNTHROID 22 T TABLOID 8	timolol maleate ophth 28 tioconazole
SEROQUEL 14, 37 SEROSTIM 21, 31 SINEMET 13 SINEMET CR 13 SINGULAIR 30, 38 SKELAXIN 27 SKELID 27	syntest D.S. 20 syntest H.S. 20 SYNTHROID 22 T TABLOID 8 TAGAMET 22, 33	timolol maleate ophth . 28 tioconazole . 24 tizanidine . 27 TOBRADEX . 29 tobramycin . 29
SEROQUEL 14, 37 SEROSTIM 21, 31 SINEMET 13 SINGEMET CR 13 SINGULAIR 30, 38 SKELAXIN 27 SKELID 27 sodium sulfacetamine/sulfur 17	syntest D.S. 20 syntest H.S. 20 SYNTHROID 22 T TABLOID 8 TAGAMET 22, 33 TALACEN 16, 34	timolol maleate ophth . 28 tioconazole . 24 tizanidine . 27 TOBRADEX . 29 tobramycin . 29 tolazamide . 22
SEROQUEL 14, 37 SEROSTIM 21, 31 SINEMET 13 SINGEMET CR 13 SINGULAIR 30, 38 SKELAXIN 27 SKELAXIN 27 SKELID 27 sodium sulfacetamine/sulfur 17 SOLARAZE 18	syntest D.S. 20 syntest H.S. 20 SYNTHROID 22 T TABLOID 8 TAGAMET 22, 33 TALACEN 16, 34 TALWIN NX 16	timolol maleate ophth . 28 tioconazole . 24 tizanidine . 27 TOBRADEX . 29 tobramycin . 29 tolazamide . 22 tolbutamide . 22
SEROQUEL 14, 37 SEROSTIM 21, 31 SINEMET 13 SINEMET CR 13 SINGULAIR 30, 38 SKELAXIN 27 SKELAXIN 27 SKELID 27 sodium sulfacetamine/sulfur 17 SOLARAZE 18 solia 20	syntest D.S. 20 syntest H.S. 20 SYNTHROID 22 T TABLOID 8 TAGAMET 22, 33 TALACEN 16, 34 TALWIN NX 16 TAMBOCOR 10	timolol maleate ophth 28 ticoconazole 24 tizanidine 27 TOBRADEX 29 tobramycin 29 tolazamide 22 tolbutamide 22 TOLECTIN 28
SEROQUEL 14, 37 SEROSTIM 21, 31 SINEMET 13 SINEMET CR 13 SINGULAIR 30, 38 SKELAXIN 27 SKELAXIN 27 sodium sulfacetamine/sulfur 17 SOLARAZE 18 solia 20 SOMAVERT 21	syntest D.S. 20 syntest H.S. 20 SYNTHROID 22 T 22 TABLOID 8 TAGAMET 22, 33 TALACEN 16, 34 TALWIN NX 16 TAMBOCOR 10 TAMIFLU 26, 38	timolol maleate ophth 28 tioconazole 24 tizanidine 27 TOBI 24 TOBRADEX 29 tobramycin 29 tolazamide 22 tolbutamide 22 TOLECTIN 28 tolmetin sodium 28
SEROQUEL 14, 37 SEROSTIM 21, 31 SINEMET 13 SINEMET CR 13 SINEMET CR 30, 38 SKELAXIN 27 SKELAXIN 27 SKELD 27 Sodium sulfacetamine/sulfur 17 SOLARAZE 18 solia 20 SOMAVERT 21 SONATA 16,39	syntest D.S. 20 syntest H.S. 20 SYNTHROID 22 T 22 TABLOID 8 TAGAMET 22, 33 TALACEN 16. 34 TALWIN NX 16 TAMBOCOR 10 TAMIFLU 26, 38 tamoxifen 8	timolol maleate ophth 28 ticoconazole 24 tizanidine 27 TOBRADEX 29 tobramycin 29 tolazamide 22 tolbutamide 22 TOLECTIN 28
SEROQUEL 14, 37 SEROSTIM 21, 31 SINEMET 13 SINEMET CR 13 SINGULAIR 30, 38 SKELAXIN 27 SKELAXIN 27 sodium sulfacetamine/sulfur 17 SOLARAZE 18 solia 20 SOMAVERT 21	syntest D.S. 20 syntest H.S. 20 SYNTHROID 22 T 22 TABLOID 8 TAGAMET 22, 33 TALACEN 16, 34 TALWIN NX 16 TAMBCOOR 10 TAMIFLU 26, 38 tamoxifen 8 TAPAZOLE 19 TARCEVA 8, 31	timolol maleate ophth 28 tioconazole 24 tizanidine 27 TOBI 24 TOBRADEX 29 tobramycin 29 tolazamide 22 tolbutamide 22 TOLECTIN 28 tolmetin sodium 28 TOPAMAX 15 TOPROL XL 10 TORADOI 39
SEROQUEL 14, 37 SEROSTIM 21, 31 SINEMET 13 SINEMET CR 13 SINGULAIR 30, 38 SKELAXIN 27 SKELID 27 sodium sulfacetamine/sulfur 17 SOLARAZE 18 solia 20 SOMAVERT 21 SONATA 16, 39 SORIATANE 18	syntest D.S. 20 syntest H.S. 20 SYNTHROID 22 T TABLOID 8 TAGAMET 22, 33 TALACEN 16, 34 TALWIN NX 16 TAMBOCOR 10 TAMIFLU 26, 38 tamoxifen 8 TAPAZOLE 19 TARGRETIN 8, 31 TARGRETIN 8, 18	timolol maleate ophth 28 tioconazole 24 tizanidine 27 TOBI 24 TOBRADEX 29 tobramycin 29 tolazamide 22 tolbutamide 22 TOLECTIN 28 tolmetin sodium 28 TOPAMAX 15 TOPROL XL 10 TORADOL 39 TORADOL ORAL 28
SEROQUEL 14, 37 SEROSTIM 21, 31 SINEMET 13 SINEMET CR 13 SINGULAIR 30, 38 SKELAXIN 27 SKELD 27 SOLARAZE 18 solia 20 SOMAVERT 21 SONATA 16, 39 SORIATANE 18 sorine 11 sotalol AF 11 sotalol hcl 11	syntest D.S. 20 syntest H.S. 20 SYNTHROID 22 T 22 TABLOID 8 TAGAMET 22, 33 TALACEN 16, 34 TALWIN NX 16 TAMBOCOR 10 TAMIFLU 26, 38 tamoxifen 8 TAPAZOLE 19 TARCEVA 8, 31 TARGRETIN 8, 18 TARKA 10	timolol maleate ophth 28 tioconazole 24 tizanidine 27 TOBL 24 TOBRADEX 29 tobramycin 29 tolazamide 22 tolbutamide 22 TOLECTIN 28 tolmetin sodium 28 TOPAMAX 15 TOPROL XL 10 TORADOL 39 TORADOL ORAL 28 torsemide 12
SEROQUEL 14, 37 SEROSTIM 21, 31 SINEMET 13 SINEMET CR 13 SINGULAIR 30, 38 SKELAXIN 27 SKELD 27 SOLARAZE 18 solia 20 SOMAVERT 21 SONATA 16, 39 SORIATANE 18 sorine 11 sotalol AF 11 sotalol hcl 11 SOTRET 17, 31	syntest D.S. 20 syntest H.S. 20 SYNTHROID 22 T 22 TABLOID 8 TAGAMET 22, 33 TALACEN 16, 34 TALWIN NX 16 TAMBOCOR 10 TAMIFLU 26, 38 tamoxifen 8 TAPAZOLE 19 TARCEVA 8, 31 TARGRETIN 8, 18 TARKA 10 TASMAR 13	timolol maleate ophth 28 tioconazole 24 tizanidine 27 TOBL 24 TOBRADEX 29 tobramycin 29 tolazamide 22 tolbutamide 22 TOLECTIN 28 tolmetin sodium 28 TOPAMAX 15 TOPROL XL 10 TORADOL 39 TORADOL ORAL 28 torsemide 12 TRACLEER 12 32 32
SEROQUEL 14, 37 SEROSTIM 21, 31 SINEMET 13 SINEMET CR 13 SINGULAIR 30, 38 SKELAXIN 27 SKELAXIN 27 SKELD 27 Sodium sulfacetamine/sulfur 17 SOLARAZE 18 solia 20 SOMAVERT 21 SONATA 16, 39 SORIATANE 18 sorine 11 sotalol AF 11 sotalol hcl 11 SOTRET 11 SOTRET 17, 31 SPECTRACEF 25	syntest D.S. 20 syntest H.S. 20 SYNTHROID 22 T TABLOID 8 TAGAMET 22, 33 TALACEN 16, 34 TALWIN NX 16 TAMBOCOR 10 TAMIFLU 26, 38 tamoxifen 8 TAPAZOLE 19 TARCEVA 8, 31 TARGRETIN 8, 18 TARKA 10 TASMAR 13 TAZORAC 18, 33	timolol maleate ophth 28 tioconazole 24 tizanidine 27 TOBL 24 TOBRADEX 29 tobramycin 29 tolazamide 22 tolbutamide 22 TOLECTIN 28 tolmetin sodium 28 TOPAMAX 15 TOPROL XL 10 TORADOL 39 TORADOL ORAL 28 torsemide 12 TRACLEER 12 32 32
SEROQUEL 14, 37 SEROSTIM 21, 31 SINEMET 13 SINEMET CR 13 SINEMET CR 30, 38 SKELAXIN 27 SKELAXIN 27 SOLED 27 SOLIF SUIF SUIF SUIF SUIF SUIF SUIF SUIF SU	syntest D.S. 20 syntest H.S. 20 SYNTHROID 22 T TABLOID 8 TAGAMET 22, 33 TALACEN 16, 34 TALWIN NX 16 TAMBOCOR 10 TAMIFLU 26, 38 tamoxifen 8 TAPAZOLE 19 TARCEVA 8, 31 TARGRETIN 8, 18 TARKA 10 TASMAR 13 TAZORAC 18, 33 taztia XT 11, 36	timolol maleate ophth 28 tioconazole 24 tizanidine 27 TOBI 24 TOBRADEX 29 tobramycin 29 tolzamide 22 tolbutamide 22 TOLECTIN 28 tolmetin sodium 28 TOPAMAX 15 TOPROL XL 10 TORADOL 39 TORADOL ORAL 28 torsemide 12 TRACLEER 12 tramadol 15 tramadol/acetaminophen 16
SEROQUEL 14, 37 SEROSTIM 21, 31 SINEMET 13 SINEMET CR 13 SINGULAIR 30, 38 SKELAXIN 27 SKELID 27 sodium sulfacetamine/sulfur 17 SOLARAZE 18 solia 20 SOMAVERT 21 SONATA 16, 39 SORIATANE 18 sorine 11 sotalol AF 11 sotalol hcl 11 SOTRET 17, 31 SPECTRACEF 25 SPIRIVA 29 spironolactone 12	syntest D.S. 20 syntest H.S. 20 SYNTHROID 22 T 22 TABLOID 8 TAGAMET 22, 33 TALACEN 16, 34 TALWIN NX 16 TAMBOCOR 10 TAMIFLU 26, 38 tamoxifen 8 TAPAZOLE 19 TARCEVA 8, 31 TARGRETIN 8, 18 TARKA 10 TASMAR 13 TAZORAC 18, 33 tebatnide 22	timolol maleate ophth 28 tioconazole 24 tizanidine 27 TOBI 24 TOBRADEX 29 tobramycin 29 tolazamide 22 tolbutamide 22 TOLECTIN 28 tolmetin sodium 28 TOPROL XL 10 TORADOL 39 TORADOL ORAL 28 torsemide 12 TRACLEER 12 tramadol 15, 34 tramadol/acetaminophen 16 TRANDATE 9
SEROQUEL 14, 37 SEROSTIM 21, 31 SINEMET 13 SINEMET CR 13 SINGULAIR 30, 38 SKELAXIN 27 SKELID 27 sodium sulfacetamine/sulfur 17 SOLARAZE 18 solia 20 SOMAVERT 21 SONATA 16, 39 SORIATANE 18 sorine 11 sotalol AF 11 sotalol hcl 11 SOTRET 17, 31 SPECTRACEF 25 SPIRIVA 29 spironolactone 12 spironolactone/	syntest D.S. 20 syntest H.S. 20 SYNTHROID 22 T 22 TABLOID 8 TAGAMET 22, 33 TALACEN 16, 34 TALWIN NX 16 TAMIFLU 26, 38 tamoxifen 8 TAPAZOLE 19 TARCEVA 8, 31 TARGRETIN 8, 18 TARKA 10 TASMAR 13 TAZORAC 18, 33 taztia XT 11, 36 tebatnide 22 TEGRETOL 14	timolol maleate ophth 28 tioconazole 24 tizanidine 27 TOBI 24 TOBRADEX 29 tobramycin 29 tolazamide 22 tolbutamide 28 TOLECTIN 28 tolmetin sodium 28 TOPAMAX 15 TOPROL XL 10 TORADOL 39 TORADOL ORAL 28 torsemide 12 TRACLEER 12 tramadol 15 tramadol/acetaminophen 16 TRANDATE 9 TRANSDERM SCOPOLAMINE 22
SEROQUEL 14, 37 SEROSTIM 21, 31 SINEMET 13 SINEMET CR 13 SINGULAIR 30, 38 SKELAXIN 27 SKELID 27 sodium sulfacetamine/sulfur 17 SOLARAZE 18 solia 20 SOMAVERT 21 SONATA 16, 39 SORIATANE 18 sorine 11 sotalol AF 11 sotalol hcl 11 SOTRET 17, 31 SPECTRACEF 25 SPIRIVA 29 spironolactone 12 spironolactone/ hydrochlorothiozide 11	syntest D.S. 20 syntest H.S. 20 SYNTHROID 22 T 22 TABLOID 8 TAGAMET 22, 33 TALACEN. 16, 34 TALWIN NX 16 TAMIFLU 26, 38 tamoxifen 8 TAPAZOLE 19 TARCEVA 8, 31 TARGRETIN 8, 18 TARKA 10 TASMAR 13 TAZORAC 18, 33 taztia XT 11 tebatnide 22 TEGRETOL 14 TECRETOL XR 15	timolol maleate ophth 28 tioconazole 24 tizanidine 27 TOBI 24 TOBRADEX 29 tobramycin 29 tolazamide 22 tolbutamide 22 TOLECTIN 28 TOPROL XL 15 TOPROL XL 10 TORADOL 39 TORADOL ORAL 28 torsemide 12 TRACLEER 12 tramadol/acetaminophen 16 TRANDATE 9 TRANSDERM SCOPOLAMINE 22 TRAVATAN 29
SEROQUEL 14, 37 SEROSTIM 21, 31 SINEMET 13 SINEMET CR 13 SINGULAIR 30, 38 SKELAXIN 27 SKELID 27 sodium sulfacetamine/sulfur 17 SOLARAZE 18 solia 20 SOMAVERT 21 SONATA 16, 39 SORIATANE 18 sorine 11 sotalol AF 11 sotalol hcl 11 SOTRET 17, 31 SPECTRACEF 25 SPIRIVA 29 spironolactone 12 spironolactone/	syntest D.S. 20 syntest H.S. 20 SYNTHROID 22 T 22 TABLOID 8 TAGAMET 22, 33 TALACEN 16, 34 TALWIN NX 16 TAMIFLU 26, 38 tamoxifen 8 TAPAZOLE 19 TARCEVA 8, 31 TARGRETIN 8, 18 TARKA 10 TASMAR 13 TAZORAC 18, 33 taztia XT 11, 36 tebatnide 22 TEGRETOL 14	timolol maleate ophth 28 tioconazole 24 tizanidine 27 TOBI 24 TOBRADEX 29 tobramycin 29 tolazamide 22 tolbutamide 28 TOLECTIN 28 tolmetin sodium 28 TOPAMAX 15 TOPROL XL 10 TORADOL 39 TORADOL ORAL 28 torsemide 12 TRACLEER 12 tramadol 15 tramadol/acetaminophen 16 TRANDATE 9 TRANSDERM SCOPOLAMINE 22
SEROQUEL 14, 37 SEROSTIM 21, 31 SINEMET 13 SINEMET CR 13 SINGULAIR 30, 38 SKELAXIN 27 SKELID 27 sodium sulfacetamine/sulfur 17 SOLARAZE 18 solia 20 SOMAVERT 21 SONATA 16, 39 SORIATANE 18 sorine 11 sotalol AF 11 sotalol hcl 11 SOTRET 17, 31 SPECTRACEF 25 SPIRIVA 29 spironolactone 12 spironolactone/ 12 hydrochlorothiazide 11 SPORANOX 26, 31	syntest D.S. 20 syntest H.S. 20 SYNTHROID 22 T 22 TABLOID 8 TAGAMET 22, 33 TALACEN. 16, 34 TALWIN NX 16 TAMIFLU 26, 38 tamoxifen 8 TAPAZOLE 19 TARCEVA 8, 31 TARGRETIN 8, 18 TARKA 10 TASMAR 13 TAZORAC 18, 33 tatia XT 11 tebatnide 22 TEGRETOL 14 TECRETOL XR 15 temazepam 16	timolol maleate ophth 28 tioconazole 24 tizanidine 27 TOBI 24 TOBRADEX 29 tobramycin 29 tolazamide 22 tolbutamide 22 TOLECTIN 28 tolmetin sodium 28 TOPAMAX 15 TOPROL XL 10 TORADOL 39 TORADOL ORAL 28 torsemide 12 TRACLEER 12 tramadol 15 tramadol/acetaminophen 16 TRANDATE 9 TRAVATAN 29 trazodone 15 TREXALL 8
SEROQUEL 14, 37 SEROSTIM 21, 31 SINEMET 13 SINEMET CR 13 SINGULAIR 30, 38 SKELAXIN 27 SKELD 27 Sodium sulfacetamine/sulfur 17 SOLARAZE 18 solia 20 SOMAVERT 21 SONATA 16, 39 SORIATANE 18 sorine 11 sotalol AF 11 sotalol hcl 11 SOTRET 17, 31 SPECTRACEF 25 SPIRIVA 29 spironolactone 12 spironolactone/ hydrochlorothiazide 11 SPORANOX 26, 31 sprintex 20	syntest D.S. 20 syntest H.S. 20 SYNTHROID 22 T TABLOID 8 TAGAMET 22, 33 TALACEN. 16, 34 TALWIN NX 16 TAMBOCOR 10 TAMIFLU 26, 38 tamoxifen 8 TAPAZOLE 19 TARCEVA 8, 31 TARGRETIN 8, 18 TARKA 10 TASMAR 13 TAZORAC 18, 33 taztia XT 11, 36 tebatnide 22 TEGRETOL 14 TECRETOL XR 15 temazepam 16 TEMODAR 8 TENEX 9 TENORETIC 10	timolol maleate ophth 28 tioconazole 24 tizanidine 27 TOBI 24 TOBRADEX 29 tobramycin 29 tolazamide 22 tolbutamide 22 TOLECTIN 28 tolmetin sodium 28 TOPROL XL 10 TORADOL 39 TORADOL ORAL 28 torsemide 12 TRACLEER 12 tramadol/acetaminophen 16 TRANDATE 9 TRANSDERM SCOPOLAMINE 22 TRAVATAN 29 trazodone 15 15 34 tretinoin 17
SEROQUEL 14, 37 SEROSTIM 21, 31 SINEMET 13 SINEMET CR 13 SINGULAIR 30, 38 SKELAXIN 27 SKELAXIN 27 SKELD 27 SOLARAZE 18 solia 20 SOMAVERT 21 SONATA 16, 39 SORIATANE 18 sorine 11 sotalol AF 11 sotalol AF 11 SOTRET 17, 31 SPECTRACEF 25 SPIRIVA 29 spironolactone 12 spironolactone/ 12 hydrochlorothiazide 11 SPORANOX 26, 31 Sprintex 20 STADOL NS 39 STALEVO 13 STARLIX 19	syntest D.S. 20 syntest H.S. 20 SYNTHROID 22 T TABLOID 8 TAGAMET 22, 33 TALACEN. 16, 34 TALWIN NX 16 TAMBOCOR 10 TAMIFLU 26, 38 tamoxifen 8 TAPAZOLE 19 TARCEVA 8, 31 TARKA 10 TASMAR 13 TAZORAC 18, 33 taztia XT 11, 36 tebatnide 22 TEGRETOL 14 TECRETOLXR 15 temazepam 16 TEMODAR 8 TENEX 9 TENORETIC 10 TENORMIN 10	timolol maleate ophth 28 tioconazole 24 tizanidine 27 TOBI 24 TOBRADEX 29 tobramycin 29 tolazamide 22 tolbutamide 22 TOLECTIN 28 tolmetin sodium 28 TOPAMAX 15 TOPROL XL 10 TORADOL 39 TORADOL ORAL 28 torsemide 12 TRACLEER 12 tramadol 15 TRANDATE 9 TRANSDERM SCOPOLAMINE 22 TRAVATAN 29 trazodone 15 tretinoin 17 31 TREXALL 8 triamcinolone 18 triamterene/ 18 triamterene/
SEROQUEL . 14, 37 SEROSTIM . 21, 31 SINEMET . 13 SINEMET CR . 13 SINGULAIR . 30, 38 SKELAXIN . 27 SKELID . 27 SOLIUM sulfacetamine/sulfur . 17 SOLARAZE . 18 solia . 20 SOMAVERT . 21 SONATA . 16, 39 SORIATANE . 18 sorine . 11 sotalol AF . 11 sotalol AF . 11 sotalol AF . 11 SOTRET . 17, 31 SPECTRACEF . 25 SPIRIVA . 29 spironolactone . 12 spironolactone/ hydrochlorothiazide . 11 SPORANOX . 26, 31 sprintex . 20 STADOL NS . 39 STALEVO . 13 STARLIX . 19 STRATTERA . 14, 33, 36	syntest D.S. 20 syntest H.S. 20 SYNTHROID 22 T TABLOID 8 TAGAMET 22, 33 TALACEN. 16, 34 TALWIN NX 16 TAMBOCOR 10 TAMIFLU 26, 38 tamoxifen 8 TAPAZOLE 19 TARCEVA 8, 31 TARGETIN 8, 18 TARKA 10 TASMAR 13 TAZORAC 18, 33 taztia XT 11, 36 tebatnide 22 TEGRETOL 14 TECRETOL XR 15 temazepam 16 TEMODAR 8 TENOR 8 TENORETIC 10 TENORMIN 10 TEQUIN 26, 31	timolol maleate ophth 28 tioconazole 24 tizanidine 27 TOBI 24 TOBRADEX 29 tobramycin 29 tolazamide 22 tolbutamide 22 TOLECTIN 28 tolmetin sodium 28 TOPAMAX 15 TOPROL XL 10 TORADOL 39 TORADOL ORAL 28 torsemide 12 TRACLEER 12 tramadol 15 TRANDATE 9 TRANSDERM SCOPOLAMINE 22 TRAVATAN 29 trazodone 15 tretinoin 17 TREXALL 8 triamcinolone 18 triamcinolone 18 triamterene/ hydrochlorothiazide 11
SEROQUEL 14, 37 SEROSTIM 21, 31 SINEMET 13 SINEMET CR 13 SINGULAIR 30, 38 SKELAXIN 27 SKELAXIN 27 SKELD 27 SOLARAZE 18 solia 20 SOMAVERT 21 SONATA 16, 39 SORIATANE 18 sorine 11 sotalol AF 11 sotalol AF 11 SOTRET 17, 31 SPECTRACEF 25 SPIRIVA 29 spironolactone 12 spironolactone/ 12 hydrochlorothiazide 11 SPORANOX 26, 31 Sprintex 20 STADOL NS 39 STALEVO 13 STARLIX 19	syntest D.S. 20 syntest H.S. 20 SYNTHROID 22 T TABLOID 8 TAGAMET 22, 33 TALACEN. 16, 34 TALWIN NX 16 TAMBOCOR 10 TAMIFLU 26, 38 tamoxifen 8 TAPAZOLE 19 TARCEVA 8, 31 TARKA 10 TASMAR 13 TAZORAC 18, 33 taztia XT 11, 36 tebatnide 22 TEGRETOL 14 TECRETOLXR 15 temazepam 16 TEMODAR 8 TENEX 9 TENORETIC 10 TENORMIN 10	timolol maleate ophth 28 tioconazole 24 tizanidine 27 TOBI 24 TOBRADEX 29 tobramycin 29 tolazamide 22 tolbutamide 22 TOLECTIN 28 tolmetin sodium 28 TOPAMAX 15 TOPROL XL 10 TORADOL 39 TORADOL ORAL 28 torsemide 12 TRACLEER 12 tramadol 15 TRANDATE 9 TRANSDERM SCOPOLAMINE 22 TRAVATAN 29 trazodone 15 tretinoin 17 31 TREXALL 8 triamcinolone 18 triamterene/ 18 triamterene/

www.aetna.com/formulary

49

Index

		V	XIBROM 29
	triazolam	<u>V</u> VAGIFEM · · · · · · · 24	XIFAXAN
	TRICOR	VAGIFEM · · · · · · · · · 24 VALCYTE · · · · · · · 26	XODOL 16
	trifluoperazine	VALCYTE	XOLAIR29
	trifluridine 29	vanatrip	XOPENEX
	TRIGLIDE 11	VANOXIDE-HC	XYREM
	trihexyphenidyl	VANTIN	ATREM
	TRILEPTAL15	VASERETIC 10 33	Υ
	TRI-LEVLEN · · · · · · · 20	VASQDILAN · · · · · · · · 12	YASMIN20
	trilyte	VASOTEC	YODOXIN
	trimethobenzamide 22	veetids	7
	trimethoprim 26	velivet	Z
	trimox 24	MNTAVIS	ZADITOR
	TRINALIN	VEPESID	ZAGAM
	trinessa 20	verapamil	ZANTAC
	TRI-NORINYL 20	verapamii extended release 33	ZARONTIN 16
	TRINSICON8	verapamil SR 1: 37	ZAROXOLYN 13
	TRIPHASIL	VERELAN PM	ZAVESCA 8.31
		VERELAN PM 11, 37	ZAZOLE
	tri-previfem	VERELAN SR······37	Z-CLINZ · · · · · · · · · · · · · 17
:	trivora20	VESANOID8	ZEBETA
	TRIZIVIR		ZEGERID 23, 32, 34, 40
	TRUSOPT . 29	VEXOL	ZELNORM
	TRUVADA	VIAGRA 12	
- ひとこのでは、100円に対抗機能	TRYCET 34	MAGRA 12 VIBRATAB 32	ZERIT 25 zero-order 28
	TUSSIONEX 30	VICODIN 16	ZESTORETIC 10. 33
	TYLENOL #3	VICODIN ES 16, 34	ZESTRIL
:	TYLENOL/CODEINE:16	vicodin HP 16, 34	ZETIA 12, 31, 38
	NLOX	VICOPROFEN 16, 34	
	U	VIDEX EC	ZIAC 10 ZIAGEN 25
	ULTRAM 15 34	VIGAMOX	ZITHROMAX25
	34	VIOKASE	ZMAX
	ULTRASE	VIRACEPT 25	ZOCOR 12, 33, 38
	ULTRASE MT	VIRAMUNE	ZODERM 17
	ULTRAVATE	VIRAZOLE 27	ZOFRAN
	UNIPHYL	VIREAD	ZOFRAN ODT
	UNI-SERP 10	VIVELLE	ZOLADEX8
	UNITHROID 22	VIVOTIF BERNIA EC32	ZOLOFT 16. 34. 39
	UNIVASC 9. 35	VOLTAREN	ZOMIG,
	URECHOLINE24	VOLTAREN XR	ZOMIG ZMT 16;40
	URELLE	VOPAC	ZONALON 18
	UREX24	vospire ER	ZONEGRAN
*	urimar T 23	WTORIN 10.33.36	ZORBTIVE. 31 zovia1/35E 20
	urin D/5	W	zovia1/35E20
	uriseptic	warfarin · · · · · 8	zovia1/50E · · · · · · 20
	URISPAS	WELCHOL11	ZOVIRAX
	urogesic blue	WELLBUTRIN 15, 34 38	ZYDONE
	UROXATRAL,	WELLBUTRIN SR 15,34 38	ZYMAR 29
	URSO 250	WELLBUTRIN XL 15. 34	ZYPREXA 14, 37
	URSO FORTE 22	WYGESIC	ZYPREXA ZYDIS 14 37
	ursodiol	Х	ZYRTEC 30, 31. 36
	UTA	XALATAN 29	ZYRTEC D 30, 31, 36
	UVADEX8	XELODA8	

50

www.aetna.com/formulary

"Aetna" is the brand name used for **products** and **services** provided by one or more of the Aetna **group** of subsidiary companies. Those companies include: Aetna Heahh Inc., Aetna Health of California Inc., Aetna Health of the Carolinas Inc., Aetna Health of Illinois Inc., Aetna Health of Washington Inc., Aetna Health Insurance Company of New York, Corporate Health Insurance Company and/or Aetna Life Insurance Company.

This material is for 'informational purposes only and contains only a partial, general description of plan benefits or programs and does not constitute a contract. Consult the plan documents (Schedule of Benefits, Certificate of Coverage. Evidence of Coverage, Group Agreement. Group Insurance Certificate. Booklet, Booklet Certificate, Group Policy) to determine governing contractual provisions, including procedures, exclusions and limitations relating to the plan. Aetna does not provide health care services and, therefore; cannot guarantee any results or outcomes. The availability of a plan or program may vary by geographic service area. Some benefits are subject to limitations or visit maximums. With the exception of Aetna Rx Home Delivery, all participating physicians, hospitals and other health care providers are independent contractors in private practice and are neither employees nor agents of Aetna. Aetna Rx Home Delivery, LLC, is a subsidiary of Aetna Inc. Aetna Specialty Pharmacy, LLC is jointly owned by Aetna and Priority Healthcare, Inc. Aetna's negotiated reimbursement rates with Aetna Rx Home Delivery and. Aetna Specialty Pharmacy may be higher than the cost those pharmacies pay or incur to purchase drugs and provide mail-order or specialty pharmacy services. For these purposes, Aetna Specialty Pharmacy's and Aetna Rx Home Delivery's cost of purchasing drugs takes into account discounts, credits and other amounts that those pharmacies may receive from wholesalers, manufacturers, suppliers and distributors. The availability of any particular provider cannot be guaranteed, and provider network composition is subject to change. Notice of the change shall be provided in accordance with applicable state law. While this material is believed to be accurate as of the print date. it is subject to change.

www.aetna.com/formulary

COMMONWEALTH REGISTER

VOLUME 28 NUMBER 08

August 24,2006

PAGE 26102

GHLITF - Additional Drug Coverage Exclusions

Drug Category	Drug Examples and/or Description
Anorexiants	Meridia, Xenical and other drugs prescribed for weight
	1088
Cosmetic - Hair Products	Rogaine, Propecta, Vaniga
Cosmetic - Wrinkles	Renova
Infertility - Injectable	Gonal-F, Pergonal, Pregnyl, Profasi, Repronex
Intertility - Injectable/ Antineoplastic Drug	Lupron
Sexual Dysfunctional Agents	Viagra, Levitra, Cialis, Caverject, MUSE, Edex
Sexual Dysfunctional Agents - Testosterone Products	Patches, gels, Injectables, Striant
Smoke Deterrents - OTC	Nicorette
Smoke Deterrents - RX	Zyban, nasal spray & inhaler
Olher	
Nutritional Supplements	Ensure, Pedialyte
Wianins	
OTC Vitamins	Self Explair



Roman C. Benavente Chairman


Dino M. Jones Vice Chairman

Marja Lee C. Taitano Secretary/Treasurer

<u>Members</u> Herman T. Guerrero Lucia Blanco-Maratita COMMONWEALTH OF THE NORTHERN MARIANA ISLANDS

STATE BOARD OF EDUCATION
PUBLIC SCHOOL SYSTEM
P.O. BOX 501370
SAIPAN, MP 96950

PUBLIC NOTICE



PROPOSED AMENDMENTS TO PUBLIC SCHOOL SYSTEM REGULATIONS REGARDING TEACHER CERTIFICATION: CHANGING PROVISIONAL CERTIFICATION NAME

The Board of Education (Board) for the Commonwealth of the Northern Mariana Islands Scott Norman Non Public School Rethereby notifies the general public of its intention to amend PSS regulations to add the PRAXIS requirement for school administrators, librarians, counselors and Curriculum Student Representative and Instruction program managers and coordinators. The amendments are noted in the Ambrose Bennett Teacher Representativattached.

> **Statutory Authority:** The proposed amendments to PSS regulations are promulgated pursuant to the Board's authority as provided by Article XV of the CNMI Constitution, Public Law 6-10 and the CNMI Administrative Procedures Act.

Goals and Objectives:

In order to ensure compliance with the No Child Left Behind Act, the CNMI must employ highly qualified teachers. To become highly qualified, teachers must, among other things, obtain state certification. Teachers with temporary or provisional certification do not meet the definition of highly qualified. The term "provisional" is not an accurate description for the CNMI initial two-year certificate. Accordingly, the Board of Education wishes to change the titles of the CNMI teaching certificates from Provisional to Basic I and Basic to Basic II.

Summary of Proposed Amendments: The proposed amendments will clarify that the CNMI initial two year teaching certificate is not a temporary or provisional certification.

Citation of Related and/or Affected Board Regulations:

PSS Regulation for Certified Personnel Chapter 2: CNMI Register History: Proposed 1/22/04; Adopted 3/23/04; Proposed Amendment 8/26/04; Amendment Adopted 10/25/04; Amendment Proposed 7/20/05; Amendment Adopted 9/22/05; Proposed Amendment 4/17/06.

Contact Person: All interested persons may examine the proposed amendments and submit written comments, positions, or statements for or against the proposed amendments to the Chairperson, Board of Education, P.O. Box 1370 CK, Saipan, MP 96950, call 664-3727 or fax 664-3711 within thirty (30) calendar days following the date of the publication in the Commonwealth Register of these amendments.

August 24, 2006

Dated this ______ day of August 2006, at Saipan, Northern Mariana Islands.

BOARD OF EDUCATION

Board of Education Chairperson

Pursuant to 1 CMC Section 2153, as amended by Public Law 10-50, the proposed amendments to Board of Education regulations, copies of which are attached hereto, have been reviewed and approved as to form and legal sufficiency by the Attorney General's Office.

CNMI Attorney General

Date: \$\begin{aligned}
21/06

Date: 8/21/06

Received By: ESTHER S. FLEMING Special Assistant for Administration **½ → AUG** 2006 **Date:**

NOTISIAN PUPBLIKU

MAPROPONE I AMENDASION SIHA PARA I REGULASION SISTEMAN ESKUELAN PUPBLIKU NI TINETEKA I SETIFIKASION I MA'ESTRA SIHA:

Matulaika I Na'an Setifikasion "Provisional"

I Kuetpon I Edukasion para I Commonwealth I Sankattan Siha Na Islas Marianas manotififika I pupbliku heneråt pot I intension-niha para u ma'amenda I regulasion I Sisteman Eskuelan Pupbliku para u ma'omentåyi I nisisidåt I PRAXIS para I Atministrasion eskuela, I Librarian I eskuela siha, Konseherun eskuela siha yan I Curriculum yan I Manehanten I Programan Ma'estro siha yan Coordinator siha. I amendasion man manota gi I checheton na dokumento.

Aturidåt I Lai: I mapropone **na** amendasion para I Regulasion I Sisteman Eskuelan Pupbliku man ma'establesi **sigun** I **aturidåt** I Kuetpo **ni** maprobeniyi **ni Atikulu** XV gi **Konstitusion** I Commonwealth I **Sankattan** Siha Na **Islas** Marianas, **Lai** Pupbliku 6-10 yan I **Akton** I **Areklamenton Atministrasion** I Commonwealth I **Sankattan** Siha Na Islas **Marianes.**

Finiho yan Diniseha: Para u ma'asigura na matatiyi I Akton No Child Left Behind, debi di u CNMI u emplea kuålifikåo na ma'estra/o siha. Yanggen para u fan kuålifikåo, debi di todu I ma'estra/o siha, gi ottro siha na manera, u gai setifikasion estådus. I ma'estra/o siha ni man gai setifikasion ni temporary osino provisional ti mafakcha yan I kuålifikåo na ma'estra/o siha. I palåbra "provisional" ti I dinanche na eksplikasion para solamente I dos åños na setifikasion para I CNMI. Sigun, I dinisehan I Kuetpon I Edukasion para u tulaika I titilun I setifikasion ma'estra/on I CNMI ginen "Provisional" para Basic I yan Basic II.

Mensåhen I Man Mapropone Na Amendasion Siha: I man **mapropone** na amendasion siha siempre a **klarifika** na solamente I dos **åños** na setifikasion **ma'estra/on** I CNMI ti **setifikasion temporary** osino provisional.

Annok I Man Achule' yan/pat Inafekta Na Regulasion I Kuetpo:

Regulasion PSS para I Man Masetifika Na Empleåo Chapter 2: Historian Rehistran I CNMI: Mapropone gi 01/22/04; Ma'adopta gi 03/23/04; Mapropone I Amendasion gi 08/26/04; Ma'adopta I Amendasion gi 10/25/04; Mapropone I Amendasion gi 07120105; Ma'adopta I Amendasion gi 09/22/05; Mapropone I Amendasion gi 04/17/06.

Petsona Ni Para Hu Ma'ågan: Todu **i** man enteresao na petsona **siña ma'eksamina i** man mapropone na **amendasion** yan regulasion siha ya hu fan **nahalom tinige'** opinion, pusision, pat **deklarasion** para pat i **kumokontra** i mapropone na amendasion siha guatto i Kabiseyon i Kuetpo, Kuetpon i Edukasion, gi **P.O.**Box 501370 CK, **Saipan,** MP 96950,

COMMONWEALTH REGISTER VOLUME 28 NUMBER 08 August 24, 2006 PAGE 26106

ågan i numiru 664-3727 pat fax gi 664-3711 gi halom trenta (30) diha siha gi kalendårio tinatitiye' i fechan i pupblikasion gi Rehistran i Commonwealth pot este na amendasion siha.

Mafecha este gi mina ________ na ha'ane gi Agostu 2006, giya Saipan I Sankattan Siha Na Islas Marianas.

KUETPON I EDUKASION

Ginen as:

Kabiseyon I Kuetpon Edukasion

Sigun i Lai 1 CMC Seksiona 2153, ni inamenda ginen i Lai Pupbliku 10-50, i mapropone na regulasion yan amendasion ni Kuetpon i Edukasion i kopia siha ni man ch'che'ton este na momento, esta man maribisa yan aprueba pot para u fotma yan ligat sufisiente ginen i Ofisinan i Abugådo Heneråt.

Fecha: Matthew T. Gregory Abugido Henerit i CNMI

Espesiåt Na Ayudante Para I Atministrasion

REGULATIONS FOR THE PUBLIC SCHOOL SYSTEM EMPLOYMENT OF CERTIFIED PERSONNEL **CHAPTER 2 - CERTIFICATION**

(a) **Purpose**

The Board of Education (BOE) and Public School System (PSS) recognizes that the delivery of high-quality and equitable educational services to all students in the Public School System, is necessary, therefore, it is imperative to recruit, hire, and retain highly trained and fully certified professional employees. To ensure that its professional employees are well prepared to provide the opportunity to the students to develop into happy, self-respecting, understanding and contributing members of the society, BOE requires that all professional employee meet the certification requirements as set forth in the regulations. This certification is designed to promote excellence and maintain a high standard of professionalism of all full-time professional employees within the school system.

(b) Definitions

- 1. "School" means any public educational institution, Head Start, kindergarten to grade twelve (12) that functions as part of the Commonwealth of the Northern Mariana Islands (CNMI) Public School System in providing educational services as established by the CNMI State Board of Education.
- 2. "Librarian" means any person who is employed by the Public School System and has the primary responsibility to operate the school library services to one or more students, but excludes library aides.
- **3**. "Teacher" means any person who is employed by the Public School System and has the primary responsibility for the education, instruction or the provision of related services for one or more students. This definition specifically includes regular classroom teachers, vocational education teachers, special education teachers, related services providers, but excludes specialized instructors, volunteer assistants, guest lecturers, teacher aides, teaching assistants and student teachers as defined herein.
- 4. "Guest Lecturer" means any person who delivers lectures/presentations to students with or without compensation, but who does so in the presence of the assigned teacher for that class of students.
- 5. "Student Teacher" means any person who is engaged in a course of study at a college or university in the field of education and as a part of that

- course of study, teaches a class of students under the supervision of a certified teacher.
- 6. "Teacher Aide/Teacher Assistant" means any person who is employed by the Public School System to assist the teacher and shares the responsibility for the care of the students' education under the direct supervision of a teacher, librarian or administrator.
- 7. "Volunteer Assistant" means any person who does not have an employment contract with the Public School System and without compensation assists the teacher and shares the responsibility for the care of the students' education under the direct supervision of a teacher, librarian or administrator.
- 8. "Instructor" means any person who is employed by the Public School System and who does not have a bachelor's degree but has specialized training/experience in a particular field or has met the minimum requirements established by PSS. This individual has the primary responsibility for the education or instruction of one or more students in a specialized area such as the bilingual program, the vocational education program or the Head Start program.
- 9. "Special Education Related Services Provider" means any person who is employed by the Public School System in a position from the following specialized areas: Deaf Education, Assistive Technology, Blind Education, Physical Therapy, Occupational Therapy, Educational Psychology, Audiology, Social Work, Recreational Therapy, Speech /Language Pathology, Behavior Specialist and any other area needed to comply with the Individual with Disabilities Education Act (IDEA).
- 10. "Professionally Licensed Related Services Provider" means any related services provider who is licensed by any state or appropriate professional board.
- 11. "School Counselor" means any person who is employed by the Public School System and provides guidance and counseling and/or any other related services for one or more students.
- 12. "School Administrator" means school principal or school vice principal employed by the Public School System and has the primary responsibility as an administrator and educational leader, ensuring equitable educational services to all students by implementing policies, procedures, and regulations as set forth by the Board of Education.
- 13. "Non-Education Degree" means any B.A., B.S., Master, or Doctoral Degree that is in any field area other than Education.

•

- 14. "States" means the 50 states of the United States, Commonwealth of Puerto Rico, Commonwealth of the Northern Mariana Islands, Territory of U.S Virgin Islands; Territory of Guam; Territory of American Samoa; and Freely Associated States (Federated States of Micronesia; Republic of the Marshall Islands; Republic of Palau).
- 15. "Equivalent Courses" means courses, workshops, Institutes or Seminars that meet the requirement minimum of 45 contact hours sanctioned by PSS Staff Development/Human Resources Office.

(c) Effect on Employment Contract

- 1. Possession of Valid Certificate: The failure of any instructor, teacher, librarian, school counselor, or school administrator to qualify to hold a valid certificate or to continue to qualify to hold a certificate during that person's contract term shall immediately render the contract of employment null and void.
- 2. Tenure Not Created by Certification: The granting of the Provisional Basic I, Specialized, Basic II, Standard Certificate withof Endorsement, OF Professional Certificate does not entitle any employee to tenure, nor does it imply, promise, or suggest continued employment with the CNMI Public School System.
- (d) Certification shall be aligned with PSS elassification and compensation plan for teachers salary schedules as set forth in Attachment #1follows:
 - 1.Employees with Provisional Certificate shall be classified as Instructor I, Classroom Teacher I, School Librarian I, School Guidance Counselor I, School Vice Principal I and II, or School Principal I to III.
 - 2. Employees with Specialized Certificate shall be classified as Instructor II.
 - 3. Employees with Basic Certificate shall be classified as Classroom Teacher II, School Librarian II, or School Guidance Counselor II.
 - 4.Employees with Standard Certificate shall be classified as Classroom Teacher III, School Librarian III, or School Guidance Counselor III.
 - 5.Employees with Professional Certificate shall be classified as Classroom
 Teacher IV, School Librarian IV, School Guidance Counselor IV, School
 Vice Principal II, School Principal I, II, or III.

26110

REGULATIONS FOR THE PUBLIC SCHOOL SYSTEM EMPLOYMENT OF CERTIFIED PERSONNEL

Chapter 2

Eligibility for all five certifications: (e)

- 1. Criminal History: The applicant must be free from any felony conviction or any crime involving moral turpitude, or indicating an unfitness to teach whether a felony or a misdemeanor. A "felony" shall mean any criminal offense punishable by one or more years of imprisonment. A "misdemeanor" shall mean any criminal offense punishable by less than one year of imprisonment.
- 2. No Disciplinary Sanctions: The applicant must not have had a suspension or revocation of his/her certificate or license by any other state or national agency.
- 3. No Physical or Mental Disability Preventing Service: The Applicant must not possess a physical or mental disability that would prevent the applicant from safely and effectively performing job-related functions or that poses a significant risk of substantial harm to the health or safety of students, coworkers, or others and such risk that cannot be eliminated or reduced by reasonable accommodation.
- 4. Core Knowledge Examination: All certification applicants, excluding professionally licensed related services providers, must take and pass PRAXIS exams starting August 1,2006. Specialized certification applicants must take and pass PRAXIS I. All Provisional Basic I, Basie Basic II, Standard and Professional certification applications must take and pass PRAXIS I and II.

Types of Certification and Requirements (f)

The Commonwealth shall have five general levels of certification for professionals in the field of education: Provisional Pasic I, Specialized, Basic Basic 11, Standard, and Professional.

1. **Provisional Basic I Certificate** is a two-year certificate for teachers, librarians, school counselors, related service providers, instructors, and school administrators.

A. **Eligibility Requirements:**

The Provisional Basic I Certificate requires that teachers, school 1. librarians, school counselors, school administrators and other

professional applicants to possess either a baccalaureate, masters, or doctoral degree resulting from a course of instruction of at least three and one-half years length at a college or university recognized by U.S. accreditation commissions approved by PSS. An applicant who possesses a baccalaureate, masters or doctoral degree resulting from a course of instruction of at least three and one-half years length at a college or university not accredited from an approved commission shall have his/her transcript of courses evaluated and certified to be equivalent to a degree conferred by accredited schools. The,certification and evaluation of program equivalency shall only be conducted by the agencies identified and approved by PSS. The applicant is responsible for the cost of the program equivalency certification. Failure to obtain such certification shall render an applicant disqualified for failure to meet the education requirement(s) of the position.

- ii. Provisional A "Basic Instructor"-CCertificate may be provided to for Instructor applicants in specialized areas who submit required documentation below (subsections iii(a)(b)(e)(f)) andmust meet the minimum requirements as set forth in the PSS classification guidelines.
- iii. Submittal of documentation requirements prior to effective date of employment. Requirements include:
 - a. Complete and signed application form,
 - b. Two passport size photos,
 - c. Official college transcripts,
 - d. Teaching certificate (if any),
 - e. Receipt of payment from PSS Treasurer for certification processing fee, and
 - f. FBI fingerprint submission.
 - g. Effective August 1,2006: Test Result showing that an applicant has taken and passed PRAXIS I and II exams, excluding professionally licensed related services providers.

B. Education: Certification Course Requirements

Prior to the two-year expiration date of the <u>ProvisionalBasic I</u>
Certificate, the applicant must provide an official transcript or certificate of completion of the <u>Basic Basic II</u> Certificate courses or applicable certification courses.

5

August 24: 2006

F

- C. **Term:** The Provisional Basic I Certificate is invalid after its expiration date and shall not be reissued. Requirements must be satisfied to upgrade to the next certification level.
- 2. **Specialized Certificate:** A Specialized Certificate is a two-year certificate specifically for instructors who do not have a bachelors degree but have specialized training/experience in a particular field or has met the minimum requirements established by PSS.

Eligibility Requirements: A.

- Meet eligibility requirements for Provisional Basic ı. Instructor Certificate.
- ii. All instructors must submit a completed and signed application form in the CNMI under the penalty of jury for a Specialized Certificate within the first quarter of employment.
 - iii. Submit receipt of payment from PSS Treasurer for certification processing fee within the first quarter of employment.
 - Test Result showing that an applicant has taken and iv. passed PRAXIS I.

B. **Education: Certification Course Requirements**

Prior to the two-year expiration date of the Provisional Basic I Certificate, the applicant must provide an official transcript or certificate of completion of specific specialized courses. Education courses for the Specialized Certificate are as follows:

- Specialized Certification in Bilingual Program: Instructors 1. assigned to teach in a Bilingual program must complete the following courses or equivalent:
 - Computer Technology a.
 - Instruction in Teaching Linguistically Diverse Students b.
 - c. Instruction in Chamorro/Carolinian Language Arts
 - Instruction in Planning and Assessment for Diverse d. Classroom
 - Instruction for Students with Disabilities e.
 - f. Instruction in Lesson Planning and Classroom Management
 - Chamorro or Carolinian Orthography g.

- ii. Specialized Certificate in Early Childhood (Head Start): Instructors teaching in the Head start program must complete the following courses or equivalent:
 - a. Computer Technology
 - b. Curriculum in Early Childhood Education
 - c. Education for Parenthood
 - d. Guiding and Nurturing
 - e. Safety and First Aid for Young Children
 - f. Administration in Early Childhood Education
 - g. Introduction to Exceptional Individuals
- iii. Specialized Certificate in Vocational Education:
 Instructors for Vocational Education classes must complete
 the following courses or equivalent:
 - a. Computer Technology
 - b. Instructional Strategies and Classroom Management
 - c. Instructional in Teaching Linguistically Diverse Students
 - d. Instruction in Planning and Assessment
 - e. Occupational Competency as approved by PSS
- C. Term: Instructors may renew the Specialized Certificate an unlimited number of times repeating the eligibility requirements every two years with proof of completion of 60 hours of seminars, workshops, or in-service training as sanctioned by PSS and/or equivalent university/college courses.
- 3. <u>BasieBasic II Certificate</u> is a three-year certificate for teachers, librarians, school counselors, and related service providers. <u>BasieBasic II</u> Certificate will be issued upon submission of completed requirements. If the applicant has met all the requirements for both the <u>BasieBasic II</u> Certificate and Standard Certificate with Endorsement, then the Standard Certificate will be issued.

A. Eligibility Requirements:

- 1. Applicant must meet eligibility requirements for Provisional Basic I Certificate.
- ii. The applicant must submit a recommendation from his/her principal or supervisor, which shall be based on the performance evaluation of the employee. Should the employee's performance evaluation meet a rating of

7

- satisfactory or above, he/she shall be issued a letter of recommendation for the Basic II Teaching Certificate.
- iii. The applicant must submit a copy of receipt from the CNMI PSS Treasurer in the amount required by the CNMI Board of Education Certification.
- iv. Test Result showing that the applicant, excluding professionally licensed related services providers, has taken and passed PRAXIS I and II exams.

B. Education: Certification Course Requirements

- i. <u>Any teacher or librarian</u> applying for the <u>Basie Basic II</u>
 Certificate must have satisfactorily completed and submitted an official transcript of the following course requirements or any identified equivalent courses as accepted by PSS, prior to the expiration date of the <u>Provisional Basic I</u> Certificate and before issuance of the <u>Basie Basic II</u> Certificate.
 - a. Multicultural Education/Teaching Linguistically Diverse Students
 - b. Teaching Reading
 - c. Inclusive Practice for Students with Learning Disability
 - d. Instructional Strategies/Classroom Management
 - e. Internship or Mentoring Program
 - f. Computer Technology
- ii. <u>Anv school counselor</u> applying for the <u>BasieBasic II</u> Certificate must have satisfactorily completed and submitted an official transcript of the following course requirements or identified equivalent as accepted by PSS, before the expiration date of the <u>ProvisionalBasic I</u> Certificate and before the issuance of the <u>BasieBasic II</u> Certificate.
 - a. Computer Technology
 - b. Test and Measurement
 - c. Introduction to Counseling
 - d. Issues and Philosophies of Culturally Diverse Schools
 - e. Multicultural Counseling
 - f. Counseling Process: Theory
 - g. Counseling Process: Practice

PAGE

- C. Term: The <u>BasieBasic II</u> Certificate shall be issued and valid for a period of three (3) years. The <u>BasieBasic II</u> Certificate is invalid after its expiration date and shall not be reissued.
- **Standard Certificate with Endorsement** is a five-year certificate for teachers, librarians, school counselors, and related service providers.

A. Eligibility Requirements:

- 1. The applicant must meet eligibility requirements for the Provisional Basic I Certificate and the Basic Basic II Certificate.
- ii. Three recommendations including performance evaluations: one (1) from an immediate supervisor or school principal, one (1) from a colleague, and one (1) from a parent, or former student describing the candidate's proficiency, skills, and competency. The performance evaluations must be based on cumulative performance over a contract term.
- iii. A signed application form in the CNMI under the penalty of perjury.
- iv. **An official** transcript showing satisfactory completion of the required courses or equivalent or a certificate of completion.
- v. A copy of receipt from the CNMI PSS Treasurer in the amount required by the CNMI Board of Education.

B. Education: Certification Course Requirements

- 1. <u>Standard Certificate with Elementary Education</u> <u>Endorsement:</u> Teacher teaching in elementary schools must complete the following courses or equivalent.
 - a. Instructional Technology
 - b. NMI History/Pacific Institute (NMI)
 - c. Reading Diagnostic
 - d. Tests and Measurements
 - e. Language Arts Method
 - f. Math Methods
 - g. Science Methods
 - h. Social Studies Methods

- i. Curriculum in Early Childhood Education
- ii. <u>Standard Certificate with Special Education Endorsement:</u>
 Special Education teachers teaching in the Special
 Education Program must complete the following courses or
 equivalent.
 - a. Instructional Technology
 - b. NMI History/Pacific Institute (NMI)
 - c. Reading Diagnostic
 - d. Tests and Measurements
 - e. Student Evaluation for Special Education
 - f. Behavioral Modification in the Classroom
 - g. Modification and Adaptation of Curriculum for Special Education Students
 - h. Medical Implication of Special Education Students in the Classroom
 - i. Current Issues in Special Education
- ii. Standard Certification with Early Childhood Special
 Education Endorsement: Teachers providing education
 services to students in the Early Childhood Intervention
 Program must complete the following courses or
 equivalent.
 - a. Instructional Technology
 - b. NMI History/Pacific Institute (NMI)
 - c. Reading Diagnostic
 - d. Tests and Measurements
 - e. Philosophical, Historical and Legal foundations of Early
 - f. Intervention and Special Education.
 - g. Health, Safety and Medical Aspects of children with special needs.
 - h. Fundamentals Child Growth and Development
 - i. Partnerships and Families
 - i. Evaluation & Assessment
 - k. Program Implementation in Natural Environments.
- iii. Standard Certificate with Early Childhood Education (Head Start) Endorsement: Teachers providing educational services to students in the Head Start Program must complete the following courses or equivalent.
 - a. Instructional Technology
 - b. NMI History/Pacific Institute (NMI)

- c. Reading Diagnostic
- d. Curriculum in Early Childhood Education
- e. Guiding and Nurturing Young Children
- f. Education for Parenthood
- g. Safety, Health and First Aid for Young Children
- h. Administration in Early Childhood Education
- i. Introduction to Exceptional Individual
- iv. Standard Certificate with Secondary Education
 Endorsement: Teacher teaching in the junior and senior
 high schools must complete the following courses or
 equivalent.
 - a. Instructional Technology
 - b. NMI History/Pacific Institute (NMI)
 - c. Reading Diagnostic
 - d. Tests and Measurement
 - e. Methods in Content Area
 - f. 3 Courses in the Content Area (9 credits)
- v. <u>Standard Certificate with Library Science Endorsement:</u>
 Librarians providing library services in elementary or secondary schools must complete the following courses or equivalent.
 - a. Instructional Technology
 - b. NMI History/Pacific Institute (NMI)
 - c. School Library Administration
 - d. Selection, Evaluation and Access of School Lib. Material
 - e. Children Literature or Young Adult Literature
 - f. School Library Material and the Curriculum
 - g. Technology and the School Library
 - vi. 1. <u>Standard Certificate with Bilingual Education</u>
 <u>Endorsement:</u> Teachers teaching bilingual program in the elementary or secondary schools must complete the following courses or equivalent.
 - a. Instructional Technology
 - b. NMI History/Pacific Institute (NMI)
 - c. Reading Diagnostic
 - d. Evaluation and Assessment in Bilingual
 - e. Historical and Philosophical Foundation of Bilingual
 - f. First and Second Language Acquisition
 - g. Chamorro or Carolinian Orthography

- 2. Any teacher who has obtained or completed the course requirements of the Specialized Certificate in Bilingual would only need to take the following courses:
- Instructional Technology
- b. NMI History/Pacific Institute (NMI)
- c. Reading Diagnostic
- vii. Standard Certificate for Special Education Related Service Provider Endorsement: Related services providers must obtain professional licensure and/or certification within the area of discipline or service and fulfill continuing education credits to maintain and renew their respective licenses. A copy of the professional licensure must be submitted to the Human Resources Office. The provider must complete the following courses or equivalent before the expiration date of the Provisional Basic I Certificate.
 - **Instructional Technology** a.
 - NMI History/Pacific Institute (NMI) b.
 - Teaching Linguistically Diverse Students c.
- Standard Certificate with School Counseling Endorsement: viii. School Counselors providing guidance and counseling services in the elementary and secondary schools must complete the following course requirements or equivalent.
 - a. NMI History/Pacific Institute
 - b. Dynamics of Individual Behavior
 - c. Individual and Group Assessment
 - d. Group Counseling
 - e. Prevention and Outreach
 - f. Career Counseling and Placement
 - g. Instructional Technology
- C. **Term:** Teachers, librarians, school counselors, and related service providers may renew the Standard Certificate with Endorsement every five years with submittal of the eligibility requirements. In addition, there must be proof of completion of 60 hours per year of seminars, workshops, or in-service training as sanctioned by PSS and/or equivalent university/college courses.
- 5. **Professional Certificate** is a ten-year certificate for qualified teachers, school counselors, and librarians and related service providers. Upon completion of the Standard Certificate with Endorsement, an applicant

may pursue the Professional Certificate. For school administrators, the Professional Certificate is a four-year certificate.

A. **Eligibility Requirements:**

- Meet the eligibility requirements of a Standard Certificate 1. with Endorsement.
- ii. A signed application form.
- iii. Three recommendations including performance evaluations: one (1) from an immediate supervisor or school principal, one (1) from a colleague, and one (1) from a parent, or former student describing the candidate's proficiency, skills, and competency. The performance evaluations must be based on cumulative performance over a contract term.
- Proof of current membership of professional education iv. association and specialized endorsement.
- A copy of receipt from the CNMI PSS Treasurer in the v. amount required by the CNMI Board of Education Certification.

В. **Education: Certification Course Requirements**

- The applicant must provide a certified copy of the 1. transcript of courses showing satisfactory completion of a master or doctorate degree in the field of education; or a masters or doctorate degree in a specialized field area. The specialized fields area shall include any of the following for classroom teachers, librarians, school counselors, and school administrators:
 - Secondary Education Masters in Specialized a. Content Area
 - b. **Special Education**
 - Early Childhood Education C.
 - d. Counseling
 - Education: Administration and Supervision e.
 - f. Other specialized area in education
- ii. The applicant must provide a certified copy of the transcript of courses showing satisfactory completion of a master or doctorate degree in the field of Special

Education; or a masters or doctorate degree in a specialized field area. The specialized fields area shall include any of the following for related service providers:

- a. Audiology
- b. Speech Language Pathology
- c. Physical Therapy
- d. Occupational Therapy
- e. Deaf and Hard of Hearing
- f. Education Psychologist
- iii. Any school principal or school vice principal applying for the Administrators' Professional Certificate must satisfactorily complete and submit official transcripts of the following course requirements or identified equivalent as accepted by PSS, before the expiration date of the ProvisionalBasic I Certificate and before the issuance of the Professional Certificate.
 - a. Introduction to School Administration
 - b. Instructional Supervision and Evaluation (Clinical Supervision)
 - c. School Law/Education Law
 - d. School Personnel
 - e. School Finance
 - f. Instructional Leadership & Supervision Seminar
 - g. Facilitative Leadership Seminar
- C. Term: Teachers, librarians, school counselors, and related service providers may renew the Professional Certificate every ten years with submittal of the eligibility requirements. School administrators may renew the Professional Certificate every four years with submittal of the eligibility requirements. In addition, all qualified applicants must provide proof of completion of 60 hours (120 hours for administrators) per year of seminars, workshops, or in-service training as sanctioned by PSS and/or equivalent university/college courses.

(g) Burden of Proof

The Commissioner of Education or Certification Officer may request additional proof of eligibility before making any certification determination. The burden of providing requested documentation is on the applicant.

(h) Renewal or Reapplication

An applicant applying for a new certificate or the renewal of a prior certificate must comply with the procedures set out in this Regulation as though applying for the first time, except that the Commissioner or Designee may waive the submission of documents, which are already on file and which do not need to be updated (e.g. college transcripts).

Certification Decision (i)

- 1. The Commissioner of Education shall appoint a Certification Officer. The Certification Officer shall act on behalf of the Commissioner of Education for certification decisions.
- 2. The Certification Officer shall render a decision on an application for a Specialized, Basic II, Standard with Endorsement or Professional Certificate within thirty (30) calendar days of receiving a completed application. The employee/applicant will be notified and the decision shall take effect immediately.
- 3. In the case of the denial of a certificate, the decision shall be placed in writing. It shall give written notice of the reasons for denial by citing the requirement(s) not met and explaining the evidence against the applicant.
- 4. The denial of any application may be appealed to the Commissioner of Education pursuant to the hearing procedures set forth herein.

Revocation and Suspension of Certificates (i)

1. Grounds for Revocation and Suspension

> The Commissioner of Education shall have the authority to suspend or revoke any certificate, whether provisional Basic I, Sspecialized, basie Basic II, Sstandard with Eendorsement or Pprofessional upon receipt of evidence that suspension or revocation is necessary.

2. Mandatory Revocation or Suspension

> The Commissioner or Designee must revoke any certificate when the holder has committed a material deception or fraud on his/her application for employment with the Public School System or on his/her application for certification, or has been convicted of any felony indicating an unfitness to teach or a crime of moral turpitude. These offenses include but are not limited to:

- A. violent felonies in which an individual threatens to cause, attempts to cause or causes serious bodily injury;
- B. sexually violent offenses as defined by CNMI law;

- C. criminal sex offense against a minor as defined by CNMI law;
- D. child abuse or neglect as defined by CNMI law or similar offenses in other jurisdictions;
- E. violations of the CNMI Minor Children Firearms Control Act or similar offenses in other jurisdictions;
- F. distribution to persons under 18 as defined by CNMI law or similar offenses in other jurisdictions;
- G. criminal histories may be evaluated based on the nature and severity of the incident; the identity of the victim; the length of time since the incident; whether any specific pattern of criminal behavior exists; and specific efforts the individual has made towards rehabilitation.

3. Grounds for Discretionary Action

The Commissioner of Education may suspend or revoke a certificate, if appropriate, upon the following grounds:

- **A.** Immoral conduct;
- B. Unprofessional conduct;
- C. Incompetence;
- D. Defiance of and refusal to obey the policies, rules, regulations and laws governing the duties of PSS certified personnel; and
- E. Substantial evidence of the commission (evidence of conviction not necessary) of a crime of moral turpitude or a felony indicating an unfitness to teach.

4. **Complaints**

A. An action to suspend or revoke a certificate must be initiated by a written complaint filed by the Commissioner or Designee and served upon the employee. The complaint shall give written notice of the charges by: i) citing any regulation violated, or any misconduct of the employee; ii) explaining the evidence against the employee; iii) stating the proposed sanction; and iv) informing the employee of the opportunity for a formal hearing. The employee shall receive the complaint twenty (20) days prior to any suspension or revocation action pursuant to 3 CMC § 1183(e). The notice and opportunity for a hearing regarding a suspension or revocation must comply with 1 CMC § 9111.

B. In the case of a denial of a certificate by the Certification Officer under \$2305 hereof, the decision shall be placed in writing. It shall give written notice of the reasons for denial by citing the requirement(s) not met and explaining the evidence against the applicant.

5. Interim Suspension

- **A.** No suspension or revocation shall take effect until a hearing, if requested, has reached a final judgment, pursuant to 1 CMC § 9111(a).
- B. If the Commissioner finds that public health, safety, or welfare imperatively requires it, the emergency summary suspension of a certificate may be ordered pending proceedings for revocation or other action pursuant to 1 CMC §9111(b).

6. Opportunity for Formal Hearing

The employee/applicant shall be provided with an opportunity to have a formal hearing regarding any denial, suspension or revocation of a certificate. The hearing will be held before the Board of Education and the majority of Board Members at the hearing will make any suspension decision. The employee/applicant must request a formal hearing in writing within ten (10) days of the receipt of his/her complaint or notice of the denial of certificate. The request shall be addressed to the Chairperson of the Board of Education.

7. Scheduling the Hearing

- A. The PSS Legal Counsel shall represent the Commissioner/Designee in presenting a complaint for revocation or suspension and in presenting the evidence supporting the denial of a certificate.
- B. The employee/applicant is entitled to retain counsel at his or her own expense or to represent him or herself in the proceeding.
- C. The Chairperson of the Board of Education shall schedule a hearing date within forty-five (45) days of the employee's request for a hearing. The date shall be set with due regard for the need of PSS to take action on the suspension or revocation and for the need of the employee to have sufficient time to adequately prepare a defense. The hearing shall not be scheduled for a date earlier than (20) twenty days after providing notice of the proposed action, as required by 3 CMC § 1183(e).

- D. The Chairperson shall provide a date for the exchange of witness lists and documents intended to be introduced at the hearing. The Chairperson may also hold a pre-hearing conference to accomplish one or more of the following tasks:
 - 1. Decide the issues for the hearing;
 - ii. Stipulate as to uncontested facts;
 - iii. Estimate the length of the hearing;
 - iv. Mark exhibits; or
 - v. Determine the admissibility of contested evidence.

8. Burden of Proof

The Commissioner/Designee, or the Certification Officer shall have the burden of proving the charge or decision by a preponderance of the evidence.

- 9. Conduct of Hearing
 - A. The hearing shall commence with a reading of the complaint or the decision of the Commissioner/Designee or Certification Officer.
 - B. Each side shall be permitted to make an opening statement. The PSS Legal Counsel shall present evidence to support the findings of the Commissioner/Designee subject to cross-examination.
 - C. The employee/applicant may present evidence to rebut the charges, or findings, subject to cross-examination. Each side may present rebuttal evidence.
 - D. After all the evidence has been presented, a closing argument may be offered on behalf of the Commissioner/Designee or Certification Officer. The employee/applicant may then present a closing argument, followed by the final summation on behalf of the Commissioner of Education/Designee or Certification Officer.
 - E. Proceedings hereunder shall be conducted consistent with the requirements of 1 CMC § 9109.
 - F. A recording shall be made of the proceeding to serve as the official record.
- 10. Evidence

- A. The formal rules of evidence do not apply. Any relevant evidence of probative value is admissible with only the weight assigned to it affected by its nature.
- B. A notary shall administer oaths to witnesses.
- C. Hearsay evidence shall be admissible and may constitute sufficient evidence if relevant and probative, of a kind that responsible persons are accustomed to relying upon in serious affairs, and such that a reasonable mind would accept the evidence as adequate to support a conclusion of ultimate fact.
- D. Where suspension, revocation or the denial of a certificate depends upon the proof of the commission of a crime, proof need only be by substantial evidence and not proof beyond a reasonable doubt. An acquittal on criminal charges is not a bar to a certificate's denial, suspension or revocation. A certified copy of conviction shall constitute prima facie evidence of the commission of the crime, which may be rebutted by a substantial showing of circumstances tending to disprove its commission.

11. Decision

- A. The decision-making process must comply with 1 CMC § 9110.
- B. The attorney for the Commissioner/Designee shall not participate in the private deliberations of the Board of Education.
- C. The Commissioner or Certification Officer shall issue a written decision with findings of fact and conclusions of law, and the reasons or bases for them, on all the material issues of fact and law presented on the record and an appropriate order invoking or denying a sanction, or in the case of a review, affirming or reversing a certification decision.
- D. The written decision and order shall be served on the employee/applicant within forty-five (45) days of the completion of the hearing process.

12. Appeal

The employee/applicant may appeal the Board of Education's decision pursuant to the procedures and time restrictions set forth in 3 CMC § 1183(e).

ATTACHMENT #1

HIGHLY QUALIFIED TEACHERS (HQT) REQUIREMENTS and COMPENSATION PLAN

APPROVED by Board Fiscal, Personnel and Administration Committee as amended on July 20, 2006

Type of	Requirements (Degree and Praxis)	Required Yrs of	Renewable		Salary
Certification		Experience	Certification		,
Non-HQT*	For Current Employees prior	to August 1,2006	Only		
	BNBS or MA/MS Degree or higher, Taken either Praxis I or Praxis II before July 31. 2006.	N/A	NO	\$	27,911.46
	BNBS or MA/MS Degree or higher, Taken Praxis I and Praxis II before July 31, 2006.	N/A	NO	\$	28,884.60
Non-HQT:	For New Employees beginnin		l Hag		
		1846	100	8	27,014,26
	BANKS ON VAVINS Depressions of Faces ancologist und Hexas			ā.	-248)(35%,±368)
Basic I** (HQT)	For Current Employees pr	rior to August 1, 20	06		
	Basic I CNMI Certificate, BNBS, Praxis I & II	up to 2 yrs	NO	\$	30,976.96
	Basic I CNMI Certificate, MNMS or higher, Praxis I & II	up to 2 yrs	NO	\$	33,289.35
Best 11:033	For New Employees Beginn	 	 		
BANBS (Depices	BABS Barist Que		1/10		\$ 2 E / F 2 F
	BAYRS, Pasas Lisit MAWS a dugler Praxs LSD	500	11/5	1	25/260.655
MANNS Regree	MANASA Jahar Pansaka Manasa Jahar Pansaka	<u> </u>	4.00		22
Basic II*** (HQT) - BNBS Degree	Basic II Certificate, BA/BS + 2yrs experience, Praxis I & II	up to 5 yrs	NO	\$	35,837.44
		<u> </u>	110	Ψ	
- MA/MS Degree	Basic II CNMI Certification, MA/MS or higher, Praxis I & II	up to 2 yrs	NO	\$	38,646.74
Standard (HQT)				1	
- BNBS Degree	Standard Certificate with Endorsement, BNBS, Praxis I & II	up to 5 yrs	YES	\$	35,837.44
		5+ vrs	YES	\$	38,646.74
- MNMS Degree	Standard Certificate with Endorsement, MAIMS or higher, Praxis	up to 3 yrs	YES	\$	38,745.42
	1811	3+ yrs	YES	\$	41,745.42
Professional (HQT)					
- BNBS Degree	Professional Certificate with Endorsement, BNBS Degree, Praxis I & II	10+ yrs	YES	\$	43,412.57
- MA/MS Degree	Professional Certificate with Endorsement, MNMS Degree or higher, Praxis I & II	10+ yrs	YES	\$	47,001.36

^{*} Non-Highly Qualified Teachers pursuant to PSS and BOE regulations (no proof in passing Praxis exams; however, submitted proof in taking required exams.)

PLEASE NOTE THE FOLLOWING:

For new employees beginning after August 1, 2006 or later: After two (2) years of consecutive service in PSS, and upon satisfying certification requirements, Employee will be classified under PSS Highly Qualified Teachers (HQT) Compensation and Requirements Chart.

Any Employee separated from PSS for more than two (2) years will be placed accordingly under Basic I For New Employees Beginning August 1, 2006 or later, regardless of valid PSS Certification upon rehire. Employees returning within the two (2) year anniversary date of separation will be placed at the appropriate Certification and Salary level.

Due to budgetary constraints, PSS will no longer implement annual step or within grade increases. Teachers will stay at the salary level set forth in the employment contract for the term of the contract unless the teacher submits proof showing full qualification at a different level. However, PSS will not adjust the salary in the initial two year HQT contract term. Any other change in salaries or Certification Type during a contract term will be completed at the discretion of PSS subject to the availability of funds. PSS will not grant salary increases for partial work on a Master's or Doctorate degree. Teachers, who are currently earning more than the above schedule, will maintain their current salary level if they are PRAXIS I and II qualified. This HQT Salary Schedule is subject to change based upon the availability of funds.

For specific certification requirements, please contact HRO.

^{**} Formerly Provisional Certificate

^{***} Formerly Basic Certificate



Commonwealth of the Northern Mariana Islands

Office of the Attorney General

2nd Floor Hon. Juan A. Sablan Memorial Bldg. Caller Box 10007, Capitol Hill Saipan, MP 96950

NOTICE AND CERTIFICATION OF ADOPTION OF OFFICE OF THE ATTORNEY GENERAL, CONSUMER COUNSEL, PART I, RETAIL ADVERTISING REGULATIONS,

Section 1 et. seq.

Civil Division Tel: (670) 664-2341/42 Fax: (670) 664-2349

Criminal Division Tel: (670) 664-2366/67/68 Fax: (670) 234-7016

Investigative Unit Tel: (670) 664-2310112 Fax: (670) 664-2319

> Dilion of Immigration

Saipan Tel: (670) 236-0922/23 Fax (670) 664-3190

Rota Tel: (670) 532-9436 Fax (670) 532-3190

TinianTel: (670) 433-3712
Fax (670) 433-3730

Domestic Violence Intervention Center Tel: (670) 664-4583/4 Fax: (670) 234-4589 I, Brian R. Caldwell, the consumer counsel who, with the concurrence of the Attorney General, promulgated the proposed Regulations of the Office of the Attorney General, Consumer Counsel, Part I, Regarding Retail Advertising Practices, Section 1, *et. seq.*, as published in the Commonwealth Register, Volume 28, Number 6, July 19,2006, at pages 25760 through and including 25778, by signature below hereby certify that as published, such proposed regulations are a true, complete and correct copy of the Regulations of the Office of the Attorney General, Consumer Counsel., which after expiration of the appropriate time for public comment have been adopted to the Regulations of the Office of the Attorney General, Consumer Counsel, as a new Part I, Section 1 through and including Section 8.1 with the following minor modification: that the word "Illinois" be stricken from the third line of Section 1.4 G on page 25771 and replaced with the word "Commonwealth". This new Part I of the Office of the Attorney General, Consumer Counsel, Regulations shall, without limitation, specify and define unfair and deceptive advertising practices within the CNMI.

I further request and direct this Notice and Certification to be published in the CNMI Commonwealth Register.

Submitted by:

BRITAN CALDWELL

Avg. 17, 2006

Concurred by:

MATTHEW T. GREGORY

Attorney General

Consumer Counsel

Filed and Recorded by:

BERNADITA B. DE LA ORUZ

Corporate Register

Aug 18, 2006

Pursuant to 1 CMC \$ 2153, as amended, and 1 CMC \$ 9104(a)(3), these adopted rules and regulations have been reviewed and approved as to form and legal sufficiency by the CNMI Attorney General's Office.

Dated this $\frac{18}{5}$

day of August, 2006.

MATTHEW T. GREGORY

Attorney General



NORTHERN MARIANAS COLLEGE **BOARD OF REGENTS**

P.O. BOX 501250 Saipan, MP 96950 Tel. (670) 234-5498/99 Fax. (670) 234-1270

CHAIRPERSON Dr. Rita Hocog Inos

MEMBERS-SAIPAN Eloise A. Furey Linsa F. Lizama Maria "Malua" Peter Charles V. Cepeda

MEMBERS - Rota Elaine Hocog-Orilla

MEMBERS-Tinian Vacant

PRESIDENT

NOTICE AND CERTIFICATION OF ADOPTION OF POSTSECONDARY EDUCATION POLICY

I, Dr. Rita Hocog Inos, Chair of the Board of Regents, which has promulgated policies/regulations for the licensing of postsecondary education institutions in the Commonwealth of the Northern Mariana Islands, as originally published in the Commonwealth Register, Volume 28, Number 06, pages 25829-25881, June 19, 2006, hereby certify that, as published, such Policy/Regulation is a true, complete and Antonio V. Deleon Guerrero correct copy of the Policy/Regulation previously proposed which, after the expiration of the appropriate time for public comment, have been adopted. I now request that this Notice and Certification be published in the Commonwealth Register.

> I declare under penalty of perjury that the foregoing is true and correct and this declaration was executed on the 9th day of August 2006, at Saipan, Commonwealth of the Northern Mariana Islands.

Certified by:

Dr. Rita Hocog Inos, Ed.D

Chair

Board of Regents

Filed by:

Bernadita B. Dela Cruz Commonwealth Registrar

Received by:

Special Assistant for Administration

Office of the Governor



COMMON

Roman C. Benavente Chairman

Dino M. Jones Vice Chairman


Maria Lee C, Taitano Secretary! Treasurer

Members Herman T. Guerrero Lucia Blanco-Maratita

Scott Normán Non Public School Rep.

Student Representative

Ambrose Bennett Teacher Representative



SAIPAN, MP 96950



Commissioner of Educatio

PUBLIC NOTICE

NOTICE AND CERTIFICATION OF ADOPTION OF AMENDMENTS TO BOARD OF EDUCATION REGULATIONS REGARDING PRAXIS TESTING FOR SCHOOL ADMINISTRATORS, LIBRARIANS, COUNSELORS AND **CURRICULUM AND INSTRUCTION EMPLOYEES**

- I, Roman C. Benavente, the Chairman of the Board of Education for the Commonwealth of the Northern Mariana Islands ("Board") pursuant to the authority provided by Article XV of the CNMI Constitution and Public Law 6-10 hereby adopt as permanent the proposed amendments to PSS Regulations as published in Volume 28, Number 4 of the Commonwealth Register dated April 17, 2006 (pages 025606-619) with minor modifications as set forth below and in the redline versions attached. A final clean copy of the regulations as amended is also attached.
 - 1. PSS Regulations for Non-Certified Personnel Chapter 7: Section **7101(2)** – see attached modification of deadline to July 31,2007.
 - 2. PSS Regulation for Non-Certified Personnel Chapter 1: Add new Part G Sections 1701-1703 – see attached changes.
 - 3. PSS Regulation for Certified Personnel Chapter 1: Sections 1601-1603 see attached modification of deadline to July 31,2007.
 - **4.** PSS Regulation for Certified Personnel Chapter 2 no change made since April 2006 publication.

I hereby certify that these amendments have been adopted after the appropriate time for public comment. Accordingly, I request that this Notice and Certification of Adoption be published in the Commonwealth Register. Pursuant to 1 CMC sec. 9105(b), these amended regulations are effective 10 days after publication.

I declare under penalty of pejury that the foregoing is true and correct and that this declaration was executed on this 97% day of August 2006, on Saipan, CNMI.

BOARD OF EDUCATION CHAIRMAN

August 24, 2006

PAGEmmissioner of Educatio Telephone : (670) 237-30 : (670) 664-37

Board QOMMONWEALTH REGISTER Telephone = (670) 237-3010 : (670) 664-3711

VOLUME 28 NUMBER 08

Approved By: Date: 8/2//06

MATHEW T. GERGORY

ATTORNEY GENERAL, CNMI

Filed By: Date: 82104

BE ADITAB. DE A CRUZ COMMONWEALTH REGISTER

H ATK FOR HE L ICSCHOOL EM EMPLOYMENT OF NON-CERTIFIED PERSONNEL

Chapter 7:

ADMINISTRATOR'S CERTIFICATION AND COMPENSATION

A. CERTIFICATION REQUIREMENTS:

- §7101. 1. Education: Graduation from an accredited colleges or universities with a Master's degree in School Administration/Supervision or a related fields. Graduate Course work shall include the following courses or their equivalent as determined by PSS:
 - a. Introduction to School Administration
 - b. Instructional Supervision and Evaluation (Clinical Supervision)
 - c. Education Law
 - d. School Personnel
 - e. School Finance
 - f. Instructional Leadership & Supervision*
 - g. Facilitative Leadership*

- 2. <u>Core Knowledge Examination</u>: All school administrators (principals and vice-principals) must take and pass PRAXIS I and the appropriate PRAXIS II exam starting Julanuary 31,2007.
- §7102. Term: The term of school administrator's certification shall be for a period of four years. The certification may be subsequently renewed for another 4 years. However, an incumbent administrator requesting a renewal of his/her certification is required to complete at least 120 hours of professional development hours, annually, sanctioned by PSS. Failure to complete the required 120 professional development hours may be a cause for suspension, revocation or non-renewal of certification and/or employment contract.
- §7103. <u>Revocation/Suspension</u>: PSS shall have the authority to suspend or revoke any administrator's certificate after complying with the notice and hearing process set forth in the teacher and librarian certification requirements (Chapter 2, Part E of the PSS Regulations for Certified Personnel).

^{*}Note: courses may be substituted with seminars, institute, or CEU courses sanctioned by PSS.

REGULATIONS FOR THE PUBLIC SCHOOL SYSTEM EMPLOYMENT OF NON-CERTIFIED PERSONNEL

Chapter 7:

ADMINISTRATOR'S CERTIFICATION AND COMPENSATION

A. CERTIFICATION REQUIREMENTS:

- \$7101. 1 Education: Graduation from an accredited colleges or universities with a Master's degree in School Administration/Supervision or a related fields. Graduate Course work shall include the following courses or their equivalent as determined by PSS:
 - a. Introduction to School Administration
 - b. Instructional Supervision and Evaluation (Clinical Supervision)
 - c. Education Law
 - d. School Personnel
 - e. School Finance
 - f. Instructional Leadership & Supervision*
 - g. Facilitative Leadership*
 - *Note: courses **may be** substituted with seminars, institute, or CEU courses sanctioned **bv** PSS.
 - 2. <u>Core Knowledge Examination</u>: All school administrators (principals and vice-principals) must take and pass PRAXIS I and the appropriate PRAXIS II exam starting July 31,2007.
- \$7102. Term: The term of school administrator's certification shall be for a period of four years. The certification may be subsequently renewed for another 4 years. However, an incumbent administrator requesting a renewal of his/her certification is required to complete at least 120 hours of professional development hours, annually, sanctioned by PSS. Failure to complete the required 120 professional development hours may be a cause for suspension, revocation or non-renewal of certification and/or employment contract.
- \$7103. Revocation/Suspension: PSS shall have the authority to suspend or revoke any administrator's certificate after complying with the notice and hearing process set forth in the teacher and librarian certification requirements (Chapter 2, Part E of the PSS Regulations for Certified Personnel).

REGULATIONS FOR THE PUBLIC SCHOOL SYSTEM EMPLOYMENT OF NON-CERTIFIED PERSONNEL PROPOSED AMENDMENT MARCH 2006

Chapter 1

G. Core Knowledge Testing Requirement

\$1701 PRAXIS. All applicants for counselor or , school administrator, or Curriculum and Instruction program manager, and coordinator, education specialist, or assistant or component coordinator under the PSS Curriculum. Instruction and Assessment (CIA) Department positions and all current employees in these positions, upon contract renewal, shall submit proof to PSS that he or she has received a passing grade on the PRAXIS core knowledge examinations. The PRAXIS requirement shall apply to all counselor, school administrator, and Curriculum and Instruction program manager and coordinator applicants and all current PSS employees. Passing scores will be determined by the Commissioner of Education and announced. Once a passing score is set by the Commissioner of Education, it may only be altered with Board of Education approval.

\$1702 Procedure.

- a) All current PSS counselors, school administrators, and program managers, coordinators, education specialists, or assistant or component coordinators under the CIA Department Curriculum and Instruction program managers and coordinators and applicants for these positions shall be required to pass PRAXIS I and PRAXIS II prior to Julanuary 31,2007.
- b) The results of the PRAXIS I and PRAXIS II examinations will determine a current employee's eligibility for contract renewal and an applicant's eligibility for employment.
- c) A current employee's failure to take the test or to obtain a passing score shall result in his or her employment contract not being renewed.
- d) An applicant's failure to take the test or to obtain a passing score shall result in ineligibility for employment.

\$1703 Timeline.

- a) All newly recruited counselors, school administrators, and Curriculum and Instruction program managers and coordinators for SY 2006/2007 program managers, coordinators, education specialists, and assistant or component coordinators under the CIA Department shall be required to have taken and passed the PRAXIS I and PRAXIS II examinations in order to qualify for employment with PSS for school year 2007-08.
- b) Beginning Julanuary 31, 2007, all counselors, school administrators, and program managers, coordinators, education specialists, and assistant or component coordinators under the CIA Department Curriculum and Instruction program

managers and coordinators employed by PSS will have taken and passed the PRAXIS I and PRAXIS II exams.

26135 **PAGE**

REGULATIONS FOR THE PUBLIC SCHOOL SYSTEM EMPLOYMENT OF NON-CERTIFIED PERSONNEL

Chapter 1

G. **Core Knowledge Testing: Requirement**

\$1701 PRAXIS. All applicants for counselor or school administrator, or program manager, coordinator, education specialist, or assistant or component coordinator under the Curriculum, Instruction and Assessment (CIA) Department and all current employees in these positions, upon contract renewal, shall submit proof to PSS that he or she has received a passing grade on the PRAXIS core knowledge examinations. Passing scores will be determined by the Commissioner of Education and announced. Once a passing score is set by the Commissioner of Education, it may only be altered with Board of Education approval.

§1702 Procedure.

- All current PSS counselors, school administrators, and program managers, coordinators, education specialists, or assistant or component coordinators under the CIA Department and applicants for these positions shall be required to pass PRAXIS I and PRAXIS II prior to July 31,2007.
- b) The results of the PRAXIS I and PRAXIS II examinations will determine a current employee's eligibility for contract renewal and an applicant's eligibility for employment.
- c) A current employee's failure to take the test or to obtain a passing score shall result in his or her employment contract not being renewed.
- d) An applicant's failure to take the test or to obtain a passing score shall result in ineligibility for employment.

§1703 <u>Timeline</u>.

- a) All newly recruited counselors, school administrators, and program managers, coordinators, education specialists, and assistant or component coordinators under the CIA Department shall be required to have taken and passed the PRAXIS I and PRAXIS II examinations in order to qualify for employment with PSS for school year 2007-08.
- b) Beginning July 31,2007, all counselors, school administrators, and program managers, coordinators, education specialists, and assistant or component coordinators under the CIA Department employed by PSS will have taken and passed the PRAXIS I and PRAXIS II exams.

REGULATIONS FOR THE PUBLIC SCHOOL SYSTEM EMPLOYMENT OF CERTIFIED PERSONNEL

Chapter 1

Core Knowledge Testing; Requirement F.

\$1601 PRAXIS. All teacher and librarian applicants and current teachers and librarians, upon contract renewal, shall submit proof to PSS that he or she has received a passing grade on the PRAXIS core knowledge examinations. The PRAXIS requirement shall apply to all teacher and librarian applicants and all current teachers and librarians, except professionally licensed related services providers. Passing scores will be determined by the Commissioner of Education and announced to teachers, librarians and applicants. Once the passing scores are set by the Commissioner of Education, the passing score may only be altered with Board of Education approval.

\$1602 Procedure.

- a) All current PSS teachers and teacher applicants shall be required to pass PRAXIS I and PRAXIS II prior to August 1,2006.
- b) All current PSS librarians and librarian applicants shall be required to pass PRAXIS I and PRAXIS II prior to Julanuary 31,2007.
- c) The results of the PRAXIS I and PRAXIS II examinations will determine a current librarian or teacher's eligibility for contract renewal and an applicant's eligibility for employment.
- d) A current librarian or teacher's failure to take the test or to obtain a passing score shall result in his or her employment contract not being renewed.
- e) A teacher or librarian applicant's failure to take the test or to obtain a passing score shall result in ineligibility for employment.

\$1603 Timeline.

- a) PRAXIS testing will be offered to teachers and teacher applicants beginning in school year (SY) 200412005.
- b) All newly recruited PSS teachers for SY 06107 shall be required to have taken and passed the PRAXIS I and PRAXIS II examinations in order to qualify for employment with PSS.
- c) Beginning August 1,2006, all teachers employed by PSS will have taken and passed the PRAXIS I and PRAXIS II exams.
- d) Beginning Julanuary 31,2007, all librarians employed by PSS will have taken and passed the PRAXIS I and PRAXIS II exams.

REGULATIONS FOR THE PUBLIC SCHOOL SYSTEM EMPLOYMENT OF CERTIFIED PERSONNEL

Chapter 1

F. Core Knowledge Testing Requirement

\$1601 PRAXIS. All teacher and librarian applicants and current teachers and librarians, upon contract renewal, shall submit proof to PSS that he or she has received a passing grade on the PRAXIS core knowledge examinations. The PRAXIS requirement shall apply to all teacher and librarian applicants and all current teachers and librarians, except professionally licensed related services providers. Passing scores will be determined by the Commissioner of Education and announced to teachers, librarians and applicants. Once the passing scores are set by the Commissioner of Education, the passing score may only be altered with Board of Education approval.

51602 Procedure.

- a) All current **PSS** teachers and teacher applicants shall be required to pass **PRAXIS** I and **PRAXIS** II prior to August 1,2006.
- b) All current **PSS** librarians and librarian applicants shall be required to pass **PRAXIS I** and **PRAXIS II** prior to July 31,2007.
- c) The results of the **PRAXIS I** and **PRAXIS II** examinations will determine a current librarian or teacher's eligibility for contract renewal and an applicant's eligibility for employment.
- d) A current librarian or teacher's failure to take the test or to obtain a passing score shall result in his or her employment contract not being renewed.
- e) A teacher or librarian applicant's failure to take the test or to obtain a passing score shall result in ineligibility for employment.

§1603 <u>Timeline</u>.

- a) **PRAXIS** testing will be offered to teachers and teacher applicants beginning in school year (SY) 2004/2005.
- b) All newly recruited **PSS** teachers for **SY** 06/07 shall be required to have taken and passed the **PRAXIS** I and **PRAXIS** II examinations in order to qualify for employment with **PSS**.
- c) Beginning August 1,2006, all teachers employed by **PSS** will have taken and passed the **PRAXIS I** and **PRAXIS II** exams.
- d) Beginning July 31,2007, all librarians employed by **PSS** will have taken and passed the **PRAXIS** I and **PRAXIS** II exams.